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ABSTRACT 
 The distinct morphological and functional properties of mammalian heart 
chambers arise from an elaborate developmental program involving cell lineage 
determination, morphogenesis, and dynamic spatiotemporal gene expression patterns. 
While a number of transcription factors have been identified for proper gene regulation in 
the chambers, the complete transcriptional network that controls these patterns remains 
poorly defined. Previous studies have implicated MEF2 transcription factors in the 
regulation of chamber-restricted enhancers. To better understand the mechanisms of 
MEF2-mediated regional gene regulation in the heart, MEF2A knockout (KO) mice, a 
model that displays a predominantly ventricular chamber phenotype, are used herein. 
Transcriptomic analysis of atrial and ventricular tissue from adult MEF2A KO hearts 
revealed extensive differences in chamber gene expression across the heart, with a larger 
proportion of dysregulated genes in atrial chambers. Thus, it is hypothesized that MEF2A 
differentially regulates expression of target genes and cellular pathways in cardiac 
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chambers. Functional pathway analysis of genes preferentially dysregulated in the atria 
and ventricles supported this hypothesis and revealed distinct MEF2A-dependent cellular 
processes in each cardiac chamber. In atria, MEF2A regulated the expression of genes 
involved in fibrosis and adhesion, whereas in ventricles, it controlled genes involved in 
inflammation and endocytosis. Additional studies uncovered preferential dysregulation of 
molecular components of these pathways in MEF2A KO hearts. Phosphorylated focal 
adhesion kinase (FAK) levels, relating to cell adhesion, were preferentially 
downregulated in KO atria, and TRAF6 proteins levels, relating to inflammation, were 
preferentially downregulated in KO ventricles. Finally, analysis of transcription factor 
binding site motifs of differentially dysregulated genes uncovered distinct MEF2A 
coregulators for the atrial and ventricular gene sets. A subset of these transcriptional 
coregulators were found to cooperate with MEF2A to activate MEF2-dependent reporters 
in vitro. In conclusion, these results suggest a mechanism in which MEF2 transcriptional 
activity is differentially recruited to fine-tune gene expression levels in each cardiac 
chamber. This regulatory mechanism ensures the optimal output of gene products for 
proper physiological function of the atrial and ventricular chambers. Lastly, one of the 
preferentially dysregulated genes, Bex1, was further characterized. Future studies will 
focus on the role of MEF2A-regulated Bex1 in the adult heart. 
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CHAPTER ONE: Introduction 
1.1 Introduction 
 The genetic program of the developing heart involves a network of signaling 
molecules and transcription factors to properly form this complex organ. Given the 
complexity of the heart, even subtle perturbations in the regulation of these pathways, or 
in the formation of a specific cardiac structure can ultimately lead to heart disease and 
death. The overall goal of this research is to understand the transcriptional regulation 
behind the gene programs and cellular pathways involved in cardiac muscle. Many key 
transcription factors involved in cardiogenesis and cardiac homeostasis have been 
identified and only a few are known to be evolutionarily conserved and important for 
muscle development. One of these factors is MEF2. 
 This thesis focuses on the role of the MEF2A transcription factor in atrial and 
ventricular chambers in the adult mouse heart. Previous findings have established MEF2 
proteins as key regulators essential in differentiation and developmental gene programs in 
mammalian cardiac muscle. The purpose of this research is to gain a better understanding 
of the cellular pathways and gene programs that MEF2A differentially regulates 
throughout the chambers of the adult heart.  
 
1.2 Myocyte enhancer factor-2 
1.2.1 Discovery and structure of MEF2 proteins 
 Myocyte enhancer factor-2 (MEF2) proteins are an evolutionarily conserved 
family of transcription factors that are present in organisms from yeast to humans. In 
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mice and humans, there are four MEF2 family members designated MEF2A, –B, –C, and 
–D, each encoded by a separate Mef2 gene. MEF2 factors are a subfamily of proteins 
belonging to the evolutionarily ancient MADS-box family of transcription factors that 
bind to A/T-rich sequences. Named after the four founding members in the family 
(MCM1 from Saccharomyces cerevisiae, AGAMOUS from Arabidopsis thaliana, 
DEFICIENS from Antirrhinum majus, and SRF from Homo sapiens), MADS-box 
proteins also bind to A/T-rich sequences (Shore & Sharrocks 1995). 
 All four mammalian MEF2 factors contain an N-terminal MADS-box, a MEF2 
domain, and a C-terminal transcriptional activation domain (Figure 1.1) (Black & Olson 
1998, McKinsey et al. 2002, Potthoff & Olson 2007). The MADS-box is 57 amino acids 
in length, located at the beginning of the amino terminus and serves as the minimal 
domain required for DNA binding. Adjacent to the MADS-box is a 29 amino acid motif 
known as the MEF2 domain. This sequence is required for high affinity DNA binding, 
dimerization, and transcriptional co-factor recruitment (Molkentin et al. 1996). Unlike 
other MADS-box transcription factors, only MEF2 proteins possess a MEF2 domain. 
MEF2 factors are capable of homo– and heterodimerization, but they are unable to 
dimerize with other MADS-box family members (Black & Olson 1998, Desjardins & 
Naya 2016). This observation suggests that specific residues within the MADS-box motif 
of MEF2 proteins confer the specificity for heterodimerization onto the MEF2 family 
(Black & Olson 1998). Lastly, the C-terminal region of MEF2 factors functions as the 
transcriptional activation domain.  
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 Due to the high similarity of Mef2 exon-intron organization between mammals 
and invertebrates, it is likely that these genes evolved from a common ancestral Mef2 
gene (Black & Olson 1998). While mammals possess four distinct Mef2 genes, 
invertebrates have a single Mef2 gene and vertebrates possess three or more (Desjardins 
& Naya 2016). Indeed, MEF2 is expressed from yeast to humans (Black & Olson 1998, 
Dodou & Treisman 1997, Gaspera et al. 2009, Hinits et al. 2012, Lilly et al. 1994).  
 
1.2.2 Tissue distribution of MEF2 proteins 
 In mammalian species, Mef2 genes display overlapping but distinct temporal and 
spatial expression patterns in embryonic and adult tissues (Edmondson et al. 1994). 
Throughout development, Mef2 expression is high in developing muscle cell lineages. In 
flies, D-mef2 is expressed throughout the unspecified mesoderm after gastrulation, and 
later expression is restricted to the cardiac, skeletal, and smooth muscle lineages (Lilly et 
al. 1994, Nguyen et al. 1994, Taylor et al. 1995). 
 It has been documented in vertebrate studies that Mef2 transcripts are ubiquitous, 
however, somatic, cardiac, and visceral muscle show an enrichment for this family of 
proteins (Potthoff & Olson 2007). In mice, Mef2c and Mef2b are the first two Mef2 genes 
to be expressed in mesodermal precursor cells at around embryonic day 7.5 (E7.5), with 
Mef2a and Mef2d genes expressed about a day later in the myocardium of the developing 
heart (Edmondson et al. 1994, Naya et al. 1999). Mef2 gene expression is also detected in 
developing skeletal and smooth muscle cell lineages. These observations demonstrate 
that the Mef2 promoters are responsive to various transcription factors, and that Mef2 
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expression levels can differ within a specific tissue type, dependent on the spatial 
expression profile of activating and repressing factors.  
 Mice carrying a lacZ reporter under the control of either the desmin MEF2 
enhancer (des-MEF2-lacZ) or c-jun MEF2 enhancer (jun-MEF2-lacZ) have been 
generated to study the expression pattern of MEF2 proteins during mouse embryogenesis 
(Naya et al. 1999). Expression of the lacZ transgene in these mice was detected as early 
as E7.5 in cardiac progenitor cells. Ultimately, MEF2-lacZ transgenic mice showed lacZ 
expression in somites, skeletal muscle, cardiac mesoderm, and the heart tube during 
embryogenesis. LacZ expression was also detected in specific regions of the brain in 
adult mice (Naya et al. 1999). 
 It is interesting to note that recent studies have shown an enrichment of MEF2A 
in atrial chambers of the mouse heart (Zhao et al. 2002). This spatially differential 
expression pattern of MEF2A throughout the heart suggests that MEF2A has a role in 
atrial chambers. However, these experiments demonstrating atrial enrichment of MEF2A 
lack controls and require a more thorough investigation with proper quantification 
analysis (Zhao et al. 2002).  
 
1.2.3 Regulation of MEF2 expression and activity 
1.2.3.1 Transcriptional regulation 
 The promoters of each Mef2 gene are activated by different factors in a tissue-
dependent manner. In skeletal muscle development the Mef2c gene is a direct target of 
the basic helix-loop-helix (bHLH) protein MyoD, whereas in the anterior heart field ISL1 
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and GATA transcription factors activate the expression of Mef2c in the developing heart 
(Dodou et al. 2004, 2003). It has been shown that Mef2a is transcriptionally 
autoregulated in the heart. Depending on different signaling activities, Mef2a splice 
variants are expressed, and transcription of the Mef2a gene is subject to positive or 
negative regulation by its own protein products (Ramachandran et al. 2008). These 
results demonstrate that the promoters of each Mef2 gene respond to different regulatory 
factors in a tissue-dependent manner.  
 
1.2.3.2 Post-transcriptional regulation 
 The 3’-untranslated region (3’-UTR) of Mef2a transcripts is subject to an 
additional level of regulation. It has been observed that the 3’-UTR of the Mef2a 
transcript functions as a cis-acting translational repressor (Black et al. 1997). While the 
molecular mechanism of this observed post-transcriptional regulation was unknown at the 
time, it was later discovered that microRNA (miRNA) 155 (miR-155) significantly 
represses MEF2A expression and subsequently impairs myoblast differentiation (Seok et 
al. 2011). Additionally, expression of miR-1 is restricted to striated muscle, and miR-1 
negatively regulates the expression of Mef2a in cardiomyocytes (Ikeda et al. 2009). 
Recently, studies have shown the 3’-UTR of Mef2d is targeted by miR-218. The targeting 
of Mef2d by miR-218 suppresses cardiac myxoma, the most common type of human 
heart tumor (Cao et al. 2015). Regulation via the 3’-UTR of Mef2 transcripts can explain 
the differences between mRNA and protein levels among different tissues types. 
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1.2.3.3 Post-translational modification 
 Post-translational modifications of MEF2 proteins play an important role in DNA-
binding activity and protein stability. The MADS-box domain in all MEF2 proteins 
contains a conserved casein kinase II (CKII) phosphorylation site (Black & Olson 1998). 
Phosphorylation of this site enhances the DNA-binding activity of MEF2C (Molkentin et 
al. 1996). Separate phosphorylation motifs in MEF2 factors have also been found to 
regulate their stability in vitro (Cox et al. 2003). Specifically, a KSPPP amino acid 
sequence is conserved in MEF2 isoforms across many species. The phosphorylation of 
the serine residue in the KSPPP motif is mediated by p38 MAPK and promotes the 
degradation of MEF2A (Cox et al. 2003). Both MEF2 and p38 MAPK are known 
regulators of cardiac development. Recent studies provide evidence for a functional role 
of a p38 MAPK/MEF2 signal transduction cascade in cardiomyocyte biology (Han & 
Molkentin 2000) 
 In addition to phosphorylation-associated covalent modifications, MEF2 factors 
have been shown to be post-translationally acetylated and SUMOylated (Small Ubiquitin-
like Modifier). Acetylation of MEF2C in skeletal muscle cells results in the enhancement 
of MEF2C DNA- and chromatin-binding activity (Angelelli et al. 2008). Mutating these 
acetylation sites affects the synergistic effect of MEF2C with bHLH factor Myogenin, 
and non-acetylatable MEF2C inhibits differentiation in C2C12 cells (Ma et al. 2005). 
MEF2A undergoes SUMOylation both in vitro and in vivo, and interestingly, mutating 
the SUMOylation site (K395) of MEF2A enhances its DNA-binding activity compared to 
wild-type MEF2A (Riquelme et al. 2006). Altogether, these studies demonstrate that 
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post-translational modifications of MEF2 proteins play an important role in the regulation 
of their transcriptional activity. 
 
1.2.4 MEF2 target genes 
 Many target genes of MEF2 signaling have been discovered. The first MEF2 
target gene was Mck (Gossett et al. 1989). This gene contained an upstream enhancer site 
harboring the MEF2 consensus sequence. Since then, researchers have continued to 
characterize direct targets of MEF2, ultimately linking MEF2 protein to a variety of 
cellular and molecular pathways in various tissues. These MEF2 gene targets have been 
discovered through detailed studies combining microarray technologies and promoter 
analysis of candidate target genes. MEF2 proteins have been shown to directly target 
numerous genes involved in different cellular processes, including myogenic factors 
(MyoD and MRF4), enzymes (aldolase A), structural proteins (desmin), and glucose 
transport proteins (GLUT4) (Black et al. 1995, Black & Olson 1998, Dechesne et al. 
1994, Hidaka et al. 1993, Kuisk et al. 1996, Liu et al. 1994). The transcription factor 
BOP is a regulator of the anterior heart field, and MEF2C can transcriptionally regulate 
Bop expression through a MEF2-responsive element in the Bop promoter (Phan et al. 
2005). ChIP-exo techniques have been used in both cardiomyocytes and skeletal muscle 
myoblasts to analyze MEF2 target genes (Wales et al. 2014). These studies revealed a 
regulation of the phosphatase gene Dusp6 by p38MAPK-MEF2 signaling (Wales et al. 
2014). It has been demonstrated that MEF2 proteins regulate distinct gene programs in 
mammalian skeletal muscle differentiation (Estrella et al. 2015). While these studies 
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show that only MEF2A is absolutely required for skeletal muscle differentiation, each 
MEF2 isoform regulates a significant subset of non-overlapping genes. Although not 
functionally tested as direct targets of MEF2, the preferential sensitivity of certain genes 
to specific MEF2 isoforms suggests that each MEF2 factor transcriptionally activates a 
different subset of target genes to regulate distinct gene programs in skeletal muscle 
differentiation. 
 The repertoire of MEF2 target genes has expanded in the past decade based on 
genome-wide expression studies, and our lab has also contributed to the identification of 
a number of MEF2 targets. Microarray analysis of MEF2A KO hearts coupled with in 
vitro promoter characterization identified both Myomaxin (Xirp2/Cmya3) and Myospryn 
(Cmya5) as target genes of MEF2 (Durham et al. 2006, Huang et al. 2006). MEF2A has 
been identified as a regulator of a costamere gene program in cardiac muscle. The 
costamere is a macromolecular complex linking the myofibrils to the myocyte membrane. 
Fifty-five known costamere-localized genes were found to be dysregulated in Mef2a KO 
hearts. Additionally, this global downregulation of costamere-localized genes was 
observed in MEF2A-deficient neonatal rat ventricular myocytes (NRVMs) but not when 
MEF2D protein levels were depleted via shRNA-mediated knockdown. These results 
show a MEF2 isoform-specific regulation of cardiac gene programs (Ewen et al. 2011). 
In a separate set of experiments, cell-cycle and differentiation programs were found to be 
antagonistically regulated in an isoform-specific manner in cardiomyocytes (Desjardins 
& Naya 2017). In these experiments, both MEF2A and MEF2D were individually 
necessary for myocyte survival, whereas MEF2C was dispensable. Additionally, MEF2A 
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or MEF2D deficiency triggered activation of cell cycle genes and downregulation of 
terminal differentiation markers. Conversely, MEF2C deficiency in NRVMs 
antagonistically regulated cell cycle genes and differentiation gene programs compared to 
MEF2A and MEF2D (Desjardins & Naya 2017).  
 Recent research shows that MEF2 regulates the expression of the Gtl2-Dio3 non-
coding RNA (ncRNA) locus (Snyder et al. 2013). This cluster harbors several long non-
coding RNAs (lncRNAs) and a mega-cluster of microRNAs. A subset of these 
microRNAs target the Wnt signaling pathway in the process of skeletal muscle 
regeneration in Mef2a-null mice (Snyder et al. 2013). 
 
1.2.5 MEF2 loss-of-function mouse models 
 Overlapping expression patterns and functional redundancy among the MEF2 
family members complicates dissecting the specific function of each vertebrate gene. 
Mef2c was the first gene of the Mef2 family to be inactivated by gene knockout in mice, 
and Mef2c-null mice die at E9.5, displaying underdevelopment of the ventricles as well 
as cardiac looping abnormalities (Lin et al. 1997). These studies demonstrate a role for 
MEF2C in early heart development and that MEF2C is absolutely required at this 
timepoint during embryogenesis. Conditional Mef2c KO mice were generated to allow 
for temporal and tissue-specific analysis of the cardiac phenotype since global knockout 
of the Mef2c gene results in early embryonic lethality (Vong et al. 2005). Delayed Cre 
recombinase-mediated removal of Mef2c in the myocardium using an alpha myosin 
heavy chain driver resulted in viable offspring. This result demonstrates that while Mef2c 
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is required for early development of the heart, Mef2c is dispensable after looping 
morphogenesis (Vong et al. 2005) 
 Mef2d-null mice do not display any obvious abnormalities under normal 
conditions, but display major alterations in cardiac remodeling upon stress (Kim et al. 
2008, Potthoff & Olson 2007). Mef2b-null mice appear normal (Black & Olson 1998). 
The lack of an observable cardiac-related phenotype in Mef2b KO mice indicates that 
MEF2B does not have an essential role in the heart, as compared to other MEF2 
isoforms. While MEF2B expression was detected in cardiac and skeletal muscle of 
developing mouse embryos, MEF2B expression was not detected in adult striated muscle 
(Morisaki et al. 1997). 
 Mef2a mutant mice fall into two phenotypic classes. The first class of Mef2a-null 
mice die perinatally between postnatal days 5 (P5) and P10. These mutant mice exhibit 
cytoarchitectural defects and right ventricular dilation (Naya et al. 2002). Defective 
cytoarchitecture in these hearts results from the misregulated expression of genes 
encoding proteins that localize to the costamere (Ewen et al. 2011). The costamere, a 
macromolecular complex, is perturbed in perinatal Mef2a-null hearts. The second class of 
mice survive to adulthood without any obvious structural defects in the heart. Instead 
these mutant mice exhibit mitochondrial deficiency and conduction abnormalities (Naya 
et al. 2002). While the Mef2a-null perinatal phenotype has been characterized, not much 
is known about the defective gene programs and cellular processes in the adult Mef2a KO 
heart. 
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1.3 The mammalian heart 
1.3.1 Cardiogenesis 
 The formation of the mammalian heart can be broken down into four main stages 
(Figure 1.2). In response to cues from adjacent endoderm (e.g., bone morphogenetic 
protein [BMP] and Wnt signaling molecules), cardiac progenitor cells are specified in the 
anterior lateral mesoderm and migrate to the ventral midline during vertebrate 
embryogenesis (Schultheiss et al. 1995). These signals are conserved across species and 
activate the expression of Nkx2-5 in vertebrates and tinman in flies (Harvey 1996). To 
date, NKX2-5 and Tinman are the earliest markers of the cardiac lineage in vertebrates 
and flies, respectively (Harvey 1996). 
 After converging at the ventral midline and forming a cardiac crescent, 
cardiomyoblasts organize into a functional linear heart tube. GATA family factors are 
involved in the formation of the linear heart tube, and loss of these GATA signals 
prevents proper formation of a linear heart tube, a defect known as cardiac bifida and  
results in embryonic lethality (Kuo et al. 1997, Molkentin et al. 1997, Reiter et al. 1999). 
After proper formation of the linear heart tube, the heart undergoes the critical event of 
rightward looping. Rightward looping of the linear heart places the systemic (left) and 
pulmonary (right) ventricles, as well as the atria, in their correct, three-dimensional 
orientation. The underlying factors governing rightward looping are still unknown. 
 In the final stage of cardiogenesis, each chamber is now distinguishable and in the 
correct position. The heart then goes through the process of chamber segmentation, 
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cardiac valve formation, and chamber growth. In these final stages of cardiac 
development, maturation of the ventricles is dependent specifically on MEF2C function. 
 
1.3.2 Chamber specification and differentiation 
 An important process in cardiogenesis is the proper specification of each chamber 
in the heart. Chamber identity and development are tightly regulated by a network of 
various transcription factors expressed throughout the heart (Figure 1.3). One example is 
the transcription factor COUP-TFII. Knockout of COUP-TFII in cardiomyocytes 
produced ventricular-like chambers in place of atrial chambers (Wu et al. 2013). 
Cardiomyocytes from these “ventricularized” chambers displayed physiological and 
morphological properties more closely resembling ventricular myocytes as opposed to 
atrial myocytes (Wu et al. 2013). Additionally, this chamber-identity switch was 
accompanied by dysregulation of 2,584 genes, many of which are differentially expressed 
between wild-type atria and ventricles. Similarly, the bHLH transcriptional repressor 
Hrt2 is necessary for the suppression of atrial genes in the ventricular myocardium (Xin 
et al. 2007). While Hrt2 KO mice die perinatally from cardiac abnormalities, conditional 
KO of Hrt2 in cardiomyocytes results in the activation of atrial genes in the ventricular 
myocardium. Conversely, expression of Hrt2 in atrial cardiomyocytes is sufficient to 
repress atrial cardiac genes (Xin et al. 2007). 
 
1.3.3 Cardiac chamber morphogenesis 
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 Proper formation of the mammalian heart involves precisely coordinated 
morphogenetic and differentiation processes that give rise to an organ with multiple, 
well-defined anatomical structures. Gene inactivation studies of cardiac-related 
transcription factors have revealed a number of genes required for the proper formation 
of the mammalian heart. As mentioned previously, Mef2c-null mice die at E9.5 
displaying underdevelopment of the ventricles as well as cardiac looping abnormalities 
(Lin et al. 1997). Nkx2.5 is expressed in the precardiac mesoderm and is one of the 
earliest markers of the cardiac muscle lineage (Srivastava & Olson 2000). Mice lacking 
Nkx2.5 display abnormal heart morphogenesis and embryonic lethality at around E9.5. 
While proper formation of the heart tube was observed, Nkx2.5 KO mice failed to 
undergo cardiac looping (Lyons et al. 1995). Mice lacking Pitx2 die before birth, 
displaying left-right asymmetry, chamber remodeling, atrial and ventricular septal defects 
in the heart (Gage et al. 1999, Liu et al. 2001). Mice with haploinsufficiency of the 
transcription factor Tbx5 (Tbx5del/+) were viable and displayed enlarged atria as well as 
conduction abnormalities and abnormal gene expression patterns (Bruneau et al. 2001). 
However, Tbx5 KO mice (Tbx5del/del) did not survive past embryonic day 10.5. Tbx5 KO 
mice also displayed impaired cardiac differentiation. In Tbx5 KO mice, expression of 
Nkx2.5 decreased at E8.5, and by E10 Nkx2.5 transcript levels were almost undetectable 
(Bruneau et al. 2001). Taken together, these observations provide evidence for a network 
of interdependent transcriptional regulatory factors involved in proper cardiac chamber 
formation in the developing heart.  
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1.3.4 MEF2 in atrial and ventricular tissue differences 
 The atria and ventricular chambers are the two main tissues in the mammalian 
heart. These two tissues serve different functions in the cardiovascular system. The 
primary role of the ventricles is to facilitate the distribution of blood to the lungs for 
oxygenation (pulmonary ventricle) and to the organs in the body (systemic ventricle) by 
pumping blood through the circulatory system. The atrial chambers of the heart receive 
and pump the blood into the ventricles. For the most part, atrial and ventricular myocytes 
have similar functions in both chambers, but surprisingly, they do not express the same 
genes. It is known that certain transcription factors expressed in the heart facilitate 
chamber identity such as COUP-TFII (Pereira et al. 1999, Wu et al. 2013). Various 
studies have shown that atrial and ventricular chambers, and to an extent left and right 
sides of respective chambers, have differential gene expression (Tabibiazar et al. 2003, 
Zhao et al. 2002). In a similar study, promoters of genes that are differentially expressed 
throughout the heart were analyzed, and promoters of atrial-enriched genes were found to 
contain MEF2 transcription factor binding sites (Zhao et al. 2002). Moreover, it was 
suggested that MEF2 plays a role in the differential expression of key genes throughout 
the heart, and more specifically, in the atrial chambers of the heart. However, the 
conclusions drawn from those studies are not entirely convincing due to the lack of 
proper controls and additional quantifications. A more thorough investigation is needed 
regarding chamber-specific roles for MEF2A as suggested by these researchers (Zhao et 
al. 2002). 
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 Interestingly, although MEF2 factors have been shown to be expressed in both 
atria and ventricular chambers for the heart, MEF2 proteins have been implicated in the 
regulation of atrial and ventricular chamber-restricted genes. Expression of a minimal 
enhancer of the Mlc2v gene in the ventricles was shown to be dependent on a MEF2 site 
(Ross et al. 1996). The atrial chamber-enriched gene ANF was shown to be co-regulated 
by MEF2 and GATA-4 and by MEF2A and PITX2C (Morin et al. 2000, Toro et al. 
2004). MEF2C has been shown to regulate the enhancers of the BOP and Hcn4 genes in 
the second heart field and atrioventricular conduction system, respectively (Phan et al. 
2005, Vedantham et al. 2013). Taken together, these observations suggest that MEF2 
factors are necessary to coordinate proper cardiac chamber-dependent gene expression.  
 
1.3.5 Chamber-related diseases in the heart 
 The differential chamber-dependent regulation of cardiac genes may provide a 
mechanism by which a diseased heart regionally reprograms gene expression according 
to a specific insult. In this instance, modulation of MEF2 activity through preferential 
interaction with coregulators would drive a chamber-specific gene regulatory response as 
part of the pathological remodeling of the heart. A MEF2-dependent transgene, a reporter 
that responds to all MEF2 isoforms, showed preferential atrial activation when mice were 
treated with various cardiac insults such as isoproterenol, angiotensin II, and thyroid 
hormone (Zhao et al. 2002). The immediate early and widely expressed bZip 
transcription factor ATF3 was also shown to be preferentially upregulated in the atrial 
chambers of mice treated with angiotensin II whereas adrenergic stimulation induced 
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ATF3 similarly in all chambers (Hasin et al. 2011). Based on these observations it is 
likely that additional TFs in the heart control differential chamber activity in response to 
specific pathological stimuli. 
 
1.4 MEF2-interacting transcriptional co-regulators 
 MEF2 proteins are primarily transcriptional activators, and MEF2 transcription 
factors interact with transcriptional co-regulators for precise regulation of target genes. 
Studies provide evidence that MEF2 is involved in interactions with transcriptional co-
factors that modulate the activity of MEF2 proteins (Feng et al. 2015, Van Rooij et al. 
2010, Toro et al. 2004). Here, I discuss the different interactions that MEF2 proteins 
participate in with other transcriptional co-regulators. These interactions include 
chromatin remodeling proteins, repressive effects, and synergistic activation of target 
genes. I also discuss potential co-regulators that have been shown to interact with MEF2 
proteins at some capacity. In Chapter 3 I will show that MEF2A interacts with these 
cofactors to further modulate and regulate the activity of target genes. 
 
1.4.1 Modulation of MEF2 transcriptional activity 
 Histone deacetylase complexes (HDACs) remove the acetyl groups from histones 
to condense the chromatin to reduce expression of certain genes. MEF2 is known to 
interact with class IIa HDACs and forms repressive complexes on MEF2 target genes 
such as matrix metalloproteinase 10 (Mmp10), myoglobin, and myogenin (Bassel-Duby 
et al. 1992, Bertos et al. 2001, Chang et al. 2006, Cheng et al. 1993). Protein kinases 
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regulated by calcium signals phosphorylate these class IIa HDACs. This phosphorylation 
then promotes nuclear-to cytoplasmic translocation of these HDACs. Phosphorylation-
mediated translocation of HDACs out of the nucleus then relieves the HDAC-mediated 
transcriptional repressive effects and leads to the activation of MEF2 (McKinsey & Olson 
2005, Zhang et al. 2002). These types of interactions provide a mechanism for the 
modulation of expression of MEF2 target genes in response to physiological and 
pathological signaling (Potthoff & Olson 2007). 
 Another interaction showing negative modulation of MEF2 activity is with the 
early growth response protein 1 (EGR1) (Feng et al. 2015). In these studies, a 
bioinformatics approach was used to identify cis-elements as binding sites for 
transcriptional co-regulators of MEF2A-dependent costamere genes (Ewen et al. 2011), 
and the early growth response (EGR) family was identified as a candidate co-regulator. 
EGR1 was found to be a potent repressor of MEF2A activity. These repressive effects 
were observed in both non-cardiac and cardiac cells. Additionally experiments showed 
that EGR1 and MEF2A interact in vivo in co-immunoprecipitation studies, and that 
costamere-localized genes are upregulated in EGR1-depleted NRVMs.  
 Previous findings in the field provide evidence that interactions between MEF2 
transcription factors and other proteins on upstream regulatory regions of genes result in 
synergistic transcriptional activation. Some examples of this include MEF2A and 
PITX2C in oral epithelial cells (Toro et al. 2004). These findings report both isoform-
specific and cell-specific synergistic activation. Interaction between the bHLH protein 
MASH1 and MEF2C has been shown to promote synergistic activation of transcription 
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through either the MASH1 or the MEF2 site in in vitro reporter assays (Black et al. 
1996). These studies demonstrate that the MEF2 domain is necessary for 
MASH1/MEF2C interaction, and that either DNA-binding site is able to promote 
synergistic activation involving both factors. It has also been shown that MEF2 isoforms 
–A, –C, and –D functionally interact with GATA-4 to cooperatively activate the ANF 
promoter (Morin et al. 2000). These findings demonstrate an additional layer of 
regulation that MEF2 interactions provide. Both repressive and synergistic activation 
effects provide evidence of the fine-tuning of transcriptional activity that MEF2 proteins 
can undergo. 
 
1.4.2 Potential MEF2A transcriptional co-regulator interactions 
 Here I discuss three sets of transcription factors with known expression and roles 
in the adult heart: HAND factors, Nkx2.5, and estrogen receptors. Aside from their roles 
in cardiac development and homeostasis, these transcription factors have distinct 
expression patterns in the heart. In Chapter 3, I present data that show that Mef2a KO 
mice display preferential gene dysregulation in a chamber-dependent manner in the adult 
heart. Additionally, bioinformatics analysis of upstream regulatory regions from 
promoters of these MEF2A-sensitive genes revealed an enrichment of HAND, Nkx, and 
estrogen receptor transcription factor binding sites, also aligning with each factor’s 
expression pattern in the heart. Altogether, these findings make HAND proteins, Nkx2.5, 
and estrogen receptors as promising candidates as co-regulators of MEF2A 
transcriptional activity in vivo.  
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1.4.2.1 The bHLH HAND factors 
 The basic helix-loop-helix (bHLH) factors HAND1 (eHAND) and HAND2 
(dHAND) are members of the Twist family of bHLH proteins. HAND factors function as 
either homo– or heterodimers binding to consensus sequences known as E-boxes 
(CANNTG) (Barnes & Firulli 2009, Conway et al. 2010, Firulli 2003). Previous studies 
describe the complementary expression of HAND1 and HAND2 in the left and right 
ventricles, respectively (Srivastava et al. 1997). Additional studies have expanded the 
expression patterns of both HAND proteins, describing HAND1 expression in the 
myocardial cuff on the cardiac outflow tract, and HAND2 expression in myocardium, 
endocardium, and epicardium (Firulli et al. 2000). Hand2-null mice die between E9.5 and 
E10.5 from cardiac and vascular defects (Srivastava et al. 1997, Yamagishi et al. 2000). 
The cardiac-related phenotypes in Hand1-null mice are more difficult to interpret due to 
extra-embryonic mesoderm that results in lethality between E8.0 and E9.0 (Firulli et al. 
1998, Riley et al. 1998). In these studies, heart morphology is altered but extra-
embryonic effects make it difficult to interpret these results. 
 HAND proteins have been shown to interact with MEF2 factors. In previous 
studies HAND2 interacts with MEF2C (Zang et al. 2004). Using the atrial natriuretic 
peptide (ANF; Nppa) promoter, HAND2 and MEF2C synergistically activated expression 
in transfected HeLa cells (Zang et al. 2004). Additional GST-pulldown and 
immunoprecipitation assays show that HAND2 and full-length MEF2C are able to 
interact in vitro and in vivo. Additional studies have shown that HAND1 and MEF2A 
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interaction results in synergistic activation of the ANF promoter (Morin et al. 2005). 
HAND1 is recruited to the promoter via a physical interaction with MEF2A. 
 In light of these observations, it possible that HAND factors interact with MEF2A 
and this interaction modulates and adds an extra layer of regulation to MEF2A-dependent 
genes in the ventricular chambers of the mammalian heart. 
 
1.4.2.2 NKX2.5 
 NKX homeobox factors are a family of evolutionarily conserved proteins. In 
Drosophila, tinman (Nkx2.5) is used a marker of cardiogenesis (Harvey 1996). NKX 
homeobox and MEF2 factors have been shown to interact. In co-immunoprecipitation 
studies, NKX2.5 and MEF2C interact in vitro (Vincentz et al. 2008). MEF2 factors and 
NKX2.5 have a similar expression pattern in the developing heart and target similar 
genes (Vincentz et al. 2008). Since MEF2C and NKX2.5 have been shown to interact and 
their spatial and temporal expression patterns are similar, it is possible that NKX2.5 and 
MEF2 factors cooperatively regulate genes in the heart. More specifically, it is possible 
that NKX2.5 and MEF2A coordinately regulate a subset of MEF2A-dependent genes in 
the heart. 
 
1.4.2.3 Estrogen receptors 
 Estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ) are two nuclear 
estrogen receptors encoded by the Esr1 and Esr2 genes, respectively (Luo & Kim 2016). 
ERα and ERβ expressed in the heart are active and are involved in the regulation of gene 
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expression (Knowlton & Lee 2012). Estrogen receptors are expressed in both cardiac 
fibroblasts and myocytes (Grohé et al. 1997). While ERα and ERβ are both expressed in 
the heart, their expression patterns are different. While no observable difference were 
present between male and female adult rat ventricles, subcellular fractionation shows 
greater localization of ERβ protein in the nucleus of ventricular myocytes in vivo, and 
female mice show higher levels of ERα in the ventricles and higher levels of ERβ in the 
atrial chambers (Lizotte et al. 2009)  
 To date there are no data to support that MEF2 and estrogen receptor proteins 
physically interact to regulate target genes. However, estrogen receptors have been 
shown to be downstream targets of MEF2 signaling. Female mice lacking class IIa 
HDAC5 and HDAC9 are protected against maladaptive cardiac remodeling after 
myocardial infarction, where normally there is an increase in expression of gene sensitive 
to estrogen levels (Van Rooij et al. 2010). Others studies have confirmed up-regulation of 
ERα during human heart failure (Mahmoodzadeh et al. 2006). Additionally, Ers1 was 
shown to be a direct target of MEF2C. Interestingly, ERα interacts with the MEF2 
binding domain of class II HDACs in vitro (Van Rooij et al. 2010). Estrogen receptors 
have also been shown to activate ANF in the rat heart (Jankowski et al. 2001). 
 Keeping in mind the expression and role of estrogen receptors in the heart, global 
transcriptome analysis in Mef2a knockout hearts coupled with bioinformatics analysis 
point to estrogen receptors as appealing candidates for interacting partners to modulate 
MEF2 transcriptional activity. 
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1.5 A novel direct-target gene of MEF2A 
1.5.1 Bex1 
 The brain expressed x-linked gene 1 (Bex1) gene is located on the X-chromosome 
in rodent and human genomes, and Bex1 RNA is expressed in the brain, heart, and liver 
(Alvarez et al. 2005). Initial experiments on BEX1 linked this small adaptor-like protein 
to the cell cycle and neurotrophin signaling in PC12 cells (Vilar et al. 2006). In these 
studies, a screen identified BEX1 as an interacting protein with the intracellular domain 
of the p75 neurotrophin receptor (p75-NTR). In PC12 cells, Bex1 levels oscillated during 
the cell cycle, and downregulation of Bex1 expression inhibited PC12 differentiation in 
response to nerve growth factor (NGF) (Vilar et al. 2006).  
 Several loss-of-function analyses have been performed to determine the role of 
BEX1 in other cell types. Bex1 KO mice appear to develop normally and are fertile, but 
were found to perform poorly in treadmill exercises compared to wild-type control mice 
(Koo et al. 2007). Intramuscular cardiotoxin injection, a widely used model for muscle 
regeneration studies, in Bex1 KO mice showed prolonged cell proliferation and delayed 
cell differentiation. These studies indicated that Bex1 plays a role in skeletal muscle 
regeneration (Koo et al. 2007). Myoblasts harvested from Bex1 KO mice showed a defect 
in myoblast-myotube fusion in vitro (Jiang et al. 2016). While some studies have begun 
to uncover the role of BEX1 in neuronal and myocyte cell types, overall information on 
BEX1 is lacking.  
 
1.5.2 Bex1 in the heart 
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 To date there are several dozen research articles about Bex1, and only a few of 
these link Bex1 to the heart. Therefore not much is known about Bex1 in the heart, and 
Bex1 studies are lacking in the cardiac biology field. There is evidence to support that 
Bex1 is involved in the proper development of the heart. Mice lacking the p75-NTR gene 
show cardiac innervation defects (Habecker et al. 2008). Since the BEX1 protein is 
downstream of the p75-NTR, it is likely that perturbation of BEX1 also leads to cardiac 
defects. In a single-cell resolution of temporal gene expression study performed on 
developing hearts (E9.5 – P21), Bex1 RNA was one of the top ten enriched transcripts in 
the left ventricular chamber of E14.5 mice (DeLaughter et al. 2016). Altogether, Bex1 
has been shown to be expressed in the brain and in the heart, an expression pattern 
similar to the MEF2 proteins. Therefore, it is possible that MEF2 regulates BEX1 
expression and links itself to neurotrophin signaling and the cell cycle in the heart. 
 
1.6 Thesis rationale 
 Atrial and ventricular chambers have differing specified roles in the function of 
the mammalian heart although gene expression and cytoarchitecture of myocytes in these 
tissues do not differ greatly. MEF2 proteins are key regulators of differentiation and gene 
programs in cardiomyocytes. While studies have shown the importance of MEF2, most 
research has focused on the ventricular chamber, and is somewhat biased in this regard. 
 This dissertation is presented in two parts. The work in Chapter Three focuses on 
dissecting the mechanisms behind the differential regulation of MEF2A-dependent genes 
and cellular pathways between atrial and ventricular chambers of the heart. MEF2 
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proteins interact with numerous transcriptional co-regulators that modulate the 
transcriptional activity on target genes. In this chapter, I present data indicating that 
MEF2A transcriptional activity is modulated by chamber-dependent expression of 
transcriptional co-regulators. This additional layer of transcriptional control is responsible 
for the chamber-dependent regulation of molecular pathways downstream of MEF2A. 
The research in Chapter Four focuses on the gene Bex1, a candidate target of MEF2A. 
BEX1 is an intracellular adaptor protein involved in neurotrophin signaling and the cell 
cycle. Additionally, Bex1 function has been implicated in muscle regeneration and 
myocyte fusion, functions similar to the role of MEF2A in skeletal muscle. These 
findings suggest a role for BEX1 in the ventricular myocardium, and potentially link 
MEF2A to neurotrophin signaling and the cell cycle in ventricular cardiomyocytes. This 
work suggests that neurotrophin signaling and the cell cycle are regulated by MEF2A 
through its interaction with the Bex1 gene in cardiomyocytes. 
 The primary goal of the research presented in this thesis is to uncover the 
differential regulation of target genes and cellular pathways by MEF2A in the adult 
mammalian heart. By doing so, we will characterize the functional role of MEF2A in 
adult cardiac chambers. Additionally, we begin to understand the mechanism of the 
chamber-dependent differential regulation of MEF2A transcriptional activity in the adult 
heart. This research will also contribute to the knowledge of differential regulation of 
other transcription factors in the developing and adult heart. 
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Figure 1.1 Amino acid sequence identity of MEF2 proteins. For each MEF2 protein 
domain across several species, amino acid sequence identity percentage is compared to 
human MEF2A (hMEF2A). With the exception of yeast MEF2, MADS-box and MEF2-
domains of MEF2 proteins across different species shows high percentage amino acid 
sequence identity. The transcriptional activation domain is divergent across all species 
and within human isoforms. Image adapted from (Potthoff & Olson 2007). 
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Figure 1.2 The four main stages of mammalian heart development. From left to right: 
Cardiac progenitor cells migrate from the anterior lateral mesoderm and converge at the 
ventral midline to form a cardiac crescent at embryonic day 7.5 (E7.5). The cardiac 
crescent cells extend to form a functional linear heart tube (E8.5), which then undergoes 
rightward looping (E8.5). After cardiac looping, each chamber is now correctly 
positioned and each cardiac chamber undergoes maturation and growth (E15.5). A, 
atrium; Ao, aorta; AVV, atrioventricular valve segment; CT, conotruncal segment; LA, 
left atrium; LV, left ventricle; PA, pulmonary artery; RA, right atrium; RV, right 
ventricle; V, ventricle. Image adapted from (Srivastava & Olson 2000). 
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Figure 1.3 Atrial and ventricular chambers expresses different transcriptional 
regulators. During mammalian cardiogenesis, the expression of different regulatory 
proteins are necessary for proper cardiac chamber development, septation, and 
maturation. Regulatory factors necessary for specific stages in mammalian cardiogenesis 
are indicated beside each arrow. Image adapted from (Srivastava & Olson 2000). 
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CHAPTER TWO: Materials and Methods 
 
2.1 Mouse colony maintenance and tissue preparation 
 Experimental procedures on animals used in these studies were approved by the 
Boston University Institutional Animal Care and Use Committees (IACUC) (Protocol 
numbers 11-001, 13-048, and 16-019). These studies were performed in accordance with 
the principals of animal care and experimentation in the Guide for the Care and Use of 
Laboratory Animals. 
 
2.1.1 Mouse husbandry 
 For MEF2A knockout studies, one Mef2a heterozygous-null (Mef2a+/-) sire and 
dam were used as a breeding pair. For Mef2a overexpressing transgenic studies, one sire 
of Mef2a+/-;Tg(αMHC:Mef2a) genotype and one dam of Mef2a+/- genotype were used as 
a breeding pairs. Pups from each litter were weaned at 21 days of age. Tail clippings 
2 mm in length were collected from each pup for genomic DNA isolation. Pup ears were 
notched in specific positions for identification purposes. Food, water, and bedding were 
overseen by the technicians and staff at the Boston University Charles River Campus 
Animal Science Center. 
 
2.1.2 Tail clipping and genomic DNA isolation 
 Clipped tails were placed in 1.5 mL microcentrifuge tubes containing 200 μL Tail 
Lysis Buffer containing Proteinase K (10 mM Tris, pH 8.0; 25 mM EDTA, pH 8.0; 
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100 mM NaCl; 1% SDS, 200 μg/mL Proteinase K). Tails were incubated at 55 °C for at 
least 12 h to overnight. 200 μL of 1:1 phenol:chloroform was added to each tube, and 
tubes were vigorously shaken for 15 – 20 sec to ensure proper mixing. 150 μL of the 
aqueous layer from each sample was transferred to a clean tube, and to each tube 375 μL 
of ice-cold 100% ethanol was added. Tubes were vigorously shaken for 15-20 sec to 
ensure proper mixing. Samples were centrifuged at 13,500 rpm for 5 min at room 
temperature, and the supernatant was removed from each tube. Pellets were washed with 
300 μL of ice-cold 70% ethanol, and samples were centrifuged at 13,500 rpm for 1 min at 
room temperature. The supernatant was removed from each tube, and pellets were 
allowed to air dry completely for at least 30 min. DNA pellets were redissolved in 200 μL 
of sterile water and then stored at -20 °C. 
 
2.1.3 Genotyping 
 Genomic tail DNA was subjected to PCR using allele-specific primers. 1 μL of 
genomic tail DNA was added to a PCR containing 1 μL primer mix, 2 μL 10 mM dNTPs, 
2.5 μL 10X Thermopol Buffer (New England Biolabs), 0.25 μL Taq Polymerase (New 
England Biolabs), and 18.25 μL sterile water. For detecting Mef2a WT and mutant 
alleles, primer mixes were created by combining 25 μL 100 μM Mef2a forward primer, 
25 μL 100 μM Neomycin forward primer, and 50 μL 100 μM Mef2a reverse primer. For 
detecting Mef2a transgenic allele, primer mixes were created by combining 25 μL 
100 μM HGH-Mef2a forward primer, 25 μL 100 μM HGH-Mef2a reverse primer, 
12.5 μL 100 μM IL-2 forward primer, 12.5 μL 100 μM IL-2 reverse primer, and 25 μL 
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sterile water. General thermocycling parameters (PTC-100 Thermal Cycler, MJ 
Research) were as follows: 1, 95 °C for 4:00 min; 2, 95 °C for 30 sec; 3, 60 °C for 30 sec; 
4, 68 °C for 30 sec; 5, go to step 2 for 29 additional cycles; 6, 68 °C for 5:00 min; 7, hold 
at 4 °C; 8, end program. 4 μL of 6X Orange-G DNA loading dye (1 ml 50X TAE buffer 
[2 M Tris, 2.5 M sodium acetate, 50 mM EDTA pH 8.0], 75 mg Orange-G, 30 mL 100% 
glycerol, final volume to 50 mL with deionized water) was added to each completed 
genotyping reaction, and samples were electrophoresed on a 0.8% agarose gel in 1X TAE 
buffer (40 mM Tris, 50 mM sodium acetate, 1 mM EDTA pH 8.0). Genotyping gels were 
imaged on a Bio-Rad imaging station under UV light.  
 
2.1.4 Tissue dissection 
 Mice were euthanized in the Boston University Animal Science Center. Atria, 
ventricles, and additional tissues were carefully dissected and thoroughly rinsed with 1X 
PBS to remove blood. Tissues were used for RNA extraction, protein extraction, 
cyrosectioning, or chromatin immunoprecipitation (ChIP) as described below. 
 
2.1.5 RNA isolation 
 Dissected tissues were homogenized in 1 mL of Trizol reagent (Life 
Technologies) using a Polytron homogenizer for 30 sec. Homogenized tissue samples 
were transferred into a 1.7 mL microcentrifuge tube, and 0.2 mL chloroform was added 
to each sample. Tubes were closed tightly, shaken vigorously for 30 sec, and then 
incubated at room temperature for 3 min. Tubes were centrifuged at 13,500 rpm for 
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10 min at 4 °C. The top aqueous layer from each sample was transferred into a new 
1.7 mL microcentrifuge tube, and to each sample 0.5 mL isopropanol was added. Tubes 
were closed tightly, shaken for 30 sec, and were incubated at -20 °C for at least 1 h for 
RNA precipitation. Precipitated samples were centrifuged at 13,500 rpm for 30 min at 
4 °C. The supernatant from each tube was carefully removed, and each pellet was washed 
with 1 mL 70% ethanol and subsequently centrifuged at 13,500 rpm for 5 min at 4 °C. 
The supernatant from each tube was carefully removed, and pellets were allowed to air 
dry for 10 min. Pellets were resuspended in 20 μL of sterile nuclease-free water. RNA 
concentration was determined using a Nanodrop (Thermo Fisher Scientific). 
 
2.1.6 Protein extraction 
 Dissected and cleaned tissues were cut into smaller pieces and each was placed 
into a 1.7 mL microcentrifuge tube. For atria and ventricles, 50 μL and 1 mL of complete 
ELB (50 mM HEPES, 250 mM M NaCl, 5 mM EDTA, 0.1% NP-40, 1 mM PMSF, 
1 mM DTT, and 1X protease inhibitor (Roche)) was added to each tube, respectively. 
Tissue pieces in complete ELB were further homogenized using a disposable 
microcentrifuge pestle. Protein lysates were allowed to incubate on ice for 10 min, and 
then clarified by centrifuging at 13,500 rpm for 10 min at 4 °C. Clarified protein lysate 
supernatants were transferred to a clean 1.7 mL microcentrifuge tube, and samples were 
stored at -80 °C. Samples probed for Histone H3 were sonicated using Digital Sonifer 
450 (Branson) prior to centrifugation. 
 
 32 
2.1.7 Tissue preparation for cryosectioning 
 Dissected and rinsed tissues were placed in a 15 mL conical tube filled with 
10 mL sucrose solution (30% sucrose, 1X PBS) to cryoprotect samples. Tissues in 
sucrose solution were incubated at 4 °C, and tissues were gently squeezed repeatedly with 
forceps for 15 sec every hour until tissues were no longer buoyant (approximately 4 h). 
Tissues were recovered from sucrose solution, quickly rinsed in 1X PBS, and placed into 
aluminum foil molds (1 cm x 1 cm x 1 cm) containing Tissue-Tek O.C.T. compound 
(Sakura Fine-Tek). A small freezing bath using dry ice and isopentane was prepared, and 
embedded tissues were partially submerged until O.C.T. compound turned opaque. 
Embedded and frozen tissues were stored at -80 °C.  
 
2.1.8 Tissue preparation for chromatin-immunoprecipitation 
 Dissected tissue and rinsed tissues were frozen slowly by placing tissues over a 
piece of aluminum foil on top of dry ice pellets. Once completely frozen, tissue samples 
were collected and placed in a pre-chilled ceramic mortar. Tissues were pulverized using 
a ceramic pestle, and small amounts of liquid nitrogen were continuously added during 
pulverization procedure to prevent samples from thawing. Frozen, pulverized tissue 
samples were collected into a 1.7 mL microcentrifuge tube and stored at -80 °C. 
 
2.2 Recombinant DNA Techniques 
2.2.1 Preparing chemically competent E. coli 
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 DH5α cells were plated on a Lysogeny Broth (LB) agar plate (10 g/L casein 
peptone, 5 g/L yeast extract, 5 g/L sodium chloride, 15 g/L agar) and incubated for 12 – 
16 h at 37 °C. 5 mL LB (10 g/L casein peptone, 5 g/L yeast extract, 5 g/L sodium 
chloride) was inoculated with a singly colony and incubated in a shaking incubator at 
225 rpm for 12 – 16 h at 37 °C. The entire liquid culture was transferred into 200 mL LB 
and DH5α cells were grown to an undiluted absorbance reading between 0.4 and 0.6 at 
600 nm wavelength. Cells were harvested by centrifugation at 3,000 g for 5 min at 4 °C. 
Cells were resuspended in 20 mL of chilled 10 mM NaCl. To each sample 80 mL of 
chilled 100 mM CaCl2 was added, and cells were centrifuged at 3,000 g for 5 min at 4 °C. 
The cell pellet was resuspended in 80 mL of chilled 100 mM CaCl2, and incubated on ice 
for 30 to 60 min. Cells were centrifuged at 3,000 g for 5 min at 4 °C. The cell pellet was 
resuspended in 17 mL 100 mM CaCl2 supplemented with 3 mL 100% glycerol. DH5α 
aliquots were generated by aliquoting 100 μL of cell suspension into 1.7 mL 
microcentrifuge tubes, which were then flash frozen using liquid nitrogen and stored 
at -80 °C. 
 
2.2.2 Transforming chemically competent E. coli 
 DH5α aliquots were thawed on ice for 15 – 20 min. 100 – 200 ng of plasmid 
DNA (5 – 10 μL of ligation reaction) was then added to each aliquot of cells and samples 
were mixed gently. The DH5α/DNA mixture was incubated on ice for 10 min. Competent 
cells were heat shocked in a 42 °C water bath for 30 sec, then immediately placed on ice 
for 2 min. 500 μL LB was added to transformed bacteria and the mixture was transferred 
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to a 14 mL snap-cap tube. Tubes were incubated in a shaking incubator at 225 rpm for 
1 h at 37 °C. 
 For plasmid DNA, 100 μL of bacteria were plated on LB agar plates containing 
the appropriate antibiotic selection drug. For ligation reactions, bacteria were transferred 
to a clean 1.7 mL microcentrifuge tube and pelleted by centrifugation at 6,000 g for 1 min 
at room temperature. The supernatant was discarded from each tube leaving behind 
approximately 100 μL of LB. Recovered cells were gently resuspended in the remaining 
100 μL of LB and plated on LB agar plates containing the appropriate antibiotic selection 
drug. LB agar plates were incubated overnight at 37 °C. After confirmation of colony 
growth, LB agar plates were stored in the cold room at 4 °C.  
 
2.2.3 Plasmid purification 
 For mini preps, 3 mL of antibiotic supplemented LB was inoculated with a single 
colony. Inoculated tubes were placed in a shaking incubator at 225 rpm for 12 – 16 h at 
37 °C. 1.5 mL of culture was transferred into a 1.7 mL microcentrifuge tube, and tubes 
were centrifuged at 13,500 rpm for 1 min. The supernatant was decanted from each tube, 
and pellets were resuspended with 100 μL Resuspension Buffer (50 mM glucose, 10 mM 
EDTA pH 8.0, 25 mM Tris pH 8.0). 200 μL Lysis Buffer (0.2 M NaOH, 1% SDS) was 
added to each tube and immediately inverted 6 – 8 times. The lysis reaction was allowed 
to proceed for no longer than 5 min, and 150 μL Neutralization Buffer (3 M potassium 
acetate, 2 M acetic acid) was then added to each tube and immediately inverted 6 – 8 
times. 400 μL phenol/chloroform was added to each tube and shaken by hand for 30 – 
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60 sec. Samples were centrifuged at 13,500 rpm for 1 min at room temperature. 400 μL 
of the aqueous phase from each sample was transferred into a new 1.7 mL 
microcentrifuge tube. 1 mL (2.5 volumes) of ice cold 100% ethanol was added to each 
tube, mixed by shaking, and tube were centrifuged at 13,500 rpm for 30 min at 4 °C. The 
supernatant from each tube was discarded, and DNA pellets were washed with 200 μL 
70% ethanol. Samples were centrifuged at 13,500 rpm for 1 min at room temperature. 
The supernatant from each tube was discarded, and DNA pellets were allowed to air dry 
for 30 min. Air-dried pellets were resuspended in 25 μL sterile water containing 
100 μg/mL of RNase. Mini preps were incubated for 15 min at 37 °C for complete RNA 
degradation. Samples were stored at -20 °C. 
 For midi preps, 3 mL of antibiotic supplemented LB was inoculated with a single 
colony. Inoculated tubes were placed in a shaking incubator at 225 rpm for 12 – 16 h at 
37 °C. 100 mL of antibiotic supplemented LB was inoculated with 3 mL of previously 
grown inoculated culture. 100 mL of inoculated culture was placed in a shaking incubator 
at 225 rpm for 12 – 16 h at 37 °C. Cells were harvested by centrifugation at 6,000 g for 
15 min at 4 °C. Plasmid DNA was isolated using the NucleoBond Midiprep Kit 
(Macherey-Nagel) following the manufacturer’s instructions. Plasmid DNA 
concentration was determined using a NanoDrop, and plasmid DNA was stored at -20 °C. 
A list of plasmids used in this thesis can be found in Table 2.2. 
 
2.2.4 Polymerase chain reaction 
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 For cloning purposes, Q5 High-Fidelity DNA Polymerase was used (New 
England Biolabs). 10 μL 5X Q5 Reaction Buffer, 1 μL 10 mM dNTPs, 2.5 μL 100 μM 
forward primer, 2.5 μL 100 μM reverse primer, 1 ng template DNA, 0.5 μL Q5 High-
Fidelity DNA Polymerase, and sterile nuclease-free water up to a final reaction volume of 
50 μL was added and mixed in a 0.65 mL PCR tube. General thermocycling parameters 
(PTC-100 Thermal Cycler, MJ Research) were as follows: 1, 98 °C for 30 sec; 2, 98 °C 
for 30 sec; 3, annealing temperature for 30 sec; 4, 72 °C for proper extension time; 5, go 
to step 2 for 29 additional cycles; 6, 72 °C for 2:00 min; 7, hold at 4 °C; 8, end program. 
Optimal annealing temperatures were calculated using NEB Tm calculator 
(https://tmcalculator.neb.com), and extension times were dependent on product length. 
 
2.2.5 Nucleic acid purification for PCR products 
 For intermediate clean-up of PCR products before restriction digestion, 
phenol/chloroform extraction was used. PCRs were transferred to a 1.7 mL 
microcentrifuge tube and sterile nuclease-free water was added to a final volume of 
200 μL. An equal volume of 1:1 phenol:chloroform was added to each sample and mixed 
vigorously for 30 sec. Samples were centrifuged at 13,500 rpm for 3 min at room 
temperature. The aqueous phase was transferred to a new 1.7 mL microcentrifuge tube, 
and 20 μL 3 M sodium acetate pH 5.2, 2 μL 20 mg/mL glycogen, and 500 μL cold 100% 
ethanol was added to each sample. Samples were incubated at -20 °C for 1 h. Tubes were 
centrifuged at 13,500 rpm for 30 min at 4 °C. The supernatant from each sample was 
removed and the pellet was washed with 250 μL cold 70% ethanol. Samples were 
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centrifuged at 13,500 rpm for 2 min at room temperature. The supernatant from each 
sample was removed and the pellets were allowed to air dry for 15 – 20 min. Air-dried 
pellets were resuspended in 20 μL of sterile nuclease-free water. 
 
2.2.6 Restriction digestion 
 Typically, DNA was digested using restriction enzymes from New England 
Biolabs. 5 μL of appropriate 10X NEB Buffer, 2 μg plasmid DNA or 20 μL cleaned PCR 
product, 10 units of each restriction enzyme (0.5 – 1 μL each depending on activity 
concentration), and sterile nuclease-free water was added to a final reaction volume of 
50 μL. Samples were incubated for 1 h at the appropriate incubation temperature. For 
restriction digestions using incompatible enzymes, an intermediate phenol/chloroform-
based nucleic acid purification step as described above was applied in between each 
restriction digestion procedure. 
 
2.2.7 Gel extraction 
 Digested plasmid DNA and PCR products were prepared for gel electrophoresis 
by adding 10 μL 6X Orange-G loading buffer to each sample. Samples were loaded onto 
a 0.8% agarose gel in 1X TAE buffer (40 mM Tris, 50 mM sodium acetate, 1 mM EDTA 
pH 8.0). Bands of interest were excised using a clean razor blade, and gel slices were 
transferred to 1.7 mL microcentrifuge tubes. DNA of interest from each gel slice was 
extracted using the QIAquick Gel Extraction Kit (QIAGEN) following the 
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manufacturer’s instructions. The DNA concentration of gel extraction samples was 
determined using a NanoDrop, and samples were stored at -20 °C. 
 
2.2.8 Ligation 
 Digested insert and vector were mixed at an equimolar ratio for a total of no 
greater than 250 ng DNA. The volume was adjusted to 7 μL with sterile water. To each 
ligation reaction, 1 μL 10 mM ATP, 1 μL 10X T4 DNA Ligase Buffer (New England 
Biolabs), and 1 μL T4 DNA Ligase (New England Biolabs) was added. Ligation 
reactions were incubated for 12 – 16 h at 16 °C. 5 – 10 μL of ligation reactions were used 
to transform chemically competent E. coli.  
 
2.3 Primary cardiomyocyte isolation and cell culture techniques 
2.3.1 Neonatal rat ventricular myocyte isolation 
 Neonatal rat ventricular myocytes (NRVMs) were extracted from two day-old 
Sprague Dawley neonatal rats (Charles River Labs, Strain Code 400). Neonatal rats were 
euthanized and decapitated. A ¼ inch incision was cut into the sternum of the neonatal 
rat, and angled to the left of the torso. Hearts were extracted and immediately placed into 
1X HBSS (Life Technologies) in a 50 mL conical tube and placed on ice. After 
processing all of the neonatal rats, the hearts were transferred to a biosafety cabinet. 1X 
HBSS was aspirated, and dissected hearts were transfected to a 6-cm dish with 5 mL of 
cold 1X HBSS. Atrial chambers were removed and discarded, and ventricles were cut 
into 3 – 4 pieces and then transferred to a new 6-cm dish containing 5 mL of cold 1X 
 39 
HBSS. Ventricles were washed by transferring tissue pieces from one 6-cm dish to 
another 6-cm dish containing 5 mL of cold 1X HBSS. Ventricle pieces were washed for 
an additional 5 times. Ventricle pieces were finally transferred to a 100 mL glass bottle 
containing 0.6 mg/mL trypsin (Life Technologies) and incubated overnight at 4 °C. 
 The next day 10 mL 10% FBS containing 1X DMEM was added to each 
trypsinzed heart solution, and samples were incubated in a shaker at 100 rpm for 3.5 min 
at 37 °C. The supernatant was discarded and 10 mL collagenase solution (1 mg/mL 
collagenase type 2 (Worthington, Cat# LS004176), 1X HBSS, pre-warmed to 37 °C 
immediately before use) was added. Tissues were collagenase treated in a shaker at 
100 rpm for 6 min at 37 °C. Subsequent supernatant fractions containing NRVMs were 
collected in a 50 mL conical tube and placed on ice. Collagenase treatment and 
supernatant collection steps were repeated 7 times. NRVMs were centrifuged at 
1,000 rpm for 4 min at room temperature and supernatant was discarded. The cell pellet 
was resuspended in 20 mL 10% FBS containing 1X DMEM, centrifuged at 1,000 rpm for 
4 min at room temperature, and the supernatant was discarded. The cell pellet was 
resuspended in 10 mL 10% FBS containing 1X DMEM and plated onto a 10-cm dish. 
NRVMs were incubated for 1 h at 37 °C in a 5% CO2 incubator (first pre-plate). NRVMs 
from the first pre-plate were collected and transferred to a new 10-cm dish. NRVMs were 
incubated for 1 h at 37 °C in a 5% CO2 incubator (second pre-plate). NRVMs from the 
second pre-plate were collected and the concentration of cells in the suspension was 
determined using a hemocytometer. NRVMs were plated at seeding density of 300,000 
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cells/well in growth media (1X DMEM, 10% FBS, 1X 
penicillin/streptomycin/glutamine) for a 6-well plate. 
 The next day dead cells were removed by changing to new growth media. The 
following day, growth media was replaced with Nutridoma media (0.5X Nutridoma, 1X 
penicillin/streptomycin/glutamine, 1X DMEM). NRVMs were transfected as described 
below (Section 2.3.4). 
 
2.3.2 Standard cell culture 
 HEK293T cells were cultured in 10-cm dishes in growth media (1X DMEM, 10% 
FBS, 1X penicillin/streptomycin/glutamine), 1X in an incubator at 37 °C with 5% CO2. 
Near confluency, cells were detached from dish using 1 mL warm 0.25% trypsin (Life 
Technologies) for 2 min at room temperature. Cells were resuspended in 5 mL growth 
media (1X DMEM, 10% FBS, 1X penicillin/streptomycin/glutamine) and passaged at a 
ratio of 1:5 to 1:10. For experiments, HEK293T cells were plated at a density of 80,000 
cells/well in a 6-well plate 
 
2.3.3 PEI transfections 
 A maximum of 2 μg of DNA was transfected per well in a 6-well plate, and a 
PEI:DNA ratio of 6 μL 1 mg/mL PEI: 1 μg DNA. Experiments were performed in 
technical triplicate (3 wells per condition), and for each condition PEI was added to 
300 μL warmed 1X DMEM and incubated for 5 min at room temperature. DNA was 
added to each mixture and incubated for an additional 15 min at room temperature. 
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Growth media from each well was removed, and cells were washed with 2 mL 1X PBS. 
1X PBS was removed from each well, and 2 mL of transfection media (10% FBS, 1X 
DMEM, antibiotic-free) was transferred into each well. The PEI/DMEM/DNA 
transfection mixture was evenly distributed among triplicate wells. 24 h post-transfection, 
transfection media was replaced with growth media, and cells were incubated for an 
additional 24 h before being used for protein extraction. 
 
2.3.4 FuGENE 6 transfections 
 A maximum of 2 μg of DNA was transfected per well in a 6-well plate, and a 
FuGENE 6:DNA ratio of 3 μL FuGENE 6: 1 μg DNA. Experiments were performed in 
technical triplicate (3 wells per condition), and for each condition FuGENE 6 was added 
to 300 μL warmed 1X DMEM and allowed to incubate for 5 min at room temperature. 
DNA was added to each mixture and allowed to incubate for an additional 15 min at 
room temperature. Growth media from each well was removed, and cells were washed 
with 2 mL 1X PBS. 1X PBS was removed from each well, and 2 mL of transfection 
media (10% FBS, 1X DMEM, antibiotic-free) was transferred into each well. 
FuGENE 6/DMEM/DNA transfection mixture was evenly distributed among triplicate 
wells. 24 h post-transfection, transfection media was replaced growth media, and cells 
were incubated for an additional 24 h before being used for protein extraction. 
 
2.3.5 RNA isolation 
 42 
 For 10-cm dishes, the media was removed by aspiration and dishes were washed 
once with 1X PBS. 1X PBS was aspirated, and 1 mL of Trizol reagent (Life 
Technologies) was added to each dish and placed on ice. Cells in Trizol reagent were 
scraped using a cell scraper, and samples were transferred to a 1.7 mL microcentrifuge 
tube. 0.2 mL chloroform was added to each sample. Tubes were closed tightly, shaken 
vigorously for 30 sec, and then incubated at room temperature for 3 min. Tubes were 
centrifuged at 13,500 rpm for 10 min at 4 °C. The top aqueous layer from each sample 
was transferred into a new 1.7 mL microcentrifuge tube, and to each sample 0.5 mL 
isopropanol was added. Tubes were closed tightly, shaken for 30 sec, and incubated 
at -20 °C for at least 1 h for RNA precipitation. Precipitated samples were centrifuged at 
13,500 rpm for 30 min at 4 °C. The supernatant from each tube was carefully removed, 
and each pellet was washed with 1 mL 70% ethanol and subsequently centrifuged at 
13,500 rpm for 5 min at 4 °C. The supernatant from each tube was carefully removed, 
and pellets were allowed to air dry for 10 min. Pellets were resuspended in 20 μL of 
sterile nuclease-free water. RNA concentration was determined using a Nanodrop 
(Thermo Fisher Scientific). 
 
2.3.6 Protein extraction 
 For luciferase assays, 350 μL of 1X Passive Lysis Buffer (Promega) was added to 
each well in a 6-well plate. Plates were continuously agitated on a horizontal shaker for 
20 min at 4 °C. Protein lysates from each well were transferred to a 1.7 mL 
microcentrifuge tube and clarified by centrifugation at 13,500 rpm for 10 min at 4 °C. 
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Clarified protein lysate supernatants were transferred to a clean 1.7 mL microcentrifuge 
tube, and samples were stored at -80 °C. 
 
2.4 Nucleic acid-based techniques 
2.4.1 Microarray sample preparation 
 Total RNA was isolated from wild-type and knockout cardiac chambers 
separately (WT atria, WT ventricles, KO atria, and KO ventricles) and pooled (n=7 per 
pool). Pooled RNA samples were diluted to a concentration of 150 ng/μl using RNase-
free sterile water and submitted to the Boston University Microarray Core Facility. 
Samples were processed and applied to individual GeneChip® Gene 1.0 ST Array 
System for Mouse (Affymetrix) arrays.  
 
2.4.2 cDNA synthesis 
 For cDNA synthesis, 2 μg of RNA was brought to a final volume of 9.3 μL with 
sterile nuclease-free water in a 0.65 mL PCR tube. To each tube, 6 μL 10 mM dNTPs and 
6.7 μL 15.4 μM random primers was added, incubated for 5 min at 65 °C, and incubated 
on ice for 5 min. To each tube, 6 μL 5X M-MLV Reaction Buffer, 1 μL M-MLV reverse 
transcriptase (Promega), and 1 μL RNasin (Promega) was added, and samples were 
incubated for one hour at 37 °C. cDNA samples were stored at -20 °C.  
 
2.4.3 Reverse transcriptase-polymerase chain reaction 
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 Synthesized cDNA was used for RT-PCR. 1 μL of cDNA was added to a PCR 
containing 1 μL primer mix, 2 μL 10 mM dNTPs, 2.5 μL 10X Thermopol Buffer (New 
England Biolabs), 0.25 μL Taq Polymerase (New England Biolabs), and 18.25 μL sterile 
water. Primer mixes for gene-specific primers were generated by mixing 25 μL 100 μM 
forward primer, 25 μL 100 μM reverse primer, and 50 μL 100 μM sterile nuclease-free 
water. General thermocycling parameters were as follows: 1, 95 °C for 4:00 min; 2, 
95 °C for 30 sec; 3, annealing temperature for 30 sec; 4, 68 °C for 30 sec; 5, go to step 2 
for a number of additional cycles; 6, 68 °C for 5:00 min; 7, hold at 4 °C; 8, end program. 
Appropriate annealing temperatures were determined using the online NEB Tm calculator 
(https://tmcalculator.neb.com), and additional cycles needed were individually 
determined for each gene to prevent saturation of amplicon signal. 4 μL of 6X Orange-G 
DNA loading dye was added to each reaction, and samples were electrophoresed on a 
0.8% agarose gel in 1X TAE buffer. Genotyping gels were imaged on a Bio-Rad imaging 
station under UV light. Densitometry analysis was performed on the imaging software 
ImageJ. 
 
2.4.4 Quantitative RT-PCR 
 Relative gene expression levels were measured by qRT-PCR. Quantitative RT-
PCR was performed in triplicate wells. Briefly, 15 μL SYBR Green Master Mix (Applied 
Biosystems), 4 μL sterile nuclease-free water, 6 μL primer mix, and 5 μL diluted cDNA 
were mixed in 0.65 mL microcentrifuge tubes. Quantitative RT-PCR assays were 
performed in technical triplicate by pipetting 8.5 μL into each of three wells of a 384-well 
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plate. Quantitative RT-PCR reactions were performed and read in a 7900HT sequence 
detection system (Applied Biosystems). qRT-PCR data were analyzed using the ΔΔCT 
method (Livak & Schmittgen 2001). For quality control purposes, primer melting curves 
of Applied Biosystems SDS files were checked for single melting peaks, and 5 μL 
samples of final qPCRs were electrophoresed on a 1% agarose gel in 1X TAE to check 
for single band amplicons. 
 
2.4.5 Chromatin immunoprecipitation 
 For chromatin immunoprecipitation, 100 mg of frozen pulverized tissue was 
transferred to a 1.7 mL microcentrifuge tube and kept frozen on dry ice. 1 mL of freshly 
prepared 1% formaldehyde in 1X PBS was added and cells were fixed for precisely 
9.5 min to avoid over fixation. Immediately 143 μL 1 M glycine was added and samples 
were gently inverted for 5 min at room temperature. Tubes were centrifuged at 3,000 rpm 
for 5 min at 4 °C, supernatant was discarded, and cells were resuspended in 1 mL cold 
1X PBS. Tubes were centrifuged again at 3,000 rpm for 5 min at 4 °C, supernatant was 
discarded, and cells were resuspended in 642 μL cold 1X PBS. The cell suspension was 
transferred to a 2 mL microcentrifuge tube and 642 μL ChIP Lysis Buffer (50 mM 
HEPES pH 7.5, 140 mM NaCl, 1 mM EDTA pH 8, 1% Triton X-100, 0.1% sodium 
deoxycholate, 0.1% SDS) and 214.2 μL 7X protease inhibitors (Roche) was added to the 
sample. Samples were incubated on ice for 20 min. Cells were sonicated until an average 
chromatin size of ~350 bp was obtained. 25 μg DNA of sonicated chromatin, 20 μL bead 
volume of Protein-G beads, 500 μL 7X protease inhibitors, 100 μL 100 mM PMSF, 
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100 μL 100 mM DTT was transferred to at 15 mL conical tube and the final volume was 
adjusted to 10 mL with IP Dilution Buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM 
EDTA, 16.7 mM Tris pH 8.1, 167 mM NaCl). 100 μL of immunoprecipitation was 
removed and used as 1% INPUT and then 3 μg of MEF2A or IgG antibodies were added 
to each immunoprecipitation reaction. Immunoprecipitations were incubated overnight at 
4 °C on a Nutator. The next day, samples were centrifuged at 2,000 g for 10 min at 4 °C 
to pellet beads-antibody-protein-chromatin complexes. Pellets were resuspended in 1 mL 
Wash Solution I (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris pH 8.1, 
150 mM NaCl) and incubated for 5 min at 4 °C on a Nutator. Samples were centrifuged 
at 2,000 g for 3 min at 4 °C. Pellets were resuspended in 1 mL Wash Solution II (0.1% 
SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris pH 8.1, 500 mM NaCl) and incubated 
for 5 min at 4 °C on a Nutator. Samples were centrifuged at 2,000 g for 3 min at 4 °C. 
Pellets were resuspended in 1 mL Wash Solution III (250 mM LiCl, 1% NP-40, 1% 
deoxycholate, 1 mM EDTA, 10 mM Tris pH 8.1) and incubated for 5 min at 4 °C on a 
Nutator. Samples were centrifuged at 2,000 g for 3 min at 4 °C. Pellets were resuspended 
in 1 ml of 1X TE, incubated for 5 min at room temperature on a Nutator, centrifuged at 
2,000 g for 3 min at room temperature for a total of three times. Pellets were resuspended 
in 250 μL Elution Buffer (1% SDS, 100 mM sodium bicarbonate), vortexed for 45 sec, 
and incubated on a Nutator for 15 min at room temperature. Samples were centrifuged at 
2,000 g for 5 min, and the supernatant was saved in a 1.7 mL microcentrifuge tube. 
Elution and centrifugation steps were repeated an additional time, and a second round of 
250 μL elution volume was combined with the previous elution tube. Elutions were 
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cleaned using phenol/chloroform extraction. Cleaned immunoprecipitation chromatin was 
analyzed using qPCR.  
 Immunoprecipitation CT values (CTIP) were normalized to 1% input CT values 
(CT1%IN). Briefly, 1% input CT values were adjusted to 100% input CT values (CT100%IN) 
by subtracting 6.64, i.e., log2(100). Then, CT100%IN values were subtracted from CTIP 
values (ΔCT100%IN – IP). Percent chromatin immunoprecipitated relative to total input 
chromatin was obtained by calculating 2 raised to the power of ΔCT100%IN – IP, then 
multiplied by 100%. 
 
2.5 Biochemical Assays 
2.5.1 Luciferase assay 
 Clarified protein lysates from HEK293T cells and NRVMs were used for 
luciferase assays. For each sample, 10 μL clarified protein lysate was dispensed into a 
1.7 mL clear microcentrifuge tube. To each sample, 50 μL of luciferase substrate reagent 
(Promega) was added, vortexed briefly for 5 sec to ensure mixing, and liquid was 
collected to the bottom of the tube with rapid downward flicking motion. Luminescence 
was measured on the GloMax 20/20 single tube luminometer (Promega). Luminescent 
readings were integrated over 10 sec. Luciferase activity readings were individually 
normalized using either β-galactosidase activity or Bradford assay readings (Schagat et 
al. 2007). 
 
2.5.2 β-galactosidase assay 
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 Clarified protein lysates from HEK293T cells were used for β-galactosidase 
assays. For each sample, 10 μL clarified protein lysate was dispensed into a 1.7 mL 
microcentrifuge tube. To each sample, 135 μL Master Mix (6.6 mM sodium phosphate 
dibasic, 4.4 mM sodium phosphate monobasic, 1.1 mM KCl, 100 μM MgSO4, 
977.8 μg/mL ortho-Nitrophenyl-β-galactosidase, 28.6 mM β-mercaptoethanol) was 
added, and reactions were vortexed and collected at the base of the tube. Once 
sufficiently yellow in color, reactions were halted by adding 250 μL 1 M sodium 
carbonate and vortexed. 200 μL of halted reactions were transferred into a 96-well plate 
and read on a spectrophotometer at a wavelength of 420 nm.  
 
2.5.3 Bradford assay 
 For generating a protein standard curve, 5 μL sample volumes containing 0 – 5 μg 
of bovine serum albumin in 0.5 μg increments were dispensed into separate wells in a 96-
well plate. For protein concentration determination in clarified lysates, 5 μL sample 
volumes were dispensed into separate wells. To each well 200 μL of diluted Bradford 
reagent (Bio-Rad, diluted 1:5 in deionized water) was added to each well, and Bradford 
reactions were incubated for a minimum of 2 min. Bradford assay plate was read on a 
spectrophotometer at a wavelength of 595 nm.  
 
2.5.4 SDS polyacrylamide gel electrophoresis 
 Protein samples were resolved on denaturing SDS polyacrylamide gels. For each 
lane, 15 μg of clarified lysate was transferred to a 1.7 mL microcentrifuge tube and 
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brought to a final volume of 30 μL with deionized water. To each sample, 5 μL of 6X 
SDS-PAGE loading dye (250 mM Tris pH 6.8, 10% SDS, 40% glycerol, 5% β-
mercaptoethanol, 0.02% bromophenol blue) was added and samples were denatured by 
heating at 95 °C for 10 min. Samples were loaded onto an discontinuous gel (5% stacking 
gel, 10% resolving gel), and 80 V of current were applied through the stacking gel, and 
180 V of current were applied through the resolving gel until the bromophenol blue dye 
front reached the lower tenth of the gel. SDS polyacrylamide gels were removed from the 
glass plates for western blotting. 
 
2.5.5 Western blotting 
 Protein samples were transferred onto a PVDF membrane (Bio-Rad) in transfer 
buffer (20 mM Tris, 150 mM glycine, 20% methanol) at 100 V for one hour. Western 
blot membranes were blocked overnight at 4 °C in 1X TBS (50 mM Tris pH 7.5, 150 mM 
NaCl) containing 5% nonfat dry milk. Membranes were then incubated in 1X TBS 
containing 5% nonfat dry milk and suitably diluted primary antibodies with shaking for 
one hour at room temperature. Membranes were washed for 5 min for a total of three 
times in 1X TBST (1X TBS containing 0.1% Tween-20). Blots were then incubated in 
1X TBST and suitably diluted secondary antibodies with shaking for one hour at room 
temperature. Membranes were washed for 5 min for a total of three times in 1X TBST. 
Proteins of interest were detected using Western Lighting Chemiluminescent Reagent 
(Perkin-Elmer) and autoradiography film. Primary antibodies used include the following: 
anti-pFAK (1:500; Santa Cruz), anti-FAK (1:1,000; Santa Cruz), anti-TRAF6 (1:1,000; 
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Santa Cruz), anti-MEF2A (1:2,000; Santa Cruz), anti-GAPDH (1:1,000; Santa Cruz), 
anti-Histone H3 (1:5,000; Cell Signaling Technology). Secondary antibodies used 
include the following: horseradish peroxidase conjugated goat anti-rabbit (1:10,000; 
PerkinElmer), and horseradish peroxidase conjugated goat anti-mouse (1:10,000; 
PerkinElmer).  
 
2.5.6 Electrophoretic mobility shift assay 
 Double-stranded oligos were generated by combining 2.5 μg of sense primer, 
2.5 μg of anti-sense primer, and 5 μL of NEB Buffer 2, and then adjusting the final 
volume to 50 μL with sterile nuclease-free water. Samples were incubated on a heat block 
for 20 min at 65 °C. The heat block was turned off and samples were allowed to cool to 
room temperature (approximately 1.5 – 2 h). Double-stranded oligos were labeled by 
combining 15 μL of sterile nuclease-free water, 20 ng of double-stranded oligos, 2.5 μL 
NEB Buffer 2, 2.5 μL ATG mix, 2.5 μL dCTP [α-32P], and 1 μL Klenow into a 1.7 mL 
microcentrifuge tube, and samples were incubated for 1 – 2 h at room temperature. To 
each labeled oligo, 25 μL of 1X TE buffer (10 mM Tris, 1 mM EDTA) and cleaned over 
a G-25 column (Roche). Counts per minute (cpm) were obtained for each labeled-double 
stranded oligo and 15 μg clarified protein lysate, 0.5 μL poly(dI-dC), 1 μL 10X gel shift 
buffer (250 mM Tris pH 7.5, 800 mM NaCl, 350 KCl, 10 mM DTT), and 1 μL labeled 
oligo (~50,000 cpm) was combined in a 1.7 mL microcentrifuge tube and brought to a 
final volume of 20 μL using sterile protease-free nuclease-free water. Samples were 
incubated for 15 min at room temperature. 6X DNA loading dye (30% glycerol, 0.35% 
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xylene cyanol, 0.25% bromophenol blue) was added to each sample and resolved over a 
5% non-denaturing polyacrylamide gel. Gels were dried on a gel dryer for one hour at 
80 °C. Dried gels were exposed to a phosphor screen overnight and screens were imaged 
on a Typhoon scanner (GE Healthcare Life Sciences). Oligo sequences used for EMSA 
are found in Table 3.6. 
 
2.6 Immunofluorescent techniques 
2.6.1 Cryosectioning 
 Tissues embedded in O.C.T. compound prepared from Section 2.1.7 were 
transferred from -80 °C to -20 °C for 4 h to allow to reach appropriate cryosectioning 
temperature. Tissues were sectioned at thickness of 16 μm (Leica CM 1850), and 
cryosections were carefully transferred onto charged slides. Cryosections were stored 
at -80 °C for long-term storage.  
 
2.6.2 Immunohistochemistry 
 Sixteen micron cryosections were fixed in PHEM fixative (4% formaldehyde, 
60 mM PIPES, 20 mM HEPES, 10 mM EGTA, 2 mM MgCl2, 3% sucrose, pH 7.2) for 
15 min. PHEM fixative was removed and sections were washed once in 1X PBS. Tissue 
sections were permeabilized in permeabilization buffer (0.3% Triton X-100, 1X PBS) for 
30 min. Permeabilization buffer was removed and sections were blocked for one hour in 
blocking buffer (10% BSA, 0.3% Triton X-100, 1X PBS). Blocking buffer was removed 
and sections were incubated with primary antibody suitably diluted in antibody dilution 
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buffer (1% BSA, 0.3% Triton X-100, 1X PBS) for 1 hour. Sections were washed three 
times in 1X PBS. Sections were incubated with secondary antibody suitably diluted in 
antibody dilution buffer for 1 hour. Sections were wash three times in 1X PBS and then 
mounted using media containing DAPI (Vectashield). Image fluorescence intensities 
were quantified using ImageJ. Briefly, MEF2A-positive nuclei were traced, and DAPI 
and MEF2A signal intensities from each channel were extracted. MEF2A signal intensity 
was normalized to respective DAPI signal intensity, and average normalized MEF2A 
signal was quantified for wild-type atria and ventricles. 
 Primary antibodies used include the following: anti-MEF2A (1:200; Santa Cruz); 
anti-PECAM (CD31; 1:200; R&D Systems) and anti-WT1 (1:200; Santa Cruz) antibodies 
were kindly gifted by Dr. William Pu (Boston Children’s Hospital). Secondary antibodies 
used include the following: Alexa Fluor 568® goat anti-rabbit (1:200; Invitrogen), Alexa 
Fluor 488® donkey anti-goat (1:200; Invitrogen), and Alexa Fluor 488® goat anti-mouse 
(1:200; Invitrogen). 
 
2.7 Computational and statistical methods 
2.7.1 Genomatix software 
 Transcription factor enrichment analysis was performed on the proximal promoter 
regions of genes preferentially dysregulated in each chamber using MatInspector 
(www.genomatix.com). Analysis was limited to regions within 50 bp of predicted MEF2 
binding sites to enrich for potential transcription factor co-regulator interactions. The 
analytical background was composed of a cross-section of genomic promoter sequences 
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to discriminate between enriched motifs and generic promoter regions. Resulting 
enriched motifs were sorted by Z-score, with a Z-score greater than positive 2.0 being 
considered significantly enriched. 
 
2.7.2 Statistical methods 
 Statistically significant differences between two populations of data were 
determined using two-tailed Student’s t-test. P-values of < 0.05 were considered to be 
statistically significant.   
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Genotyping primers 
Primer Sequence (5’  3’) 
Mef2a Fwd GCTAGCCAACATTTCACCTTTGAGATCT 
Mef2a Rev CAACGATATCCGAGTTCGTCCTGCTTTC 
Neomycin Fwd TTGGCTACCCGTGATATTGCTGAAGAGC 
HGH-Mef2a Fwd GTCTGACTAGGTGTCCTTCT 
HGH-Mef2a Rev CGTCCTCCTGCTGGTATAG 
IL-2 Fwd TGGCATCGATTACCTCAGTCCCCCT 
IL-2 Rev CCAGAACATGCCGCAGAGGTCCA 
 
Table 2.1 Genotyping primers used in this thesis. Primers are listed 5’ to ’3’. 
Annealing temperatures for genotyping reactions were determined using NEB Tm 
calculator (https://tmcalculator.neb.com). 
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Reporter constructs 
Plasmid Source 
pGL3Basic-1.5kb-Xirp2-Luciferase (Huang et al. 2006) 
pGL3Basic-0.3kb-Xirp2-Luciferase (Huang et al. 2006) 
pGL3Basic-Bex1-Luciferase (proximal enhancer) Cloned in-lab 
pGL3Promoter-Bex1-Luciferase (distal enhancer) (Medrano & Naya 2017) 
pGL3Promoter-Itga7-Luciferase (Medrano & Naya 2017) 
Overexpression constructs 
Plasmid Source 
pCMV-β-galactosidase (Snyder et al. 2013) 
pCDNA1-MEF2A Dr. Tod Gulick (Sanford Burnham Med. Research Institute) 
pCGN-HA-Nkx2.5 Previously cloned in-lab (Dr. Christine Snyder) 
pCDNA3-HAND1 Dr. Anthony Firulli (Indiana U. School of Med.) 
pCDNA3-HAND2 Dr. Anthony Firulli (Indiana U. School of Med.) 
pCR3.1-ERα Dr. Sang Jun Han (Baylor College of Med.) 
pCMV-3Tag-9-ERβ Dr. Sang Jun Han (Baylor College of Med.) 
 
Table 2.2 Reporter and overexpression plasmids used in this thesis. Reporter 
plasmids and overexpression plasmids were previously cloned in-lab or received from 
outside investigators as noted in the table above. 
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CHAPTER THREE: MEF2A modulates different signaling pathways in atria and 
ventricles of the heart 
 
This research was originally presented in the Journal of Biological Chemistry. Medrano 
JL, Naya FJ (2017). The transcription factor MEF2A fine-tunes gene expression in the 
atrial and ventricular chambers of the adult heart. J Biol Chem doi: 
10.1074/jbc.M117.806422 [Epub ahead of print]  
 
3.1 Introduction 
 The atrial and ventricular chambers of the mammalian heart have distinct 
anatomical and functional properties that are necessary for the coordinated and efficient 
pumping of blood. These differences arise from morphogenetic events coupled to cell 
specification pathways within myocyte and non-myocyte lineages that create the atria and 
ventricles from a linear heart tube (Buckingham et al. 2005, Moorman & Christoffels 
2003). Moreover, these developmental programs lead to regional gene expression 
patterns that are unique to the atrial and ventricular chambers (Barth et al. 2005, Ng et al. 
2010, Tabibiazar et al. 2003). The importance of these gene expression patterns is 
highlighted by cardiac defects in mouse model systems that display distinct atrial and 
ventricular chamber dysregulation (Bruneau et al. 2001, Singh et al. 2005, Tessari et al. 
2008, Wang et al. 2010, Wu et al. 2013, Xin et al. 2007). 
 The establishment of atrial and ventricular identity from cardiomyocyte 
precursors occurs early in the developing heart (Evans et al. 2010, Paige et al. 2015, 
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Später et al. 2014). Throughout development these gene programs undergo dynamic gene 
regulation to ultimately express a fixed, compartment-specific gene expression pattern 
postnatally. Investigating the transcriptional regulation of chamber-restricted genes has 
led to the identification of a number of enhancers and transcription factors required for 
distinct regional expression patterns in the heart (Habets et al. 2002, Lien et al. 1999, 
Reecy et al. 1999, Searcy et al. 1998, Tanaka et al. 1999). 
 The myocyte enhancer factor 2 (MEF2) family of transcription factors includes 
key regulators of cardiac muscle differentiation and development (Desjardins & Naya 
2016, Potthoff & Olson 2007). Interestingly, MEF2 proteins have been implicated in the 
regulation of atrial and ventricular chamber-restricted genes (Ross et al. 1996, Small & 
Krieg 2004). Based on their reported uniform expression throughout the heart it is 
unlikely that MEF2 proteins alone drive chamber-specific gene programs. Nevertheless, 
these observations suggest that MEF2 proteins play an important modulatory role in the 
regional expression of cardiac genes. 
 Previously, we described the variable penetrance of cardiac defects in global 
MEF2A knockout (KO) mice. Perinatal MEF2A-deficient hearts displayed dilation of the 
right and left ventricles including structurally compromised cardiomyocytes (Ewen et al. 
2011, Naya et al. 2002). By contrast, adult MEF2A mutant hearts did not display 
ventricular dilation, but interestingly showed compensatory activation of a MEF2-
dependent reporter that was largely restricted to the ventricles. Because both young and 
adult mutant hearts display predominantly ventricular phenotypes these observations 
suggest that the atria and ventricles are differentially affected by the loss of MEF2A. 
 58 
 In this chapter, I discuss about the cardiac chamber-dependent transcriptional 
regulation of MEF2A-sensitive genes in the adult heart. To delve deeper into a potential 
regional requirement of MEF2A in the heart, we performed genome-wide expression 
profiling of atrial and ventricular chambers from adult MEF2A KO mice. We found that 
genes uniformly expressed throughout the heart displayed preferential chamber 
dysregulation to the loss of MEF2A. Only a small fraction of the dysregulated genes 
throughout the heart were similarly affected in both atria and ventricles of MEF2A 
mutant hearts. To understand the transcriptional basis of this regional gene dysregulation 
pattern, we computationally analyzed the promoter regions of genes preferentially 
dysregulated in the atrial and ventricular chambers, and identified a distinct complement 
of transcription factor binding sites in each gene set. Our results demonstrate that MEF2A 
is required for proper atrial and ventricular gene expression but does not confer chamber 
identity. These findings provide insight into the complex transcriptional mechanisms of 
region-specific cardiomyocyte gene expression in the mammalian heart. 
 
3.2 Differential gene dysregulation in cardiac chambers of MEF2A knockout mice. 
 Global MEF2A deficiency in mice results in two distinct cardiac phenotypes 
(Naya et al. 2002). Most MEF2A knockout (KO) mice (~80%) die perinatally and 
display various cardiac defects including dilation of the right and left ventricles. A subset 
of KO mice survive to adulthood and also have cardiac abnormalities. However, these 
adult mutant hearts do not display ventricular dilation, instead a MEF2-responsive lacZ 
reporter is primarily upregulated in the right and left ventricles, likely resulting from 
 59 
stress-induced activation of MEF2D (Naya et al. 2002). Given the predominant 
ventricular phenotypes in MEF2A mutant hearts, we hypothesized that the atria and 
ventricles have a differential requirement for MEF2A in cardiac chamber gene regulation. 
 To characterize potential differences in cardiac chamber gene regulation mediated 
by MEF2A, we dissected atrial (left and right combined) and ventricular (left and right) 
tissue from adult wild-type (WT) and MEF2A KO hearts, and analyzed the extracted 
RNA via microarray. As shown in Figure 3.1, this analysis revealed a total of 686 genes 
dysregulated by at least 1.5-fold. Interestingly, the scatter plots suggested a greater 
number of genes dysregulated in MEF2A KO atria compared to KO ventricles. Indeed, 
detailed examination of the 686 dysregulated genes revealed that 481 genes (70%) were 
preferentially dysregulated in the atrial chambers of MEF2A KO hearts, even though the 
vast majority of these genes were uniformly expressed in the atrial and ventricular 
chambers of WT hearts (Figure 3.2, Appendix A.1). By contrast, only 158 genes (23%) 
were preferentially dysregulated in mutant ventricles, and the majority of these did not 
display chamber-enriched expression in WT hearts. The remaining 47 genes (7%) were 
dysregulated by at least 1.5-fold in both chambers of the mutant hearts. Chamber-
enriched genes, i.e., genes displaying 2.0-fold or more expression in one WT chamber 
relative to the other, accounted for a small percent of the dysregulated genes in each KO 
chamber (Table 3.1). 
 While the atrial chambers had more dysregulated genes, the extent of 
dysregulation was similar in each compartment. Genes preferentially affected in the atria 
were dysregulated on average by 1.76-fold and genes preferentially affected in the 
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ventricles were dysregulated on average by 1.87-fold (Table 3.2). Interestingly, the 
average fold dysregulation was far greater for those genes affected in both chambers: 2.4-
fold in atria and 2.6-fold in ventricles. Although there were more dysregulated genes in 
MEF2A KO atria, the proportion of up- and down-regulated genes was similar in both 
KO atria and ventricles (Table 3.3). Taken together, this expression profiling analysis 
revealed differential chamber sensitivity of genes to the loss of MEF2A despite its 
reported uniform expression throughout all chambers of the heart. Furthermore, most 
genes sensitive to the loss of MEF2A in both chambers were dysregulated in a similar 
direction. Finally, the abundance of preferentially dysregulated genes in MEF2A KO 
atria is in stark contrast to the more obvious ventricular phenotypes in these mutant 
hearts. 
 
3.3 Validation of MEF2A-sensitive genes 
 To confirm the differential chamber sensitivity, we examined a subset of genes 
from each of the dysregulated gene sets by qRT-PCR. All genes selected for this analysis 
are expressed throughout the heart but showed preferential dysregulation in one chamber 
or were affected in both. As depicted in Figure 3.3 A, Arhgef19, Chrdl2, Clic6, Itga7, and 
Shisa6 were significantly dysregulated in the atria, but not in the ventricles. Likewise, 
expression of Bex1, Fbxo44, Fgf16, Pknox2, and Slitrk4 was dysregulated in the 
ventricles, but not in the atria (Figure 3.3 B). Finally, Aqp4, Arhgap20, Asb4, Fgf14, and 
Pde7a genes were significantly dysregulated, either up- or down-regulated in both atria 
and ventricles of the heart (Figure 3.3 C). 
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3.4 Top canonical dysregulated pathways 
 To determine whether the preferentially dysregulated genes function in distinct 
pathways we performed Ingenuity® Pathway Analysis (IPA, Qiagen) on the three gene 
sets. As shown in Table 3.4, those genes preferentially dysregulated in MEF2A KO atria 
function in fibrosis, stem cell pluripotency, and adhesion. Genes dysregulated primarily 
in the mutant ventricles function in amino acid metabolism and endocytosis signaling. 
The cohort dysregulated in both chambers function in folate transformation and 
ubiquitination pathways, though enrichment in these processes was modest given the 
small number of genes in this category. These results suggest that dysfunction in adult 
MEF2A KO hearts arises not from a globally defective pathway but the cumulative effect 
of abnormal regulation of distinct cellular processes in each cardiac compartment. 
 
3.5 Dysregulated pathways in vivo 
 To assess whether these cellular processes were perturbed in a chamber-specific 
fashion, we analyzed expression or activity of selected components from the canonical 
pathways identified in the IPA (Table 3.4) in MEF2A KO hearts. Specifically, we 
subjected atrial and ventricular tissue lysates from adult wild-type and MEF2A KO hearts 
to western blot analysis for FAK (Focal adhesion kinase) and TRAF6 (TNF receptor 
associated factor 6). Among their roles in diverse signal transduction cascades, FAK and 
TRAF6 activities are modulated by the integrin/adhesion and MSP-RON (Macrophage 
stimulating protein – Recepteur d’Origine Nantais) pathways, respectively (Franchini 
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2012, Li et al. 2015, Mitra & Schlaepfer 2006, Yao et al. 2013). Adhesion was among the 
top dysregulated pathways in MEF2A KO atria whereas MSP-RON, a receptor tyrosine 
kinase pathway involved in cancer and inflammation (Li et al. 2015, Yao et al. 2013), 
was the top dysregulated pathway in mutant ventricles. As shown in Figure 3.4 and 
Figure 3.5, we detected a modest but significant downregulation of phosphorylated FAK, 
an indicator of its activity, in MEF2A KO atria but not ventricles. Conversely, TRAF6 
was preferentially and significantly downregulated in the ventricles of adult MEF2A 
mutant hearts. These data highlight the distinct cellular responses of the cardiac chambers 
to the loss of a broadly expressed transcription factor and provide support for differential 
gene regulatory activity of MEF2A in the atria and ventricles of the heart. 
 
3.6 MEF2A expression is similar throughout the adult heart 
 A previous study described enrichment of MEF2A protein in the atrial chambers 
of the adult mouse heart (Zhao et al. 2002). Since a majority of the dysregulated genes 
were preferentially affected in the atria we sought to determine whether this expression 
pattern could explain the differential sensitivity to MEF2A. Initially, we examined Mef2a 
transcript levels in both cardiac chambers. RT-PCR analysis revealed similar transcript 
levels of Mef2a between adult wild-type atrial and ventricular cardiac chambers (Figure 
3.6). This is in contrast to a previous report describing enrichment of MEF2 protein in the 
atrial chambers in adult mice (Zhao et al. 2002). Additionally, we analyzed expression of 
Mef2a splice isoforms (Yu et al. 1992), but found no difference in any alternatively 
spliced transcripts between atrial and ventricular tissue. 
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 To address the discrepancy between observed Mef2a transcript levels and 
previously reported atrial enrichment of MEF2A protein levels, we compared MEF2A 
protein levels between atria and ventricles by performing immunohistochemistry on adult 
cardiac sections using anti-MEF2A antibody (Santa Cruz sc-313). Similar to a previously 
published report (Zhao et al. 2002), MEF2A immunoreactivity appeared higher in the 
atrial chambers compared to the ventricles of the heart (Figure 3.7). Because the 
increased signal in the atria may reflect the higher density of atrial myocytes, owing to 
their smaller size, we normalized the MEF2 signal to DAPI-positive cells in each 
chamber. On normalization of MEF2A-positive myocytes to nuclear DAPI-positive cells, 
a similar fold difference was observed between WT atria and ventricles (Figure 3.8). In a 
complementary set of experiments, MEF2A protein levels were evaluated by western 
blotting using whole tissue lysates from each cardiac chamber. Again, MEF2A protein 
levels appeared higher in atrial lysates compared to ventricular lysates (Figure 3.9). 
However, MEF2A protein levels were found to be similar between atria and ventricles 
when normalized to the nuclear protein histone H3 (Figure 3.10). To further define the 
expression domain of MEF2A in the adult heart, we co-stained adult cardiac sections 
with epicardial or endocardial markers. As shown in Figure 3.11, MEF2A signal did not 
overlap with that of either PECAM (endocardium) or WT1 (epicardium). Nuclear 
MEF2A signal was mainly localized to the myocardium in adult wild-type hearts. These 
results clearly demonstrate that MEF2A is not preferentially expressed in the atria of the 
adult heart and the apparent chamber-specific differences can be explained by the 
different sizes and densities of atrial and ventricular myocytes per mass of tissue. 
 64 
Moreover, MEF2A is restricted to the myocardium in the atria and ventricles thereby 
ruling out expression differences arising from additional regions of the adult heart. 
 
3.7 MEF2 DNA binding in vitro and in vivo 
 We next asked whether differences in MEF2 DNA-binding activity could account 
for the preferential dysregulation of MEF2A-sensitive genes in Mef2a KO hearts. 
Initially, electrophoretic mobility shift assays were performed to evaluate MEF2 binding 
from atrial and ventricular lysates in vitro. Similar to the western blot analysis, gel shift 
assays using whole tissue lysates from each chamber showed greater MEF2 DNA-
binding activity in atrial lysates (Figure 3.12 left panel). As a control we used a probe 
harboring the CaRG element, the consensus binding site for SRF, a cardiac TF uniformly 
expressed in the heart (Figure 3.12 right panel) (Belaguli et al. 1997, Miano 2003). 
Because SRF also showed this differential DNA-binding pattern, after normalization 
there was no significant difference in MEF2 binding activity (Figure 3.12 right graph). 
Moreover, the reduction in MEF2 DNA-binding activity from MEF2A KO atrial and 
ventricular lysates appeared to be similar (Figure 3.13). These results demonstrate that 
total MEF2 DNA-binding activity does not differ between the cardiac chambers. 
 Next, we examined endogenous MEF2 genomic binding to promoter regions of 
selected dysregulated genes to determine whether differences in MEF2A binding in vivo 
could help explain the observed preferential dysregulation.  For this analysis, we focused 
on the same set of dysregulated genes described in Figure 3.3. Predicted MEF2 sites 
(Figure 3.14 left chart) were identified in the upstream regions of these genes based on 
 65 
available ENCODE MEF2A ChIP-seq data (accession numbers ENCSR806JZK and 
ENCSR867SDZ) and the MEF2 consensus sequence (5’-YTAWWWWTAG-3’). We 
chose to analyze the 5,000 bp proximal promoter of these genes to identify candidate 
MEF2 enhancers based on previous promoter analysis studies performed in our lab 
(Estrella et al. 2015, Huang et al. 2006). While there was slight variability in the MEF2 
consensus sequence these minor differences did not group together with genes displaying 
similar preferential dysregulation. Chromatin immunoprecipitation (ChIP) was performed 
on cross-linked atrial and ventricular tissue from adult wild-type hearts using MEF2A 
antibodies (Santa Cruz) that we previously reported preferentially recognize MEF2A 
(Snyder et al. 2013). As shown in Figure 3.14, MEF2A associates at the predicted MEF2 
sites. Multiple attempts to assess binding of MEF2A to these genes in ventricular tissue 
by ChIP were unsuccessful. Nevertheless, the similarity of MEF2A association to these 
genomic regions in WT atrial chambers, whose genes display differences in chamber 
sensitivity, does not explain the differential chamber dysregulation profile. 
 To bolster the in vivo ChIP analysis and demonstrate that the dysregulated target 
genes are directly regulated by MEF2A, we cloned the genomic regions harboring the 
candidate MEF2 binding site from a representative gene in each category: Itga7 
(preferentially dysregulated in the atria) and Bex1 (preferentially dysregulated in the 
ventricles). As shown in Figure 3.15, transfection of MEF2A significantly stimulated the 
activation of both pGL3p-Itga7 (2.9-fold) and pGL3p-Bex1 (2.3-fold) in HEK293T cells. 
 
3.8 Candidate MEF2A co-factors 
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 The lack of any obvious difference in MEF2A expression or binding activity 
between atria and ventricles suggests that differential sensitivity of genes in the cardiac 
chambers results from the ability of MEF2A to interact with a distinct set of cofactors. 
Toward this end, we performed transcription factor (TF) binding motif analysis using 
MatInspector (Genomatix) on dysregulated genes from each group (i.e., promoters of 
genes preferentially dysregulated in KO atria, promoters of genes preferentially 
dysregulated in KO ventricles, and promoters of genes dysregulated in KO atria and 
ventricles). This analysis revealed a distinct set of enriched TF binding sites in each gene 
set (Table 3.5). 
 Of the top enriched TF binding sites in each cardiac chamber category, we 
focused on those bound by the estrogen receptor (ER, V$EREF), NKX homeodomain 
(V$NKXH), and the HAND family (V$HAND). The ER binding site was found to be 
overrepresented in genes preferentially dysregulated in the atria, the NKX homeodomain 
site was enriched in the preferential ventricular cohort, and the HAND binding site was 
found in genes dysregulated in both chambers. The ER is known to have a protective 
effect on the heart (Van Rooij et al. 2010), and differences in cardiac chamber expression 
of ER isoforms (α and β) have been reported (Lizotte et al. 2009). Members of the NKX 
and HAND family are core cardiac TFs important in cardiac gene regulation and 
development (Akazawa & Komuro 2005, Bartlett et al. 2010, Firulli 2003, Vincentz et al. 
2011). While the primary cardiac NKX member, Nkx2.5, is not enriched in a specific 
cardiac chamber a null mutation of this gene in mice results in ventricular morphogenesis 
defects (Tanaka et al. 1999). Similarly, mutations in HAND genes result in cardiac 
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chamber morphogenesis defects (Firulli et al. 2010, Srivastava et al. 1997). While the 
two primary gene products, HAND1 and 2, are each expressed in distinct chambers, 
when taken together HAND transcriptional activity is present throughout all 
compartments of the heart (Thattaliyath et al. 2002). 
 
3.9 Transcriptional cooperativity between MEF2A and candidate co-factors 
 To test potential transcriptional cooperativity between MEF2A and the candidate 
TFs (estrogen receptors, Nkx2.5, and HAND factors), we used the 1.5 kb proximal 
promoter of the Xirp2 (myomaxin and Xinβ) gene as a readout. Although this gene was 
not part of the differential gene set it is an established, direct target of MEF2A and 
harbors multiple DNA binding sites for these candidate TFs (Figure 3.16). The 1.5 kb 
proximal promoter of Xirp2 contains two predicted estrogen response elements, four 
predicted Nkx2.5 response elements, and two predicted HAND-binding sites (Figure 
3.16). 
 As shown in Figure 3.17, the 1.5 kb Xirp2-luciferase reporter was significantly 
activated by MEF2A alone (2.1 – 2.8-fold). This reporter was also activated by ERβ 
(1.6-fold, top graph), Nkx2.5 (1.4-fold, middle graph), and HAND2 (4.5-fold, bottom 
graph) individually. By contrast, the 1.5 kb Xirp2 reporter was not significantly activated 
by ERα (upper graph) or HAND1 (lower graph) alone. However, co-transfection of 
MEF2A with ERβ, Nkx2.5, and HAND2, and to a lesser extent HAND1, resulted in 
significant cooperative activity. 
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 To demonstrate that MEF2A and these TFs function cooperatively in cardiac 
muscle we performed the same reporter gene analysis in neonatal rat ventricular 
myocytes (NRVMs). Because the 1.5 kb Xirp2-luciferase reporter showed an exceedingly 
high basal activity in NRVMs in the absence of any transfected TF, we used a 0.3 kb 
Xirp2-luciferase reporter (Figure 3.16 lower schematic). This minimal promoter, which 
contains the conserved -75 MEF2 site and lacks all but a single predicted binding site for 
ER, Nkx2.5, and HAND, displayed lower basal activity in NRVMs (data not shown). 
ERα, Nkx2.5, HAND1, or HAND2 individually did not significantly activate the 0.3 kb 
Xirp2-luciferase reporter (Figure 3.18), whereas ERβ alone had a modest but significant 
effect on the reporter (1.7-fold, top graph). Co-transfection of MEF2A with ERβ, 
Nkx2.5, and HAND2, and to a lesser extent ERα and HAND1 resulted in significant 
cooperative activation. Co-transfection of MEF2A with Nkx2.5 resulted in cooperative 
activation of at least 4.2-fold over individual activation from MEF2A or Nkx2.5 alone. 
Similarly, co-transfection of MEF2A with ERβ and MEF2A with ERα resulted in 
cooperative activation of at least 4.6-fold and 2.9-fold over activation from individual 
transfections, respectively. Finally, co-transfection of MEF2A with HAND2 and MEF2A 
with HAND1 resulted in cooperative activation of at least 3.1-fold and 2.0-fold over 
activation from individual transfections, respectively. It is interesting to note that in both 
HEK293T cells and NRVMs, ERβ and HAND2 displayed higher cooperative activity 
compared to ERα and HAND1 protein isoforms. These results demonstrate that MEF2A 
interacts with at least three TFs predicted to have enriched binding sites in the 
preferentially dysregulated gene sets between the atria and ventricles. 
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3.10 Discussion 
 Defining the molecular mechanisms by which atrial and ventricular 
cardiomyocytes develop their distinct cellular and functional properties is essential for 
refining approaches to promote specific myocyte lineages from precursor populations, 
including embryonic and induced pluripotent stem cells, and for directed reprogramming 
of cardiomyocytes. In this report we demonstrate that genes uniformly expressed 
throughout the adult heart are differentially sensitive to the loss of MEF2A. This 
preferential dysregulation is predicted to affect distinct pathways in the cardiac chambers 
of MEF2A KO mice making the mutant phenotype far more complex than previously 
recognized (Naya et al. 2002). Taken together, our results suggest that proper chamber 
gene regulation in the heart is not only driven by lineage restricted TFs, but also by 
broadly expressed cardiac TFs that impart robustness to gene expression patterns in 
myocytes within each compartment. 
 It is intriguing that genes expressed uniformly throughout the heart display 
preferential chamber sensitivity to a broadly expressed transcription factor such as 
MEF2A. This is not entirely surprising since cardiac genes display dynamic 
spatiotemporal expression patterns in development, reflecting the activity of multiple 
enhancers (Christoffels et al. 2004, Dupays & Mohun 2016, Rana et al. 2013). The core 
cardiac TFs Nkx2.5 and MEF2C are prime examples of genes that undergo chamber-
dependent transcriptional regulation. Both TFs are uniformly expressed throughout the 
developing heart yet analysis of their transcriptional regulatory regions has uncovered 
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enhancers active in distinct compartments in the developing heart (Barnes et al. 2016, 
Lien et al. 1999, Reecy et al. 1999, Searcy et al. 1998, Tanaka et al. 1999). While each 
enhancer is active in a specific compartment, their collective activity drives uniform 
expression through the heart. Perhaps the preferential dysregulation of MEF2A target 
genes reflects region-specific enhancers embedded in these genes that are dependent on 
MEF2 transcriptional activity. 
 It is curious that there were more dysregulated genes in the atria even though 
MEF2A KO hearts appear to have more prominent ventricular phenotypes. It is possible 
that the collection of genes dysregulated in the ventricular chambers, based on their 
function in myocytes and despite the relatively small number, triggers a more readily 
observable defect in this compartment. Alternatively, the pathology caused by the cohort 
of dysregulated atrial genes may be subtle or the atrial chambers may be more resistant to 
changes in gene expression. For example, cellular adhesion was among the top 
dysregulated pathways in the MEF2A KO atria. We examined the localization of N-
cadherin, a prototypical adhesion molecule important in the heart, in adult MEF2A KO 
atria and did not find significant differences compared to wild-type. Similarly, the extent 
of fibrosis in these mutant hearts was highly variable and did not appear to be 
significantly different between atria and ventricles (data not shown). More detailed 
analyses will be required to determine the specific cellular defects in MEF2A mutant 
hearts. 
 MEF2 has been implicated in chamber-specific gene expression. An enhancer of 
the Mlc2v gene was shown to be active in the ventricles of the mouse heart. This minimal 
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enhancer harbors a MEF2-binding site and when mutated ventricular expression is lost 
(Ross et al. 1996). In addition, the atrial-enriched ANF gene has been shown to be co-
regulated by GATA4 and MEF2 (Morin et al. 2000) and MEF2A and Pitx2 (Toro et al. 
2004). MEF2C is required for the proper regulation of enhancers of the Hcn4 and BOP 
genes in the atrioventricular conduction system and right ventricle, respectively (Phan et 
al. 2005, Vedantham et al. 2013). Finally, though not functionally tested, the atrial Mlc2a 
and sarcolipin genes harbor candidate MEF2 sites in their upstream regulatory regions 
(Small & Krieg 2004). Taken together, these observations strongly suggest that MEF2 
proteins function to coordinate proper cardiac chamber gene expression. 
 Regarding the computational analysis of MEF2A-sensitive cardiac chamber gene 
programs, prior studies have shown that MEF2 proteins collaborate with the NKX and 
HAND family of transcription factors. MEF2C and Nkx2.5 were shown to genetically 
interact and required for proper ventricular chamber development in mice (Vincentz et al. 
2008). Moreover, these factors functioned cooperatively to activate heterologous 
promoters. Our computational analysis is consistent with these observations suggesting 
that Nkx binding sites are significantly enriched in genes displaying preferential 
dysregulation in ventricular chambers in MEF2A KO hearts. In a similar fashion, 
MEF2A and MEF2C were each shown to interact with HAND proteins (Morin et al. 
2005). HAND proteins display an intricate expression pattern in the developing heart. 
HAND1 is expressed in the myocardial cuff on the cardiac outflow tract. HAND2 is 
expressed in myocardium, endocardium, and epicardium as well as the underlying 
pharyngeal mesoderm of the second heart field. Thus, our analysis revealing 
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overrepresentation of the HAND E-box motif in genes that are dysregulated by MEF2A 
KO in both chambers seems logical based on the reported spatiotemporal expression 
patterns. Presumably, MEF2A interacts with specific HAND protein isoforms to regulate 
genes in distinct regions of the heart. Because MEF2 interacts with both HAND proteins 
we observe similar dysregulation of this gene cohort in both cardiac chambers. 
 Expression of estrogen receptor isoforms has been described in the heart of adult 
rodents. In rats, ERα mRNA is more abundant in atria compared to ventricles whereas 
ERβ is uniformly expressed (Jankowski et al. 2001). However, in mice, ERα protein 
appears to be more abundant in ventricles, but similar to the rat study ERβ is expressed in 
both chambers. These expression patterns do not strictly correlate with the 
overrepresentation of ER binding sites in the atrial preferentially dysregulated genes in 
MEF2A KO hearts. This suggests that additional mechanisms beyond MEF2-ER 
cooperativity are required for the observed chamber sensitivity of these genes. 
 This study has identified a preferential gene regulatory response of MEF2A in 
chambers of the adult mouse heart. Characterization of transcriptional pathways in the 
chambers of the heart will lead to a deeper understanding of the mechanisms of region-
specific cardiomyocyte function. This information can be used to develop therapies that 
selectively target dysfunctional regions of the heart in diseases such as atrial fibrillation 
or arrhythmogenic right ventricular cardiomyopathy. 
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Figure 3.1 MEF2A differentially regulates genes in the adult mouse heart. Scatter 
plots depicting gene expression differences in MEF2A KO atria and ventricles. Wild-type 
(WT) and MEF2A KO atria microarray intensities (left graph), and WT and MEF2A KO 
ventricles microarray intensities (right graph) were plotted against one another. In each 
graph, genes upregulated by at least 1.5-fold in MEF2A KO mice are plotted in green 
(FC ≥ 1.5), genes downregulated by at least -1.5-fold in MEF2A KO mice are plotted in 
red (FC ≥ -1.5), and genes with no greater than 1.5-fold difference in either direction are 
plotted in black (-1.5 < FC < 1.5). Of the 21,212 gene probe sets on the Mouse 
Affymetrix GeneChip® Gene 1.0 ST Array System, 686 well-annotated genes were 
dysregulated by at least 1.5-fold or greater in adult MEF2A KO hearts. 
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Figure 3.2 MEF2A regulates distinct and overlapping genes in the adult heart. Venn 
diagram summarizes dysregulated gene expression profiles in KO atria (A), KO 
ventricles (V), and both (A+V). Of the 21,212 gene probe sets on the Mouse Affymetrix 
GeneChip® Gene 1.0 ST Array System, 686 well-annotated genes were dysregulated by 
at least 1.5-fold in adult Mef2a KO hearts as compared to WT control hearts. Of the 686 
dysregulated genes in the Mef2a KO hearts, 481 were preferentially dysregulated in 
Mef2a KO atria, 158 were preferentially dysregulated in Mef2a KO ventricles, and 47 
were dysregulated in both Mef2a KO atria and ventricles. 
 
  
 75 
 
  
 76 
Figure 3.3 MEF2A-sensitive genes display cardiac-chamber specific dysregulation in 
adult MEF2A KO hearts. A, Quantitative RT-PCR analysis revealed that Arhgef19, 
Chrdl2, Clic6, Itga7, and Shisa6 were preferentially dysregulated in adult MEF2A KO 
atria by more than 2-fold when compared to their expression in KO ventricles. 
Expression levels for each gene in KO atria and ventricles were normalized to their 
respective WT cardiac region. B, Quantitative RT-PCR analysis revealed that Bex1, 
Fbxo44, Fgf16, Pknox2, and Slitrk4 were dysregulated in KO ventricles by more than 
2-fold compared to KO atrial tissue. C, Quantitative RT-PCR analysis revealed that 
Aqp4, Arhgap20, Asb4, Fgf14, and Pde7a were dysregulated by more than 1.5-fold in 
both KO atria and ventricles. KO gene expression comparisons for atrial and ventricular 
tissues were performed using WT littermate controls. Error bars represent standard 
deviation (n ≥ 3); *, p < 0.05; **, p < 0.01; ***, p < 0.001.   
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Figure 3.4 Atria and ventricles of adult MEF2A KO hearts each display 
perturbations in distinct signaling pathways. Immunoblot analysis of phospho-FAK 
(p-FAK) and total FAK, TRAF6, and GAPDH proteins levels in WT and KO samples in 
atrial and ventricular lystates. 15 μg of cleared lysate was loaded onto each lane. 
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Figure 3.5 Preferential dysregulation of cell signaling pathways in cardiac chambers 
of MEF2A KO mice. Quantification of p-FAK and TRAF6 protein signals in WT and 
KO samples in atrial and ventricular lysates. p-FAK levels were normalized to total FAK 
levels before normalizing to GAPDH levels, and TRAF6 levels were normalized to 
GAPDH levels. Quantified KO levels were normalized to respective WT levels for each 
tissue comparison. Error bars represent standard deviation (n = 3); n.s., not significant; 
*, p < 0.05; **, p < 0.01. 
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Figure 3.6 Mef2a displays similar mRNA levels in adult wild-type hearts. RT-PCR 
analysis of Mef2a, Nkx2.5, and 18S mRNA levels in WT atria and ventricles. Numbers 
below Mef2a and Nkx2.5 bands represent average band intensity when normalized against 
18S (n = 4, quantifications normalized to atrial tissue). 
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Figure 3.7 MEF2A protein is expressed in atrial and ventricular chambers of adult 
wild-type hearts. Immunohistochemical detection of MEF2A expression (red) in WT 
atria and ventricles, counterstained with DAPI (blue). 10X WT atrium and ventricle (top 
panels; A = atrium; V = ventricle), 60X WT atrium (middle panels), and 60X WT 
ventricle (bottom panels) fluorescent images were acquired. 
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Figure 3.8 Immunofluorescent MEF2A levels are similar between wild-type atrial 
and ventricular chambers. Quantification of MEF2A nuclear signal using 60X WT 
atrium and ventricle images. MEF2A signal was normalized to total DNA (DAPI) signal. 
Average MEF2A/DAPI signal was normalized to WT ventricles. Error bars represent 
standard deviation. 
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Figure 3.9 MEF2A levels appear enriched in WT atrial chambers. Immunoblot 
analysis of MEF2A, Histone H3, and GAPDH protein levels in WT atrial and ventricular 
lysates. 15 μg of cleared lysate was loaded in  each lane. 
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Figure 3.10 MEF2A levels normalized to nuclear control are similar between atrial 
and ventricular chambers. Quantification of MEF2A protein signal in atrial and 
ventricular lysates. MEF2A signal was normalized to total Histone H3 levels (left graph), 
or to GAPDH levels (right graph) for each lane. Error bars represent standard deviation 
(n ≥ 3); n.s., not significant; ***, p < 0.001. 
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Figure 3.11 MEF2A protein is restricted to the myocardium in adult hearts. 
Immunohistochemical detection of MEF2A in myocardium but not epicardium or 
endocardium in WT atria and ventricles. MEF2A (red), PECAM (green; top and middle 
panels), and WT1 (green; bottom panels) counterstained with DAPI (blue). 60X WT 
atrium (top panels), 40X WT ventricle (middle panels), and 10X WT atrium and ventricle 
(bottom panels) fluorescent images were acquired (arrows indicate MEF2A-positive 
nuclei; the asterisk indicates PECAM staining; arrowheads indicate PECAM and WT1 
focused staining in middle and bottom panels respectively; A = atrium; V = ventricle). 
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Figure 3.12 MEF2A DNA-binding activity. Electrophoretic mobility shift assays of 
MEF2 (left panel) and SRF (right panel) DNA-binding activity in lysates from WT atria 
and ventricles. Quantification of MEF2 DNA-binding activity relative to SRF binding 
activity (right graph). Average fold change was normalized to WT ventricles. Oligo 
sequences used for EMSA are found in Table 3.6. Error bars represent standard deviation 
of biological replicates; n.s., not significant. 
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Figure 3.13 MEF2 DNA-binding activity is reduced in MEF2A KO hearts. Gel shift 
assay of MEF2 DNA binding activity in lysates from WT and KO cardiac chambers. 
MEF2 KO/WT chamber gel shift signal reduction quantification (right graph). MEF2 
DNA-binding activity signal in KO chambers was normalized against respective WT 
chamber. Error bars represent standard deviation of biological replicates; n.s., not 
significant. 
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Figure 3.14 MEF2A associates with chromatin containing predicted MEF2 
enhancers of dysregulated genes in vivo. 5,000 bp upstream regulatory region for 15 
MEF2A-sensitive genes were scanned for predicted MEF2 sites using the Integrative 
Genomics Viewer (Broad Institute), ENCODE experimental datasets (accession numbers 
ENCSR806JZK and ENCSR867SDZ), and the MEF2 consensus sequence 5’-
YTAWWWWTAG-3’. For Fbxo44, an optimal MEF2 site was located upstream of the 
original -5,000 bp search parameter. Formaldehyde fixed and sonicated chromatin was 
isolated from Mef2a WT whole hearts. ChIP assay was performed with a MEF2A 
polyclonal antibody, and immunoprecipitated chromatin was subjected to quantitative 
PCR with primers designed to amplify ~100 bp of promoter sequence containing 
predicted MEF2 sites. Error bars represent standard deviation of technical triplicates of 
qPCR samples.  
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Figure 3.15 Transcriptional activation of predicted MEF2 enhancers in MEF2A-
sensitive genes. MEF2A-dependent activation of a luciferase reporter harboring a 500 bp 
upstream genomic region surrounding a MEF2 binding site (-2347) of the Itga7 gene (left 
graph). MEF2A-dependent activation of a luciferase reporter harboring a 500 bp genomic 
region surrounding a MEF2 binding site (-2859) of the Bex1 gene (right graph). Error 
bars represent standard deviation of biological replicates; **, p < 0.01; ***, p < 0.001. 
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Figure 3.16 Xirp2-Luciferase constructs used in this study. Schematic of the 
pGL3basic-1.5kb-Xirp2-Luciferase construct (top), and the pGL3basic-0.3kb-Xirp2-
Luciferase construct (bottom). The functional MEF2 (-75), and predicted EREF, HAND, 
and NKXH binding sites position are shown relative to the luciferase reporter gene. 
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Figure 3.17 MEF2A cooperatively interacts with transcription cofactors in 
HEK293T cells. Activation of the 1.5 kb Xirp2-luciferase reporter in HEK293T cells by 
MEF2A (top, middle, bottom graphs), ERα and β expression constructs (top), NKX2.5 
expression construct (middle), or HAND expression constructs (bottom). Fold changes 
are normalized to reporter-alone condition (1.0) in each graph. Fold-change activation 
with overexpression plasmids over 1.5kb-Xirp2-Luciferase reporter alone are: 2.3 
(+MEF2A), 0.8 (+ERα), 1.5 (+ERβ), 1.2 (+MEF2A +ERα), and 6.8 (+MEF2A +ERβ) 
(top graph); 2.1 (+MEF2A), 1.4 (+NKX2.5), and 4.0 (+MEF2A +NKX2.5) (middle 
graph); 2.8 (+MEF2A), 1.4 (+HAND1), 4.5 (+HAND2), 3.6 (+MEF2A +HAND1), 9.1 
(+MEF2A +HAND2) (bottom graph). Error bars represent standard deviation (n ≥ 3); 
n.s., not significant; *, p < 0.05; **, p < 0.01; ***, p < 0.001.    
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Figure 3.18 MEF2A cooperatively interacts with transcription cofactors in neonatal 
rat ventricular myocytes. Activation of the 0.3 kb Xirp2-luciferase reporter in NRVMs 
by MEF2A (top, middle, bottom), ERα and β expression constructs (top), NKX2.5 
expression construct (middle), or HAND expression constructs (bottom). Fold changes 
are normalized to reporter-alone condition (1.0) in each graph. Fold-change activation 
with overexpression plasmids over 0.3kb-Xirp2-Luciferase reporter alone are: 0.8 
(+MEF2A), 1.4 (+ERα), 1.7 (+ERβ), 4.0 (+MEF2A +ERα), and 8.4 (+MEF2A +ERβ) 
(top graph); 0.8 (+MEF2A), 1.1 (+NKX2.5), and 4.8 (+MEF2A +NKX2.5) (middle 
graph); 0.8 (+MEF2A), 0.7 (+HAND1), 0.8 (+HAND2), 1.5 (+MEF2A +HAND1), 2.4 
(+MEF2A +HAND2) (bottom graph). Error bars represent standard deviation (n = 3); 
n.s., not significant; *, p < 0.05; **, p < 0.01; ***, p < 0.001.    
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Table 3.1 A majority of MEF2A-sensitive genes are similarly expressed throughout 
wild-type hearts. Of the total 686 dysregulated genes between WT and KO hearts, 481 
genes (70%) were preferentially dysregulated in KO atria, 158 genes (23%) were 
preferentially dysregulated in KO ventricles, and the remaining 47 genes (7%) were 
dysregulated in both KO cardiac chambers. These genes were further categorized based 
on their chamber expression profile (chamber enrichment is specified as 2.0-fold or 
greater expression in one chamber relative to the other) in WT hearts. Most of the 
preferentially dysregulated genes are similarly expressed in both atria and ventricles of 
WT hearts. 
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Table 3.2 Average fold dysregulation of preferentially dysregulated genes. Average 
fold dysregulation of each three gene sets. Averages are calculated as absolute values. 
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Table 3.3 Directionality of gene dysregulation in MEF2A KO cardiac chambers. 
Analysis of direction of dysregulation in each gene set. Similar number of genes were up- 
and down-regulated in each. 6 out of the 47 genes dysregulated in both KO atria and 
ventricles are up- and downregulated in different chamber types. 
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Table 3.4 Top canonical pathways dysregulated in MEF2A KO hearts. Three gene 
sets (481 genes dysregulated in KO atria, 158 genes dysregulated in KO ventricles, and 
47 genes dysregulated in KO atria and ventricles) were analyzed using the Qiagen 
Ingenuity Pathway Analysis. The top affected canonical pathways are listed for each gene 
set. Ratios for each pathway report the number of dysregulated genes from each data set 
(numerator) and the total number of associated genes (denominator). In a separate KEGG 
Pathway analysis, cell adhesion was the top pathway predicted to be dysregulated in the 
set of genes preferentially dysregulated in MEF2A KO atria. 
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Table 3.5 Candidate co-factor analysis of MEF2A-dependent genes. The 5,000 bp 
proximal promoters from the three dysregulation gene sets were analyzed for predicted 
MEF2 sites, and then analyzed for additional neighboring transcription factor binding 
sites within 50 bp of predicted MEF2 sites (Genomatix). In each gene set, over 
representation (number left of slash) and Z-score (number right of slash) for each 
MEF2-TF module is calculated (Z-score greater than 2 is considered statistically 
significant). Over representation is the fold increase of MEF2-TF module found in each 
promoter dataset compared to a background promoter dataset. For each gene set, the top 
10 overrepresented MEF2-TF modules are listed and rearranged according to 
representation in each gene set. The three co-factor families studied in this chapter are 
estrogen receptors (V$EREF family weight matrices), Nkx2.5 (V$NKXH family weight 
matrices), and HAND proteins (V$HAND family weight matrices). Individual positional 
weight matrices for each family can be accessed in the Genomatix Matrix Family Library 
(Version 3.3; www.genomatrix.de).  
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Table 3.6 Primers used for gene dysregulation in MEF2A KO mice. A list of RT-PCR 
and quantitative RT-PCR primers used for expression analysis, and oligonucleotides used 
for gel electrophoretic shift assays. All sequences are listed 5’ to 3’. Sequences listed in 
bold font indicate identical primers. 
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CHAPTER FOUR: Bex1 is a target of MEF2A signaling 
 
Parts of this research are in preparation for a submission to the open access journal PLOS 
One. 
 
4.1 Introduction 
 Proper formation of the mammalian heart is dependent on coordinated gene 
expression. Members of the myocyte enhancer factor-2 (MEF2) family of transcription 
factors play a critical role in the expression of gene programs, and cardiac-specific 
cellular pathways (Desjardins & Naya 2016). Research from the Naya Lab has 
continually expanded the function of MEF2 isoforms through characterization studies of 
target genes and MEF2-sensitive cellular pathways. MEF2 proteins have been found to 
control a costamere gene program in cardiac muscle, cytoarchitectural target genes 
including Myomaxin and Myospryin, the Gtl2-Dio3 non-coding RNA locus, and cell 
cycle related target genes such as Pten (Clark & Naya 2015, Durham et al. 2006, Estrella 
et al. 2015, Ewen et al. 2011, Huang et al. 2006). Additionally, MEF2 isoforms have 
been documented to display antagonistic roles in regulating cell cycle and differentiation 
gene programs in cardiac myocytes (Desjardins & Naya 2017). These characterization 
studies include global transcriptome analysis in loss-of-function and gain-of-function 
models, paired with DNA binding activity, predicted binding site characterization, and 
transcriptional activation assays. 
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 In this chapter I discuss experiments related to Bex1 as a about the potential 
MEF2 target gene. In the microarray study described in Chapter Three, Bex1 is the 
fourth-most preferentially dysregulated gene in Mef2a knockout (KO) ventricles, with no 
enrichment in wild-type (WT) atria or ventricles (Appendix A.1.2.3). The Bex1 gene 
encodes a 128 amino acid protein in mice and interacts with the intracellular domain of 
the p75 neurotrophin receptor (Figure 4.1). This interaction with the p75 neurotrophin 
links the BEX1 protein to both neurotrophin signaling and the cell cycle (Vilar et al. 
2006). Through various promoter analysis and transcriptional activation studies, we show 
that Bex1 is a direct target gene of MEF2A. The results described in this chapter also 
suggest that the BEX1 protein has a role in the nucleus of cardiomyocytes, and that 
MEF2A is involved in neurotrophin signaling and the cell cycle through its interaction 
with the Bex1 gene. 
 
4.2 Overlapping expression of Bex1 and MEF2 in mouse tissues 
 To establish a more comprehensive expression pattern of Bex1 in mice, I 
examined Bex1 transcript levels in several tissues. Messenger RNA was collected from 
smooth muscle (stomach), skeletal muscle (tibialis anterior), cardiac atria and ventricles, 
brain, lung, kidney, and liver, and semi-quantitative RT-PCR was performed using Bex1-
specific primers (Figure 4.2). Bex1 mRNA expression levels were lowest in liver 
samples, and all samples were normalized to this value. Skeletal muscle and cardiac 
ventricles showed the highest levels of Bex1 expression, 5.5- and 2.6-fold higher relative 
to Bex1 expression levels in liver, respectively. Cardiac atria and brain showed less Bex1 
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expression than in skeletal muscle and cardiac ventricles, but both were approximately 
2.1-fold higher compared to liver. These results show that Bex1 expression patterns in the 
adult mouse overlaps with the expression pattern of MEF2. While ubiquitously 
expressed, MEF2 factors are highly expressed in cardiac, skeletal, and smooth muscle 
tissues, and to a lesser extent, in the brain (Black & Olson 1998, Desjardins & Naya 
2016, Potthoff & Olson 2007). This overlapping expression pattern between Mef2 factors 
and Bex1 transcripts supports the hypothesis that Bex1 is a target of MEF2.  
 
4.3 Bex1 is coordinately dysregulated in various MEF2A models 
 The microarray experiment described in Chapter Three showed that Bex1 mRNA 
levels are downregulated by 2.1-fold in Mef2a KO ventricles as compared to WT 
ventricles (Appendix A.1.2.3). Data from our lab also confirm that Bex1 is coordinately 
dysregulated in other MEF2A loss- and gain-of-function models. In separate microarray 
experiments, our lab has observed downregulation of Bex1 in MEF2A loss-of-function 
studies. Knocking down MEF2A in neonatal rat ventricular myocytes (NRVMs) resulted 
in a 3.9-fold downregulation of Bex1 mRNA levels (Desjardins & Naya 2017). Using 
whole hearts in Mef2a KO and Mef2a overexpression transgenic models, Bex1 was 
downregulated by 2.5-fold and upregulated by 4.0-fold, respectively (unpublished data). 
These results demonstrate that Bex1 is sensitive to the levels of MEF2A in 
cardiomyocytes, and we hypothesized that Bex1 is a direct target gene of MEF2A. 
 
4.4 Bex1 mRNA levels are sensitive to MEF2A levels in vivo 
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 To further characterize the MEF2A-dependent dysregulation of Bex1 in the adult 
heart, I took advantage of two MEF2A models used in our lab: the Mef2a knockout and 
transgenic Mef2a overexpressor mouse lines. I isolated mRNA from wild-type, Mef2a 
heterozygous, Mef2a homozygous-null, wild-type possessing a single transgenic Mef2a 
overexpressor allele, and Mef2a homozygous-null possessing a single transgenic Mef2a 
overexpressor allele (Figure 4.3). Compared to wild-type levels, Mef2a heterozygous and 
homozygous-null mice showed a 1.7-fold and 1.9-fold reduction in Bex1 mRNA 
expression levels, respectively. Mice that harbor a single transgenic allele overexpressing 
Mef2a in the wild-type background [Mef2a+/+; Tg(αMHC:Mef2a)] showed a 1.5-fold 
increase in Bex1 transcripts via RT-PCR. Interestingly, mice that contain a single 
transgenic overexpressor allele in the homozygous-null background [Mef2a-/-; 
Tg(αMHC:Mef2a)] show Bex1 levels similar to those observed in wild-type mice. While 
loss of a single wild-type allele is sufficient to reduce Bex1 mRNA expression levels by 
nearly 50% as demonstrated in Mef2a heterozygous- and homozygous-null mice, the 
transgenic allele is sufficient to restore Bex1 expression to near wild-type levels in the 
homozygous-null background. These results further demonstrate that Bex1 is sensitive to 
levels of MEF2A in the adult heart, and support our hypothesis that Bex1 is a target of 
MEF2A. 
 
4.5 Bex1 regulatory sequences respond to MEF2A levels in vitro 
 To identify MEF2-responsive elements in the mouse Bex1 promoter, I subjected 
the 5,000 bp proximal promoter region upstream of the transcription start site (TSS) to a 
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transcription factor binding site search (http://rulai.cshl.edu/TRED). Searching for 
predicted MEF2 binding sites using a MEF2 positional weight matrix 
(http://jaspar.genereg.net/) revealed one candidate site 995 bp upstream of the TSS (5’-
CTATATTTAT-3’; proximal MEF2 binding site) and a second candidate site 2,859 bp 
upstream of the TSS (5’-CTATAAATAG-3’; distal MEF2 binding site). It is interesting 
to note that while the distal MEF2 binding site in the Bex1 promoter had a higher score 
(TRED score = 8.78) than the proximal MEF2 binding site (TRED score = 7.24), 
alignments of the mouse Bex1 regulatory sequences show that this distal MEF2 site is not 
conserved across several mammalian species including human, rat, and mouse (Figure 
4.4). However, the proximal MEF2 site is conserved across eight different species in the 
alignment (Figure 4.4) 
 To characterize the candidate MEF2 binding sites, I subcloned promoter 
fragments containing the proximal MEF2 and distal MEF2 site into luciferase reporter 
constructs (pGL3-Basic and pGL3-Promoter, respectively). Although the predicted 
proximal MEF2 binding site was conserved across several mammalian species, it showed 
a modest 1.5-fold activation over basal levels when transfected with human MEF2A 
over-expression plasmids in HEK293T cells. While the distal MEF2 binding site was not 
conserved across mammalian species, it showed higher transcriptional activation. The 
predicted distal MEF2 binding site showed 2.3-fold activation over basal levels when 
transfected with human MEF2A over-expression plasmids in HEK293T cells (Figure 
4.5). These data show that human MEF2A can transcriptionally activate the Bex1 gene 
through two upstream MEF2 enhancer sites. 
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4.6 MEF2A binds to Bex1 upstream regulatory regions in vivo 
 To support the reporter activation studies of the proximal and distal MEF2 
binding sites, I subjected chromatin isolated from adult mouse ventricles to 
immunoprecipitation followed by quantitative PCR (ChIP-qPCR) to assess MEF2A 
occupancy on the Bex1 promoter. 
 Using a MEF2 antibody which has higher preferentially affinity to MEF2A than 
to other MEF2 isoforms (Snyder et al. 2013), ChIP-qPCR studies revealed that 1.3% of 
input chromatin containing the proximal MEF2 binding site co-immunoprecipitates with 
MEF2A, while 2.0% of input chromatin containing the distal MEF2 site co-
immunoprecipitates with MEF2A (Figure 4.6). As a negative control, 0.3% of input 
chromatin containing the proximal MEF2 binding site and 0.1% of input chromatin 
containing the distal MEF2 site co-immunoprecipitated when using rabbit IgG antibody. 
These results suggest that MEF2A occupies regulatory regions in the Bex1 promoter in 
vivo, and that MEF2A has a higher preference for the distal site compared to the proximal 
site by 1.6-fold by comparing percent of immunoprecipitated input chromatin. 
 
4.7 Discussion 
 This chapter describes experiments indicating that the mouse Bex1 gene is a direct 
target gene of mouse MEF2A. We show through several in vitro and in vivo studies that 
MEF2A levels affect Bex1 expression in cardiomyocytes. In MEF2A-deficient ventricles, 
we observe a downregulation of Bex1 transcript levels. Conversely, we observe an 
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upregulation of Bex1 expression in the ventricles of transgenic Mef2a overexpressing 
mice. These results clearly demonstrate that Bex1 expression is sensitive to MEF2A 
levels in the heart. We also show through ChIP-qPCR studies that MEF2A occupies the 
promoter of the Bex1 gene. We observe a 1.5-fold increase in chromatin binding of 
MEF2A on the distal MEF2 binding site compared to the proximal MEF2 binding site. 
Additionally, luciferase reporter experiments show that both the proximal and distal 
regions of the promoter harboring the predicted MEF2 sites are able to respond to 
MEF2A in in vitro reporter assays. 
 It is interesting to note that Bex1 expression is not enriched in wild-type atrial nor 
ventricular tissues, but it is preferentially dysregulated in Mef2a KO hearts. These 
observations indicate that Bex1 expression between atrial and ventricular chambers is 
differentially regulated, and that MEF2A may interact with transcriptional co-regulators 
to fine-tune the expression of Bex1 in the adult mouse heart. Previous studies suggest that 
the BEX1 protein localizes to the cytosol due to its interaction with the intracellular 
domain of p75-NTR (Vilar et al. 2006). We are interested in characterizing the cellular 
localization pattern of the BEX1 protein in cardiomyocytes. Altogether, these studies 
point to a new role and function for MEF2A in the adult heart through its ability to 
upregulate Bex1 transcription. 
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Figure 4.1 BEX1 in neurotrophin signaling. BEX1 has been shown to interact with the 
intracellular domain of the p75 neurotrophin receptor. Cell survival, regulation of the 
actin cytoskeleton, and apoptosis are all downstream cellular processes of neurotrophin 
signaling (Reichardt 2006). 
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Figure 4.2 Expression of Bex1 in mouse tissues. Bex1 mRNA transcript levels 
normalized to 18S ribosomal RNA were quantified across different tissues in mice. Bex1 
expression levels in all tissues were then normalized to liver expression levels. Skeletal 
muscle and cardiac ventricles show the highest expression levels of Bex1, while liver and 
lungs showed the lowest expression levels. 
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Figure 4.3 Bex1 expression is sensitive to MEF2A levels in vivo. A, RT-PCR analysis 
of Bex1 mRNA and 18S ribosomal RNA levels in ventricles of different Mef2a genotypes 
in mice. B, Quantification of Bex1 mRNA levels normalized to 18S ribosomal RNA 
levels in ventricles of the indicated Mef2a genotypes.  
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Figure 4.4 Sequence alignment of MEF2 sites. Mouse Bex1 upstream regulatory 
sequences containing either the proximal MEF2 site (-995 bp) or the distal MEF2 site 
(-2,859 bp) were compared to human, rat, rabbit, cow, pig, dog, and cat Bex1 upstream 
regulatory regions of respective species. The mouse Bex1 proximal MEF2 site (top 
alignment) and the mouse Bex1 distal MEF2 site (bottom alignment) are highlighted in 
yellow. In the Bex1 distal MEF2 site alignment for human, rabbit, cow, pig, dog, and cat 
(asterisk), upstream regulatory sequences were not found within the -5,000 bp promoter 
region immediately upstream of the TSS. Instead, BLAST (NCBI) was performed to find 
the closest matching sequence on the X chromosome.  
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Figure 4.5 MEF2A activates Bex1 gene expression in vitro. A, proximal (-995 bp) and 
distal (-2859 bp) candidate MEF2 binding sites were subcloned into pGL3-Basic and 
pGL3-Promoter, respectively. B, luciferase reporter assays of cloned predicted MEF2 
sites display activation with transiently transfected human MEF2A in HEK293T cells. 
MEF2A transcriptional activation was tested using the distal MEF2 enhancer 
(pGL3Promoter-disBex1-Luciferase, left graph) and the proximal MEF2 enhancer 
(pGL3Basic-proxBex1-Luciferase, right graph). Luciferase readings were normalized to 
an internal beta-galactosidase transfection control and normalized to reporter-alone.  
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Figure 4.6 MEF2A binds to Bex1 upstream regulatory regions in vivo. ChIP analysis 
was performed with IgG as a negative control antibody, or a MEF2A-specific antibody 
(Santa Cruz sc-313). Immunoprecipitated chromatin was subjected to quantitative PCR 
with primers designed to amplify ~100 bp of upstream regulatory sequence containing 
the distal or proximal MEF2 site. MEF2A displays greater enrichment on the distal site 
by 1.5-fold (2.0% INPUT in distal MEF2 site over 1.3% INPUT in proximal MEF2 site). 
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RT-PCR primers 
Primer Sequence (5’  3’) 
Bex1 Fwd TGAGCATCTCTAGAAAGAGG 
Bex1 Rev GGTCCCATCTATAGTGAGC 
Bex1 MEF2 enhancer sites 
Primer Sequence (5’  3’) 
proxMEF2 Fwd CCTTTTTCCAAGGTCCAAAAACAGC 
proxMEF2 Rev GTGCCACTTGCGTCAGAAGC 
disMEF2 Fwd ACTGCCCAGCTAGCCAAAGACATTC 
disMEF2 Rev CATGGTGGTGCACGCCTTTAATCC 
ChIP-qPCR 
Primer Sequence (5’  3’) 
proxMEF2 Fwd GCTGCCCTGTCCTTTTTCCAA 
proxMEF2 Rev CCAACCATCTGTCTCTCCTGCT 
disMEF2 Fwd ATGTGTTACAGGGAGACTGGAAA 
disMEF2 Rev GGCAAGCACTCTAACAACCG 
 
Table 4.1 Primers used for Bex1 expression and promoter analysis. Primers are listed 
5’ to ’3’. Annealing temperatures for RT-PCR reactions and cloning PCR reactions using 
Q5 High-Fidelity Polymerase (New England Biolabs) were determined using NEB Tm 
calculator (https://tmcalculator.neb.com). ChIP-qPCR annealing temperature were 60 °C. 
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CHAPTER FIVE: Discussion 
5.1 Discussion 
 MEF2A is a central regulator of gene programs in the adult heart. Studies have 
shown that MEF2A controls a spectrum of gene programs in cardiomyocytes including 
cell cycle pathways and a costamere gene program (Estrella et al. 2015, Ewen et al. 
2011). While previous investigations have described the cellular defects in adult Mef2a 
knockout hearts (Naya et al. 2002), the molecular changes in adult MEF2A mutant hearts 
are poorly understood. 
 In Chapter Three I presented an analysis cardiac chamber-dependent 
transcriptional regulation of MEF2A-sensitive genes in the adult heart. These results 
suggest that MEF2A differentially regulates distinct pathways in the atrial and ventricular 
chambers of the heart. I validated a subset of preferentially dysregulated genes, 
supporting the dysregulation trends observed in the MEF2A-dependent transcriptome 
microarray. With this in mind, I sought to identify cellular pathways that were also 
affected in a chamber-dependent manner. Using a bioinformatics approach, I identified 
cell adhesion and the MSP-RON pathway as candidate dysregulated pathways in Mef2a 
KO atria and ventricles, respectively. By analyzing molecular components of these 
pathways, I found that phosphorylated FAK levels were downregulated in atrial chambers 
and TRAF6 protein levels were downregulated in ventricular chambers. These results 
imply that MEF2A also regulates signaling pathways in the heart in a chamber-dependent 
manner. 
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  To understand the molecular mechanisms behind the chamber-dependent 
preferential dysregulation I analyzed the 5 kb proximal upstream regulatory region of the 
preferentially dysregulated genes in each separate chamber. I discovered a number of 
potential transcriptional co-regulators of MEF2A. Additionally, certain co-regulator 
candidates were shown to display chamber-specific expression patterns coinciding with 
their transcription factor module prediction. Namely, I discovered that estrogen 
receptor β, NKX2.5, and HAND factors can modulate the transcriptional activity of 
MEF2A. These observations suggest that interactions between MEF2A and distinct 
transcriptional co-regulators further modulate and fine-tune the expression of 
downstream cardiac gene programs and cellular processes in cardiac chambers. 
 In Chapter Four I describe the Bex1 gene as a new target gene of MEF2A. BEX1 
has been shown to be involved in the cell cycle and neurotrophin signaling through its 
interaction with the p75 neurotrophin receptor (p75-NTR). I show that Bex1 transcript 
expression overlaps with Mef2 expression patterns in cardiac and skeletal muscle as well 
as in the brain. I show that proximal and distal upstream regulatory sequences of the Bex1 
gene contain computationally predicted MEF2 binding sites. The proximal binding site is 
conserved across many mammalian species, while the non-conserved distal site in the 
mouse genome shows greater transcriptional activation in reporter assays. I demonstrate 
that MEF2A is able to activate transcription on reporter constructs in vitro using these 
two predicted MEF2 sites, and to occupy regions of chromatin harboring the 
aforementioned MEF2 enhancer sites in vivo.  
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5.2 Future Perspectives 
5.2.1 Assembling the MEF2A-specfic cardiac transcriptome 
 Cardiac morphogenesis involves a precisely controlled network of transcriptional 
regulatory factors for proper chamber development. In addition to the considerable 
number of proteins in this network, genetic redundancy and interdependent interactions 
between many of these regulatory factors adds an extra layer of complexity when 
attempting to characterize functional roles for each transcription factor. My findings 
demonstrate that MEF2A in the adult heart cooperates with transcriptional co-regulators 
to modulate the expression of downstream genes and suggests that MEF2A has chamber-
dependent roles in the adult heart. Since temporal and spatial expression patterns of 
regulatory factors change during and after cardiogenesis, these observations suggest that 
MEF2A also has chamber-dependent roles in the developing heart that are different from 
those in the adult heart. Recent advances in sequencing technologies have allowed 
researchers to collect global genomic and transcriptomic datasets. Therefore, we are 
interested in establishing a comprehensive data set of MEF2A target genes in the cardiac 
transcriptome. This data set would allow us to further study other uncharacterized cellular 
pathways that are defective in developing Mef2a KO hearts. 
 To assemble an exhaustive list of MEF2A target genes in the heart, we would 
compare MEF2A ChIP-seq data with Mef2a knockout RNA-seq data. One way to 
perform this study is by expressing both MEF2A-Flag and MEF2A-GFP proteins in adult 
mice. In this manner, MEF2A homodimers comprised of one MEF2A-Flag and one 
MEF2A-GFP protein would functionally bind to target genes. Prepared chromatin can 
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then be subjected to a series of immunoprecipitations to enrich for MEF2A-homodimer 
bound chromatin. By immunoprecipitating chromatin using a GFP-specific antibody, and 
then repeating the immunoprecipitation using a Flag epitope-specific antibody, chromatin 
bound by MEF2A-homodimers can be obtained and used for ChIP-seq studies. With this 
sample set, we can probe the genome for MEF2A-homodimer bound chromatin. In a 
parallel assay, we would use deep sequencing techniques in Mef2a KO mice to identify 
MEF2A-sensitive genes. By combining the results of these two separate studies, we can 
determine the complete MEF2A-homodimer target gene set. The results from these data 
sets will allow us to determine which genes are targets of MEF2A to further study 
uncharacterized defective gene programs cellular processes in developing MEF2A KO 
hearts. These results will allow us to gain insight into some of the developmental 
processes in cardiac morphogenesis and the molecular mechanisms behind congenital 
heart diseases. 
 
5.2.2 Characterizing chamber-specific transcriptional co-regulators of MEF2A in 
the heart 
 The complexities of gene regulatory networks, and the interactions between 
transcriptional regulatory factors make it difficult to obtain a global picture of these 
molecular processes. Understanding the regulatory interactions that MEF2A participates 
in would provide greater insight into how other transcription factors might be regulated 
and a better understanding of the transcriptional regulatory network in the heart. 
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 From our bioinformatics promoter screen in Chapter Three, we primarily focused 
our efforts on validating estrogen receptors, NKX2.5, HAND factors as co-regulators of 
MEF2A transcriptional activity. These three candidates were the most appealing in our 
initial efforts because of their established expression patterns in the heart. It is possible 
that other MEF2A transcriptional co-regulators exist aside from the aforementioned 
proteins. To search for other MEF2A transcriptional co-regulators, the dataset from the 
coupled ChIP-seq/RNA-seq study described in section 5.2.1 can be used to determine the 
direct targets of MEF2A and which MEF2 enhancer sites are bound by MEF2A. With 
this comprehensive gene list, an extensive bioinformatics analysis can be performed to 
search for other potential transcriptional co-regulators. The co-regulator study in Chapter 
Three was limited to the 5,000 bp proximal upstream regulatory region of preferentially 
dysregulated genes between atria and ventricles. By analyzing a coupled ChIP-seq/RNA-
seq dataset, we can identify other co-regulators of MEF2A in order to gain insight into 
cardiac gene regulation. The co-regulator study in Chapter Three was also performed in 
combined atrial and combined ventricular chambers. It is known that the transcriptome 
between left and right tissues of atrial and ventricular chambers are not identical, and 
left/right chamber differences are present in their respective gene expression signatures 
(Tabibiazar et al. 2003). A refined study using ChIP-seq/RNA-seq coupled techniques 
would reveal interesting results if left and right chambers were analyzed separately in the 
atria and ventricles of the heart. From the studies presented in this dissertation, we 
demonstrate drastic spatial differences in global regulation patterns between different 
tissues of the same organ. 
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5.2.3 The cardiac specific and MEF2A related role of BEX1 in the adult heart 
 While our lab has gained considerable information regarding the transcriptional 
regulation of Bex1 by MEF2A cardiomyocytes, much still remains to be characterized. 
Recently, neurotrophins and their receptors have been shown to be essential in heart 
development, and mice lacking p75-NTR display reduced cardiac parasympathetic 
innervation (Caporali & Emanueli 2009, Habecker et al. 2008). As a small adaptor 
protein of p75-NTR, it is important to understand the role Bex1 has in cardiomyocytes. 
The BEX1 protein has been implicated in both neurotrophin signaling and the cell cycle 
(Vilar et al. 2006). These observations point to a role for MEF2A in neurotrophin 
signaling and the cell cycle in ventricular cardiomyocytes. It would be interesting to 
confirm a preferential dysregulation of downstream neurotrophin-dependent cellular 
processes and cell cycle components in ventricular chambers compared to atria. 
 Since little information is known about Bex1 and its role in the heart, it would be 
interesting to characterize the MEF2A-related role of Bex1 in the adult heart. Bex1 KO 
mice appear to develop normally with skeletal muscle regeneration defects following 
intramuscular injection of cardiotoxin (Koo et al. 2007). These mice can be used to study 
the role of Bex1 in cardiomyocytes, possibly following prolonged cardiac stress or acute 
injury to the heart. Another way to approach this study is to characterize global 
transcriptomic differences between MEF2A-knockdown NRVMs and MEF2A-
knockdown NRVMs overexpressing BEX1. Knockdown of MEF2A in NRVMs would 
lead to Bex1 downregulation and lead to dysregulation of downstream neurotrophin 
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signaling-related cellular processes. By overexpressing Bex1 in MEF2A-deficient 
NRVMs, we would observe attenuation of pathways and processes dependent on 
MEF2A-BEX1 signaling. Additionally, it is interesting to note the lack of a conserved 
distal MEF2 enhancer in the upstream regulatory region of the human Bex1 gene. Lack of 
this enhancer in the human Bex1 upstream regulatory region would suggest that Bex1 
expression levels in humans compared to mice are controlled by different transcriptional 
regulatory mechanisms to maintain cellular processes downstream of BEX1 in the heart. 
By uncovering pathways and cellular processes attenuated by BEX1 overexpression, we 
can determine the role of BEX1 in the context of MEF2A.  
 
5.2.4 Chamber-dependent regulation of Bex1 spatial expression in the heart 
 It is interesting to note that Bex1 mRNA levels are similar between atrial and 
ventricular chambers in wild-type mice, yet Bex1 levels are not affected in KO atria and 
Bex1 is one of the most dysregulated genes in KO ventricles, downregulated by 2.1-fold 
compared to WT levels. This observation reinforces that MEF2A interacts with 
transcriptional co-regulators to modulate the expression of target genes in different 
chambers of the heart. In Chapter Three, Bex1 was part of the subset of genes that was 
preferentially dysregulated in Mef2a KO ventricles displaying no preferential enrichment 
in wild-type tissues. Through several in silico and in vitro analysis, we confirm that 
MEF2A and NKX2.5 cooperatively interact to regulate the transcription of target genes. 
However, NKX2.5 may not be the only transcriptional co-regulator interacting with 
MEF2A to fine-tune the expression of Bex1 in the heart. 
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 A detailed characterization of Bex1 transcriptional regulatory elements responsive 
to transcription factors and co-regulators expressed in the heart would provide a better 
understanding of Bex1 regulation in the heart. Additionally, by gaining knowledge of 
Bex1 regulation, we can deepen our understanding of the mechanisms behind cardiac 
chamber differences. 
 
5.3 Conclusion 
 The experiments proposed in this chapter will allow us to gain a greater 
understanding of global transcriptional regulatory differences between different chambers 
and cell types in the heart. Understanding the mechanisms behind uncharacterized 
defective pathways and cellular processes in various heart disease models will give 
greater insight into new avenues for treating various forms of cardiovascular disease. By 
doing so, we will be able to develop and advance existing therapies in treating congenital 
heart defects. 
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APPENDIX 
A.1 Tables from microarray analysis 
Complete microarray dataset in “log-base-2” format is available on NCBI (GEO 
accession GSE95364). Microarray gene expression comparisons in Table A.1.1, Table 
A.1.2, and Table A.1.3 have been converted to fold-change values (i.e., upregulation is 
greater than 1.0, and downregulation is less than -1.0). Genes that were validated by 
qPCR in Section 3.3 are colored below: red for genes preferentially dysregulated in 
MEF2A KO atria, blue for genes preferentially dysregulated in MEF2A KO ventricles, 
and purple for genes dysregulated in MEF2A KO atria and ventricles. 
A.1.1 Table of genes dysregulated in KO atria 
A.1.1.1 Genes enriched in WT atrial chambers 
Gene 
Number 
Symbol Description KOA/
WTA 
Fold 
KOV/
WTV 
Fold 
KOA/
KOV 
Fold 
WTA/
WTV 
Fold 
381489 Rxfp1 relaxin/insulin-like family peptide 
receptor 1 
-7.07 -1.15 1.10 6.75 
57349 Ppbp pro-platelet basic protein -4.36 -1.03 1.35 5.73 
19220 Ptgfr prostaglandin F receptor -4.05 -1.21 2.17 7.28 
74513 Neto2 neuropilin (NRP) and tolloid 
(TLL)-like 2 
-3.56 -1.35 -1.08 2.45 
18166 Npy1r neuropeptide Y receptor Y1 -3.34 -1.11 7.02 21.1 
13106 Cyp2e1 cytochrome P450, family 2, 
subfamily e, polypeptide 1 
-3.29 1.06 1.03 3.60 
20360 Sema6c sema domain, transmembrane 
domain (TM), and cytoplasmic 
domain, (semaphorin) 6C 
-2.90 -1.13 1.51 3.88 
64011 Nrgn neurogranin -2.46 1.09 -1.05 2.55 
12797 Cnn1 calponin 1 -2.44 -1.01 2.30 5.55 
64214 Rgs18 regulator of G-protein signaling 18 -2.40 -1.02 -1.08 2.17 
19337 Rab33a RAB33A, member of RAS 
oncogene family 
-2.38 1.20 3.17 9.04 
11484 Aspa aspartoacylase -2.24 -1.42 1.31 2.07 
71703 Armcx3 armadillo repeat containing, X-
linked 3 
-2.11 -1.24 1.53 2.60 
19088 Prkar2b protein kinase, cAMP dependent 
regulatory, type II beta 
-2.11 1.16 1.22 2.99 
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71724 Aox3 aldehyde oxidase 3 -2.11 -1.06 2.70 5.40 
241263 Gpr158 G protein-coupled receptor 158 -2.03 1.20 1.70 4.15 
235106 Ntm neurotrimin -2.00 -1.20 1.64 2.73 
21743 Inmt indolethylamine N-
methyltransferase 
-2.00 1.06 3.45 7.33 
14658 Glrb glycine receptor, beta subunit -1.97 -1.03 1.77 3.39 
246317 Neto1 neuropilin (NRP) and tolloid 
(TLL)-like 1 
-1.95 -1.25 1.49 2.32 
20249 Scd1 stearoyl-Coenzyme A desaturase 1 -1.90 -1.16 2.20 3.62 
57262 Retnla resistin like alpha -1.89 -1.35 1.47 2.06 
664883 Nova1 neuro-oncological ventral antigen 
1 
-1.88 -1.06 1.60 2.85 
654812 Angptl7 angiopoietin-like 7 -1.85 1.11 1.23 2.52 
50908 C1s complement component 1, s 
subcomponent 
-1.85 1.09 1.16 2.33 
73748 Gadl1 glutamate decarboxylase-like 1 -1.79 -1.06 5.49 9.30 
246104 Rhbdl3 rhomboid, veinlet-like 3 
(Drosophila) 
-1.78 -1.37 1.78 2.31 
244198 Olfml1 olfactomedin-like 1 -1.76 -1.11 1.30 2.06 
74071 Ifltd1 intermediate filament tail domain 
containing 1 
-1.73 1.21 13.5 28.2 
54612 Sfrp5 secreted frizzled-related sequence 
protein 5 
-1.71 -1.04 1.75 2.87 
16000 Igf1 insulin-like growth factor 1 -1.70 -1.14 1.40 2.09 
73086 Rps6ka5 ribosomal protein S6 kinase, 
polypeptide 5 
-1.69 -1.10 1.96 3.01 
13008 Csrp2 cysteine and glycine-rich protein 2 -1.67 -1.26 2.72 3.62 
76829 Dok5 docking protein 5 -1.66 -1.02 1.76 2.88 
14579 Gem GTP binding protein (gene 
overexpressed in skeletal muscle) 
-1.64 1.11 1.31 2.39 
23967 Osr1 odd-skipped related 1 (Drosophila) -1.64 -1.27 4.38 5.64 
54635 Pdgfc platelet-derived growth factor, C 
polypeptide 
-1.64 -1.26 3.70 4.80 
18124 Nr4a3 nuclear receptor subfamily 4, 
group A, member 3 
-1.63 1.09 2.00 3.54 
20563 Slit2 slit homolog 2 (Drosophila) -1.62 -1.16 1.54 2.14 
13865 Nr2f1 nuclear receptor subfamily 2, 
group F, member 1 
-1.61 -1.14 1.79 2.55 
15370 Nr4a1 nuclear receptor subfamily 4, 
group A, member 1 
-1.61 -1.05 1.79 2.74 
21957 Tnnt3 troponin T3, skeletal, fast -1.58 1.13 1.14 2.03 
19888 Rp1 retinitis pigmentosa 1 (human) -1.57 -1.34 4.49 5.27 
56277 Tmem45a transmembrane protein 45a -1.56 -1.27 1.95 2.39 
217430 Pqlc3 PQ loop repeat containing -1.55 -1.12 1.51 2.08 
19225 Ptgs2 prostaglandin-endoperoxide 
synthase 2 
-1.55 -1.09 2.13 3.05 
14396 Gabra3 gamma-aminobutyric acid 
(GABA) A receptor, subunit alpha 
3 
-1.55 1.09 2.32 3.90 
18595 Pdgfra platelet derived growth factor 
receptor, alpha polypeptide 
-1.55 -1.16 1.52 2.02 
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76453 Prss23 protease, serine, 23 -1.54 1.02 1.55 2.44 
56429 Dpt dermatopontin -1.54 -1.12 1.75 2.41 
73732 Muc16 mucin 16 -1.53 -1.02 2.93 4.42 
240058 Cpne5 copine V -1.52 -1.12 7.95 10.8 
13487 Slc26a3 solute carrier family 26, member 3 -1.52 -1.00 2.85 4.30 
218294 Cdc14b CDC14 cell division cycle 14 
homolog B (S. cerevisiae) 
-1.52 -1.07 1.48 2.10 
17751 Mt3 metallothionein 3 1.54 1.31 2.47 2.10 
240638 Slc16a12 solute carrier family 16 
(monocarboxylic acid 
transporters), member 12 
1.55 1.20 3.08 2.39 
66438 Hamp2 hepcidin antimicrobial peptide 2 1.56 1.18 4.37 3.30 
546161 Fbxw18 F-box and WD-40 domain protein 
18 
1.59 1.15 28.3 20.4 
77836 Mlana melan-A 1.60 1.14 24.2 17.2 
71233 Enkur enkurin, TRPC channel interacting 
protein 
1.63 1.07 3.27 2.14 
320981 Enpp6 ectonucleotide 
pyrophosphatase/phosphodiesteras
e 6 
1.65 1.34 4.94 4.01 
74438 Clvs1 clavesin 1 1.71 -1.12 4.51 2.36 
382105 Fbxw15 F-box and WD-40 domain protein 
15 
1.71 -1.07 9.69 5.27 
24050 40789 septin 3 1.82 1.06 5.64 3.27 
170738 Kcnh7 potassium voltage-gated channel, 
subfamily H (eag-related), 
member 7 
1.89 -1.07 9.24 4.58 
12160 Bmp5 bone morphogenetic protein 5 2.03 1.20 9.03 5.35 
56808 Cacna2d2 calcium channel, voltage-
dependent, alpha 2/delta subunit 2 
2.21 1.03 16.8 7.87 
26950 Vsnl1 visinin-like 1 2.50 1.27 18.2 9.24 
 
A.1.1.2 Genes enriched in WT ventricular chambers 
Gene 
Number 
Symbol Description KOA/
WTA 
Fold 
KOV/
WTV 
Fold 
KOA/
KOV 
Fold 
WTA/
WTV 
Fold 
68016 Murc muscle-related coiled-coil protein -3.57 -1.12 -9.13 -2.86 
11607 Agtr1a angiotensin II receptor, type 1a -2.12 -1.05 -5.53 -2.75 
78910 Asb15 ankyrin repeat and SOCS box-
containing 15 
-1.67 -1.03 -5.47 -3.39 
76294 Asb5 ankyrin repeat and SOCs box-
containing 5 
-1.56 -1.16 -5.05 -3.75 
68854 Asb11 ankyrin repeat and SOCS box-
containing 11 
-1.56 -1.21 -2.69 -2.09 
71007 D7Ertd44
3e 
DNA segment, Chr 7, ERATO 
Doi 443, expressed 
1.51 1.34 -2.27 -2.55 
16373 Irx3 Iroquois related homeobox 3 
(Drosophila) 
1.52 -1.25 -1.10 -2.11 
11475 Acta2 actin, alpha 2, smooth muscle, 
aorta 
1.53 1.29 -2.04 -2.42 
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72088 Ush1c Usher syndrome 1C homolog 
(human) 
1.53 1.03 -1.83 -2.73 
353211 Prune2 prune homolog 2 (Drosophila) 1.57 1.10 -2.35 -3.36 
213989 Tmem82 transmembrane protein 82 1.57 -1.15 -1.62 -2.92 
17137 Magea1 melanoma antigen, family A, 1 1.57 -1.22 -1.17 -2.25 
55987 Cpxm2 carboxypeptidase X 2 (M14 
family) 
1.58 1.07 -2.31 -3.40 
258154 Olfr1029 olfactory receptor 1029 1.58 -1.09 -1.62 -2.80 
17762 Mapt microtubule-associated protein tau 1.63 1.09 -2.12 -3.17 
16509 Kcne1 potassium voltage-gated channel, 
Isk-related subfamily, member 1 
1.75 -1.03 -2.49 -4.46 
67149 Nkain1 Na+/K+ transporting ATPase 
interacting 1 
1.82 1.07 -2.12 -3.62 
17329 Cxcl9 chemokine (C-X-C motif) ligand 9 1.96 1.46 -2.05 -2.75 
380863 Tmem171 transmembrane protein 171 2.00 1.12 -1.47 -2.60 
73010 Gpr22 G protein-coupled receptor 22 2.02 1.09 -2.96 -5.48 
19215 Ptgds prostaglandin D2 synthase (brain) 2.98 1.19 -1.47 -3.69 
338417 Scgb1c1 secretoglobin, family 1C, member 
1 
3.18 -1.18 1.03 -3.62 
 
A.1.1.3 No enrichment in either WT atria or ventricles 
Gene 
Number 
Symbol Description KOA/
WTA 
Fold 
KOV/
WTV 
Fold 
KOA/
KOV 
Fold 
WTA/
WTV 
Fold 
231086 Hadhb hydroxyacyl-Coenzyme A 
dehydrogenase/3-ketoacyl-
Coenzyme A thiolase/enoyl-
Coenzyme A hydratase 
(trifunctional protein), beta 
subunit 
-3.35 1.00 -6.32 -1.88 
15951 Ifi204 interferon activated gene 204 -3.07 -1.31 -1.79 1.30 
353208 Zfp931 zinc finger protein 931 -2.88 1.42 -6.28 -1.54 
353374 Snord61 small nucleolar RNA, C/D box 61 -2.79 -1.28 -2.40 -1.10 
20383 Srsf3 serine/arginine-rich splicing factor 
3 
-2.71 1.14 -2.09 1.48 
18619 Penk preproenkephalin -2.53 -1.20 -1.56 1.35 
72397 Rbm12b RNA binding motif protein 12B -2.51 1.08 -1.67 1.62 
73710 Tubb2b tubulin, beta 2B -2.48 -1.06 -1.41 1.67 
15289 Hmgb1 high mobility group box 1 -2.44 1.04 -2.45 1.03 
12340 Capza1 capping protein (actin filament) 
muscle Z-line, alpha 1 
-2.43 1.23 -2.77 1.08 
27210 Snord34 small nucleolar RNA, C/D box 34 -2.42 -1.08 -1.31 1.72 
621893 Hist2h2ab histone cluster 2, H2ab -2.41 1.09 -2.37 1.11 
76022 Gon4l gon-4-like (C.elegans) -2.34 -1.20 -1.89 1.03 
80828 Snord82 small nucleolar RNA, C/D box 82 -2.29 -1.14 -1.41 1.43 
66167 Ccdc72 coiled-coil domain containing 72 -2.26 -1.01 -1.97 1.14 
226695 Ifi205 interferon activated gene 205 -2.16 -1.13 -1.43 1.34 
382245 Tmem29 transmembrane protein 29 -2.13 1.05 -1.62 1.38 
57264 Retn resistin -2.10 -1.09 -1.08 1.79 
69837 Pcgf1 polycomb group ring finger 1 -2.00 -1.10 -1.40 1.29 
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73738 Haus7 HAUS augmin-like complex, 
subunit 7 
-1.98 -1.28 -1.94 -1.25 
20259 Scin scinderin -1.97 -1.43 -1.60 -1.16 
319636 Fsd1l fibronectin type III and SPRY 
domain containing 1-like 
-1.96 -1.04 -3.51 -1.87 
68219 Nudt21 nudix (nucleoside diphosphate 
linked moiety X)-type motif 21 
-1.93 1.43 -2.07 1.33 
16404 Itga7 integrin alpha 7 -1.92 -1.18 -2.68 -1.65 
225825 Cd226 CD226 antigen -1.91 -1.13 -1.22 1.38 
234736 Rfwd3 ring finger and WD repeat domain 
3 
-1.90 -1.43 -1.48 -1.11 
26874 Abcd2 ATP-binding cassette, sub-family 
D (ALD), member 2 
-1.89 -1.35 -1.63 -1.16 
20091 Rps3a ribosomal protein S3A -1.89 -1.06 -1.44 1.24 
494519 Abpd androgen binding protein delta -1.87 -1.31 1.01 1.44 
223696 Tomm22 translocase of outer mitochondrial 
membrane 22 homolog (yeast) 
-1.86 -1.08 -2.17 -1.26 
667118 Zbed6 zinc finger, BED domain 
containing 6 
-1.85 1.02 -1.45 1.30 
545938 Zfp607 zinc finger proten 607 -1.84 1.06 -2.09 -1.07 
170938 Zfp617 zinc finger protein 617 -1.84 -1.03 -2.02 -1.13 
72560 Naalad2 N-acetylated alpha-linked acidic 
dipeptidase 2 
-1.83 -1.08 -1.09 1.54 
24001 Tiam2 T-cell lymphoma invasion and 
metastasis 2 
-1.83 -1.08 -1.08 1.57 
381067 Zfp229 zinc finger protein -1.80 -1.13 -1.72 -1.08 
17022 Lum lumican -1.79 -1.03 1.12 1.93 
14455 Gas5 growth arrest specific 5 -1.79 -1.09 -1.27 1.28 
20720 Serpine2 serine (or cysteine) peptidase 
inhibitor, clade E, member 2 
-1.78 -1.13 1.22 1.92 
21402 Skp1a S-phase kinase-associated protein 
1A 
-1.75 1.06 -1.72 1.08 
65103 Arl6ip6 ADP-ribosylation factor-like 6 
interacting protein 6 
-1.75 1.03 -1.70 1.06 
27209 Snord32a small nucleolar RNA, C/D box 
32A 
-1.74 -1.14 -1.19 1.28 
244923 Klhl31 kelch-like 31 (Drosophila) -1.73 -1.13 -2.57 -1.69 
56077 Dgke diacylglycerol kinase, epsilon -1.72 -1.20 -1.56 -1.09 
16518 Kcnj2 potassium inwardly-rectifying 
channel, subfamily J, member 2 
-1.72 -1.23 -1.90 -1.36 
214048 Larp1b La ribonucleoprotein domain 
family, member 1B 
-1.71 -1.02 -2.57 -1.53 
16500 Kcnb1 potassium voltage gated channel, 
Shab-related subfamily, member 1 
-1.71 -1.09 -2.63 -1.67 
13136 Cd55 CD55 antigen -1.70 -1.22 1.20 1.68 
67771 Arpc5 actin related protein 2/3 complex, 
subunit 5 
-1.70 1.06 -1.52 1.18 
18263 Odc1 ornithine decarboxylase, structural 
1 
-1.70 1.09 -2.55 -1.38 
234911 Mmp27 matrix metallopeptidase 27 -1.69 -1.39 1.30 1.58 
75458 Cklf chemokine-like factor -1.69 -1.23 1.37 1.88 
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16948 Lox lysyl oxidase -1.69 -1.36 -1.07 1.16 
407800 Ecm2 extracellular matrix protein 2, 
female organ and adipocyte 
specific 
-1.69 -1.19 -1.01 1.41 
66190 Acer3 alkaline ceramidase 3 -1.69 -1.18 -1.14 1.26 
271005 Klhdc1 kelch domain containing 1 -1.69 -1.38 -2.11 -1.72 
14727 Gp49a glycoprotein 49 A -1.69 -1.50 -1.47 -1.31 
30926 Glrx3 glutaredoxin 3 -1.68 1.04 -2.57 -1.47 
78506 Efha2 EF-hand domain family, member 
A2 
-1.67 1.05 -1.79 -1.02 
20229 Sat1 spermidine/spermine N1-acetyl 
transferase 1 
-1.67 -1.05 -1.04 1.54 
15129 Hbb-b1 hemoglobin, beta adult major 
chain 
-1.67 -1.06 -2.64 -1.67 
17420 Mnat1 menage a trois 1 -1.67 -1.03 -1.58 1.03 
67148 Fam103a1 family with sequence similarity 
103, member A1 
-1.67 -1.16 -1.25 1.15 
66222 Serpinb1a serine (or cysteine) peptidase 
inhibitor, clade B, member 1a 
-1.66 -1.26 -1.27 1.05 
245902 Ccdc15 coiled-coil domain containing 15 -1.66 -1.10 -1.27 1.19 
11450 Adipoq adiponectin, C1Q and collagen 
domain containing 
-1.66 -1.08 -1.11 1.38 
21808 Tgfb2 transforming growth factor, beta 2 -1.66 1.06 -1.15 1.53 
17181 Matn2 matrilin 2 -1.66 1.04 1.11 1.93 
14299 Ncs1 neuronal calcium sensor 1 -1.65 -1.24 -1.32 1.00 
209558 Enpp3 ectonucleotide 
pyrophosphatase/phosphodiesteras
e 3 
-1.65 -1.23 1.42 1.91 
628438 Hspe1-rs1 heat shock protein 1 (chaperonin 
10), related sequence 1 
-1.64 -1.11 -1.71 -1.16 
67733 Itgb3bp integrin beta 3 binding protein 
(beta3-endonexin) 
-1.64 -1.01 -1.36 1.18 
75316 Taf1d TATA box binding protein (Tbp)-
associated factor, RNA 
polymerase I, D 
-1.64 -1.21 -1.34 1.00 
79560 Ublcp1 ubiquitin-like domain containing 
CTD phosphatase 1 
-1.63 -1.16 -1.62 -1.15 
50720 Sacs sacsin -1.63 -1.11 -2.08 -1.41 
12212 Chic1 cysteine-rich hydrophobic domain 
1 
-1.62 1.12 -1.11 1.64 
12589 Ift81 intraflagellar transport 81 homolog 
(Chlamydomonas) 
-1.62 -1.16 -1.66 -1.19 
214804 Syde2 synapse defective 1, Rho GTPase, 
homolog 2 (C. elegans) 
-1.62 -1.34 1.33 1.61 
16420 Itgb6 integrin beta 6 -1.61 -1.42 -1.86 -1.64 
18933 Prrx1 paired related homeobox 1 -1.61 -1.23 -2.18 -1.67 
226548 Aph1a anterior pharynx defective 1a 
homolog (C. elegans) 
-1.61 1.24 -1.46 1.37 
70676 Gulp1 GULP, engulfment adaptor PTB 
domain containing 1 
-1.61 -1.17 -1.3 1.05 
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66488 Fam136a family with sequence similarity 
136, member A 
-1.60 1.15 -2.98 -1.60 
107476 Acaca acetyl-Coenzyme A carboxylase 
alpha 
-1.60 1.12 1.00 1.81 
142687 Asb14 ankyrin repeat and SOCS box-
containing 14 
-1.60 -1.43 -2.15 -1.91 
19258 Ptpn4 protein tyrosine phosphatase, non-
receptor type 4 
-1.60 -1.13 -1.80 -1.26 
93761 Smarca1 SWI/SNF related, matrix 
associated, actin dependent 
regulator of chromatin, subfamily 
a, member 1 
-1.60 -1.17 1.01 1.39 
258571 Olfr1033 olfactory receptor 1033 -1.6 -1.28 -1.93 -1.54 
242735 Lrrc38 leucine rich repeat containing 38 -1.59 -1.10 1.00 1.45 
66573 Dzip1 DAZ interacting protein 1 -1.59 -1.07 1.10 1.64 
234344 Naf1 nuclear assembly factor 1 
homolog (S. cerevisiae) 
-1.59 -1.09 -1.10 1.31 
224585 Zfp160 zinc finger protein 160 -1.59 1.11 -1.22 1.44 
383619 Aim2 absent in melanoma 2 -1.59 -1.26 -1.3 -1.03 
18669 Abcb1b ATP-binding cassette, sub-family 
B (MDR/TAP), member 1B 
-1.59 -1.09 -1.15 1.26 
26399 Map2k6 mitogen-activated protein kinase 
kinase 6 
-1.59 -1.28 1.25 1.55 
83964 Jam3 junction adhesion molecule 3 -1.58 -1.19 1.32 1.75 
381236 Lipo1 lipase, member O1 -1.58 -1.11 -1.04 1.35 
66789 Alg14 asparagine-linked glycosylation 14 
homolog (yeast) 
-1.58 -1.03 -1.17 1.31 
64050 Yeats4 YEATS domain containing 4 -1.58 -1.09 -1.64 -1.14 
67010 Rbm7 RNA binding motif protein 7 -1.57 -1.00 -1.43 1.1 
245026 Col6a6 collagen, type VI, alpha 6 -1.57 -1.11 1.02 1.45 
252966 Cables2 CDK5 and Abl enzyme substrate 2 -1.57 1.01 -1.82 -1.14 
74600 Mrpl47 mitochondrial ribosomal protein 
L47 
-1.56 -1.09 -2.35 -1.63 
66799 Ube2w ubiquitin-conjugating enzyme 
E2W (putative) 
-1.56 1.06 -1.41 1.17 
240067 Zfp952 zinc finger protein 952 -1.56 1.03 -1.56 1.03 
67115 Rpl14 ribosomal protein L14 -1.56 -1.27 -1.34 -1.09 
213056 Fam126b family with sequence similarity 
126, member B 
-1.56 1.14 -1.99 -1.11 
13684 Eif4e eukaryotic translation initiation 
factor 4E 
-1.56 1.02 -2.04 -1.27 
109676 Ank2 ankyrin 2, brain -1.56 -1.10 -1.91 -1.36 
21898 Tlr4 toll-like receptor 4 -1.56 1.01 -2.60 -1.64 
14677 Gnai1 guanine nucleotide binding protein 
(G protein), alpha inhibiting 1 
-1.56 -1.06 1.20 1.76 
75894 Adal adenosine deaminase-like -1.56 -1.10 -1.4 1.01 
449630 Snord15a small nucleolar RNA, C/D box 
15A 
-1.55 -1.20 -1.45 -1.12 
66205 Cd302 CD302 antigen -1.55 -1.19 1.17 1.54 
227485 Cdh19 cadherin 19, type 2 -1.55 -1.38 1.02 1.15 
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66341 Eid3 EP300 interacting inhibitor of 
differentiation 3 
-1.55 -1.03 -1.30 1.15 
170823 Glmn glomulin, FKBP associated 
protein 
-1.55 -1.14 -1.27 1.06 
74385 Mudeng MU-2/AP1M2 domain containing, 
death-inducing 
-1.55 -1.04 -1.33 1.10 
27207 Rps11 ribosomal protein S11 -1.54 -1.06 -1.23 1.17 
56334 Tmed2 transmembrane emp24 domain 
trafficking protein 2 
-1.54 -1.13 -1.07 1.26 
18148 Npm1 nucleophosmin 1 -1.54 -1.08 -1.32 1.07 
16341 Eif3e eukaryotic translation initiation 
factor 3, subunit E 
-1.54 1.06 -1.62 1.01 
258668 Olfr823 olfactory receptor 823 -1.54 1.46 -1.30 1.72 
14173 Fgf2 fibroblast growth factor 2 -1.53 -1.06 1.06 1.53 
213068 Tmem71 transmembrane protein 71 -1.53 -1.13 -1.94 -1.44 
381831 Igkv4-58 immunoglobulin kappa variable 4-
58 
-1.53 1.44 -1.60 1.38 
244713 Zfp317 zinc finger protein 317 -1.53 -1.08 -1.32 1.05 
56050 Cyp39a1 cytochrome P450, family 39, 
subfamily a, polypeptide 1 
-1.53 -1.22 -1.07 1.15 
233276 Tubgcp5 tubulin, gamma complex 
associated protein 5 
-1.53 -1.13 -1.16 1.14 
408067 Zfp874b zinc finger protein 874b -1.52 -1.03 -1.37 1.07 
14105 Srsf10 serine/arginine-rich splicing factor 
10 
-1.52 -1.17 -1.27 1.01 
16329 Inpp1 inositol polyphosphate-1-
phosphatase 
-1.52 -1.17 -1.69 -1.30 
93737 Pard6g par-6 partitioning defective 6 
homolog gamma (C. elegans) 
-1.52 -1.10 1.10 1.52 
76915 Mnd1 meiotic nuclear divisions 1 
homolog (S. cerevisiae) 
-1.52 1.26 -1.22 1.57 
434423 Dppa5a developmental pluripotency 
associated 5A 
-1.52 1.04 -1.30 1.22 
20230 Satb1 special AT-rich sequence binding 
protein 1 
-1.52 -1.19 -1.40 -1.10 
330323 Fam188b family with sequence similarity 
188, member B 
-1.52 1.02 1.11 1.73 
20688 Sp4 trans-acting transcription factor 4 -1.52 -1.11 -1.13 1.20 
228003 Kbtbd10 kelch repeat and BTB (POZ) 
domain containing 10 
-1.51 -1.40 1.00 1.08 
21780 Tfam transcription factor A, 
mitochondrial 
-1.51 1.01 -2.13 -1.38 
13823 Epb4.1l3 erythrocyte protein band 4.1-like 3 -1.51 -1.17 1.43 1.84 
229780 Ccdc76 coiled-coil domain containing 76 -1.51 1.07 -1.45 1.11 
241568 Lrrc4c leucine rich repeat containing 4C -1.51 -1.07 -1.06 1.32 
66254 Dimt1 DIM1 dimethyladenosine 
transferase 1-like (S. cerevisiae) 
-1.51 1.07 -1.43 1.13 
66880 Rsrc1 arginine/serine-rich coiled-coil 1 -1.51 -1.08 -1.29 1.08 
68526 Gpr155 G protein-coupled receptor 155 -1.50 -1.32 -1.14 -1.01 
269132 Glt25d2 glycosyltransferase 25 domain 
containing 2 
-1.50 -1.07 -1.57 -1.12 
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242050 Igsf10 immunoglobulin superfamily, 
member 10 
-1.50 -1.14 1.16 1.53 
15109 Hal histidine ammonia lyase -1.50 -1.27 1.03 1.21 
17084 Ly86 lymphocyte antigen 86 -1.50 -1.04 -1.05 1.37 
18491 Pappa pregnancy-associated plasma 
protein A 
-1.50 -1.24 1.49 1.80 
140483 Hnmt histamine N-methyltransferase -1.50 -1.30 1.27 1.46 
104943 Fam110c family with sequence similarity 
110, member C 
-1.50 -1.08 1.14 1.58 
436583 Snora74a small nucleolar RNA, H/ACA box 
74A 
-1.50 -1.27 -1.23 -1.04 
226182 Taf5 TAF5 RNA polymerase II, TATA 
box binding protein (TBP)-
associated factor 
-1.50 -1.17 -1.19 1.06 
72504 Taf4b TAF4B RNA polymerase II, 
TATA box binding protein (TBP)-
associated factor 
-1.50 -1.07 -1.76 -1.26 
56078 Car5b carbonic anhydrase 5b, 
mitochondrial 
-1.50 1.18 -1.27 1.39 
21953 Tnni2 troponin I, skeletal, fast 2 -1.50 -1.15 1.10 1.43 
15426 Hoxc8 homeobox C8 1.50 1.07 1.17 -1.19 
114889 Vsx1 visual system homeobox 1 
homolog (zebrafish) 
1.50 -1.04 1.40 -1.11 
54651 Usp27x ubiquitin specific peptidase 27, X 
chromosome 
1.50 -1.07 1.57 -1.02 
258377 Olfr654 olfactory receptor 654 1.50 -1.03 1.47 -1.05 
14086 Fscn1 fascin homolog 1, actin bundling 
protein (Strongylocentrotus 
purpuratus) 
1.50 1.18 -1.16 -1.47 
68509 Ptx4 pentraxin 4 1.50 1.07 1.44 1.02 
18588 Pde6g phosphodiesterase 6G, cGMP-
specific, rod, gamma 
1.50 -1.23 1.60 -1.16 
545817 Cyp2w1 cytochrome P450, family 2, 
subfamily w, polypeptide 1 
1.50 -1.03 1.46 -1.06 
56811 Dkk2 dickkopf homolog 2 (Xenopus 
laevis) 
1.50 -1.08 1.34 -1.21 
269356 Slc4a11 solute carrier family 4, sodium 
bicarbonate transporter-like, 
member 11 
1.50 -1.09 1.27 -1.29 
625823 Vmn1r1 vomeronasal 1 receptor 1 1.50 -1.08 1.50 -1.08 
56365 Clcnkb chloride channel Kb 1.50 1.10 1.18 -1.15 
14773 Grk5 G protein-coupled receptor kinase 
5 
1.51 1.47 -1.03 -1.06 
244550 Podnl1 podocan-like 1 1.51 1.17 1.37 1.06 
259172 Mfrp membrane-type frizzled-related 
protein 
1.51 -1.01 1.63 1.06 
15486 Hsd17b2 hydroxysteroid (17-beta) 
dehydrogenase 2 
1.51 -1.09 2.05 1.23 
170761 Pdzd3 PDZ domain containing 3 1.51 1.04 1.06 -1.35 
69638 Enho energy homeostasis associated 1.51 -1.17 1.71 -1.04 
18261 Ocm oncomodulin 1.51 1.28 1.10 -1.07 
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235582 Glyctk glycerate kinase 1.51 1.06 1.43 1.01 
16198 Il9 interleukin 9 1.51 -1.12 1.57 -1.08 
108114 Slc22a7 solute carrier family 22 (organic 
anion transporter), member 7 
1.51 1.01 1.66 1.11 
18787 Serpine1 serine (or cysteine) peptidase 
inhibitor, clade E, member 1 
1.51 1.43 -1.32 -1.40 
12534 Cdk1 cyclin-dependent kinase 1 1.51 -1.04 1.06 -1.48 
258833 Olfr1132 olfactory receptor 1132 1.51 -1.00 1.28 -1.17 
243090 BC05107
6 
cDNA sequence BC051076 1.51 -1.08 1.36 -1.20 
22773 Zic3 zinc finger protein of the 
cerebellum 3 
1.51 -1.19 1.39 -1.29 
235628 Prss42 protease, serine, 42 1.51 -1.02 1.40 -1.09 
66727 Hrasls5 HRAS-like suppressor family, 
member 5 
1.51 -1.22 1.61 -1.14 
70274 Ly6g6e lymphocyte antigen 6 complex, 
locus G6E 
1.51 1.04 1.33 -1.08 
69655 Cd164l2 CD164 sialomucin-like 2 1.51 -1.21 1.60 -1.14 
16668 Krt18 keratin 18 1.51 -1.08 2.34 1.41 
14580 Gfap glial fibrillary acidic protein 1.52 -1.09 1.36 -1.21 
245865 Spag4 sperm associated antigen 4 1.52 1.05 1.30 -1.09 
235044 BC01824
2 
cDNA sequence BC018242 1.52 1.14 1.04 -1.27 
626299 Vmn1r19
4 
vomeronasal 1 receptor 194 1.52 1.22 1.15 -1.08 
18292 Sebox SEBOX homeobox 1.52 -1.24 1.41 -1.33 
19094 Mapk11 mitogen-activated protein kinase 
11 
1.52 -1.01 -1.07 -1.66 
57442 Kcne3 potassium voltage-gated channel, 
Isk-related subfamily, gene 3 
1.52 1.00 1.24 -1.21 
80986 Ckap2 cytoskeleton associated protein 2 1.53 -1.00 1.10 -1.39 
11425 Apoc4 apolipoprotein C-IV 1.53 1.01 1.37 -1.09 
667441 Trav3-1 T cell receptor alpha variable 3-1 1.53 1.15 1.68 1.27 
70571 Tcerg1l transcription elongation regulator 
1-like 
1.53 1.09 1.28 -1.08 
18332 Olfr33 olfactory receptor 33 1.53 -1.02 1.30 -1.19 
13446 Doc2a double C2, alpha 1.53 1.03 1.46 -1.01 
110785 Iglc1 immunoglobulin lambda constant 
1 
1.53 1.44 1.03 -1.03 
12209 Brs3 bombesin-like receptor 3 1.53 -1.09 1.56 -1.07 
20505 Slc34a1 solute carrier family 34 (sodium 
phosphate), member 1 
1.53 -1.12 1.46 -1.18 
20204 Prrx2 paired related homeobox 2 1.53 -1.15 2.88 1.62 
20211 Saa4 serum amyloid A 4 1.53 1.11 1.22 -1.12 
271424 Ip6k3 inositol hexaphosphate kinase 3 1.54 -1.23 -1.00 -1.90 
73259 Cib4 calcium and integrin binding 
family member 4 
1.54 -1.02 1.37 -1.14 
21414 Tcf7 transcription factor 7, T-cell 
specific 
1.54 1.10 1.53 1.10 
277978 Exoc3l exocyst complex component 3-like 1.54 1.13 1.26 -1.07 
69564 Itgb1bp3 integrin beta 1 binding protein 3 1.54 1.12 2.54 1.85 
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11488 Adam11 a disintegrin and metallopeptidase 
domain 11 
1.54 -1.11 2.32 1.34 
72040 Cdhr5 cadherin-related family member 5 1.54 1.15 1.23 -1.08 
21960 Tnr tenascin R 1.54 1.21 1.30 1.02 
212937 Tifab TRAF-interacting protein with 
forkhead-associated domain, 
family member B 
1.54 -1.02 1.14 -1.38 
20871 Aurkc aurora kinase C 1.54 1.08 1.20 -1.18 
11989 Slc7a3 solute carrier family 7 (cationic 
amino acid transporter, y+ 
system), member 3 
1.54 1.32 1.33 1.14 
69219 Ddah1 dimethylarginine 
dimethylaminohydrolase 1 
1.54 1.37 -1.53 -1.72 
12563 Cdh6 cadherin 6 1.54 1.48 -1.20 -1.25 
104080 Nxph4 neurexophilin 4 1.55 1.03 1.34 -1.11 
16005 Igfals insulin-like growth factor binding 
protein, acid labile subunit 
1.55 1.26 -1.34 -1.65 
280635 Emilin3 elastin microfibril interfacer 3 1.55 1.05 1.25 -1.16 
12518 Cd79a CD79A antigen (immunoglobulin-
associated alpha) 
1.55 1.06 1.21 -1.20 
71664 Mettl7b methyltransferase like 7B 1.55 -1.08 1.44 -1.16 
654821 Gcnt7 glucosaminyl (N-acetyl) 
transferase family member 7 
1.55 1.05 1.33 -1.10 
224840 Treml4 triggering receptor expressed on 
myeloid cells-like 4 
1.55 1.02 1.30 -1.16 
234700 Nrn1l neuritin 1-like 1.55 -1.06 1.59 -1.03 
18329 Olfr30 olfactory receptor 30 1.55 -1.10 1.61 -1.05 
258303 Olfr518 olfactory receptor 518 1.55 -1.00 1.41 -1.10 
14562 Gdf3 growth differentiation factor 3 1.55 -1.10 1.51 -1.12 
170828 Vgll1 vestigial like 1 homolog 
(Drosophila) 
1.55 -1.14 1.51 -1.18 
74673 Spdyb speedy homolog B (Xenopus 
laevis) 
1.55 -1.09 1.18 -1.44 
21405 Hnf1a HNF1 homeobox A 1.55 1.08 1.42 -1.00 
18349 Olfr5 olfactory receptor 5 1.56 -1.00 1.42 -1.10 
258423 Olfr1510 olfactory receptor 1510 1.56 -1.03 1.55 -1.03 
11470 Actl7a actin-like 7a 1.56 -1.08 1.53 -1.10 
16560 Kif1a kinesin family member 1A 1.56 1.00 2.48 1.60 
259116 Olfr559 olfactory receptor 559 1.56 -1.23 1.32 -1.45 
18781 Pla2g2c phospholipase A2, group IIC 1.56 1.18 1.36 1.03 
74488 Lrrc15 leucine rich repeat containing 15 1.56 1.16 -1.01 -1.36 
69539 Trnp1 TMF1-regulated nuclear protein 1 1.57 1.11 1.62 1.15 
19039 Lgals3bp lectin, galactoside-binding, 
soluble, 3 binding protein 
1.57 1.16 1.12 -1.20 
20389 Sftpc surfactant associated protein C 1.57 -1.25 1.60 -1.23 
14766 Gpr56 G protein-coupled receptor 56 1.57 1.05 -1.13 -1.69 
620235 Siglec15 sialic acid binding Ig-like lectin 15 1.57 -1.02 1.49 -1.07 
78088 Ankrd56 ankyrin repeat domain 56 1.57 1.00 1.57 1.00 
210673 Prrt3 proline-rich transmembrane 
protein 3 
1.57 -1.16 1.25 -1.45 
54419 Cldn6 claudin 6 1.57 1.02 1.43 -1.07 
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328699 Gabrr3 gamma-aminobutyric acid 
(GABA) receptor, rho 3 
1.57 1.00 1.29 -1.21 
12684 Cideb cell death-inducing DNA 
fragmentation factor, alpha 
subunit-like effector B 
1.58 1.34 1.43 1.21 
330890 Piwil4 piwi-like homolog 4 (Drosophila) 1.58 1.29 1.48 1.21 
11925 Neurog3 neurogenin 3 1.58 1.02 1.60 1.03 
630294 H2-t9 MHC class Ib T9 1.58 1.44 1.67 1.52 
11872 Art2b ADP-ribosyltransferase 2b 1.58 1.00 1.35 -1.17 
114712 Ferd3l Fer3-like (Drosophila) 1.58 1.05 1.37 -1.09 
21853 Timeless timeless homolog (Drosophila) 1.58 1.14 1.06 -1.30 
67874 Rprm reprimo, TP53 dependent G2 
arrest mediator candidate 
1.58 1.08 1.40 -1.04 
77531 Anks1b ankyrin repeat and sterile alpha 
motif domain containing 1B 
1.58 1.07 1.16 -1.26 
259111 Olfr974 olfactory receptor 974 1.58 -1.05 1.34 -1.24 
114640 Pth2 parathyroid hormone 2 1.59 1.06 1.60 1.07 
76527 Il34 interleukin 34 1.59 -1.11 1.06 -1.67 
94179 Krt23 keratin 23 1.59 1.11 1.36 -1.04 
13088 Cyp2b10 cytochrome P450, family 2, 
subfamily b, polypeptide 10 
1.59 -1.11 2.20 1.24 
14990 H2-M2 histocompatibility 2, M region 
locus 2 
1.59 1.00 1.71 1.07 
13392 Dlx2 distal-less homeobox 2 1.59 1.01 1.33 -1.17 
258309 Olfr657 olfactory receptor 657 1.59 -1.33 1.33 -1.60 
17144 Magea8 melanoma antigen, family A, 8 1.59 -1.08 1.52 -1.14 
257932 Olfr332 olfactory receptor 332 1.59 1.16 1.37 1.00 
280621 BC08949
1 
cDNA sequence BC089491 1.59 1.42 1.36 1.21 
14068 F7 coagulation factor VII 1.59 -1.30 1.55 -1.34 
625530 Dub3 deubiquitinating enzyme 3 1.60 -1.29 1.62 -1.27 
72269 Cda cytidine deaminase 1.60 1.15 1.53 1.11 
23966 Odz4 odd Oz/ten-m homolog 4 
(Drosophila) 
1.60 1.05 1.19 -1.26 
17386 Mmp13 matrix metallopeptidase 13 1.60 1.10 1.04 -1.39 
546648 Klhdc7b kelch domain containing 7B 1.60 -1.07 1.44 -1.19 
106014 Fam19a5 family with sequence similarity 
19, member A5 
1.60 1.12 1.08 -1.32 
104245 Slc6a5 solute carrier family 6 
(neurotransmitter transporter, 
glycine), member 5 
1.61 1.05 1.26 -1.20 
56293 Amac1 acyl-malonyl condensing enzyme 
1 
1.61 1.19 1.28 -1.05 
620105 Igkv1-35 immunoglobulin kappa chain 
variable 1-35 
1.61 -1.13 1.54 -1.17 
11838 Arc activity regulated cytoskeletal-
associated protein 
1.61 1.43 1.25 1.11 
73340 Nptxr neuronal pentraxin receptor 1.61 1.01 1.25 -1.26 
231821 Adap1 ArfGAP with dual PH domains 1 1.61 -1.02 1.92 1.15 
319217 Vmn2r7 vomeronasal 2, receptor 7 1.61 1.10 1.30 -1.12 
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22784 Slc30a3 solute carrier family 30 (zinc 
transporter), member 3 
1.62 -1.02 1.47 -1.12 
271711 Tmem169 transmembrane protein 169 1.63 -1.24 1.66 -1.22 
211027 Trav3-4 T cell receptor alpha variable 3-4 1.63 1.49 1.63 1.49 
109332 Cdcp1 CUB domain containing protein 1 1.63 -1.43 3.34 1.43 
140806 Il25 interleukin 25 1.63 1.21 1.10 -1.22 
20344 Selp selectin, platelet 1.63 1.33 1.40 1.14 
11648 Akp3 alkaline phosphatase 3, intestine, 
not Mn requiring 
1.63 1.22 1.18 -1.12 
16517 Kcnj16 potassium inwardly-rectifying 
channel, subfamily J, member 16 
1.63 -1.15 1.59 -1.19 
230579 Fam151a family with sequence simliarity 
151, member A 
1.63 1.07 1.30 -1.16 
235416 Lman1l lectin, mannose-binding 1 like 1.63 1.13 1.38 -1.04 
15376 Foxa2 forkhead box A2 1.64 1.03 1.19 -1.33 
213765 BC12533
2 
cDNA sequence BC125332 1.65 -1.10 1.60 -1.14 
12143 Blk B lymphoid kinase 1.65 1.18 1.17 -1.19 
226781 Slc30a10 solute carrier family 30, member 
10 
1.65 1.07 1.10 -1.39 
225471 Ticam2 toll-like receptor adaptor molecule 
2 
1.65 1.08 1.31 -1.15 
106407 Osta organic solute transporter alpha 1.66 1.14 1.40 -1.03 
272382 Spib Spi-B transcription factor (Spi-
1/PU.1 related) 
1.66 1.08 1.40 -1.10 
330863 Trim67 tripartite motif-containing 67 1.66 -1.09 2.57 1.41 
71562 Afmid arylformamidase 1.66 1.36 1.81 1.48 
404316 Olfr403 olfactory receptor 403 1.66 1.13 1.18 -1.23 
258087 Olfr963 olfactory receptor 963 1.67 -1.09 1.30 -1.40 
667550 Igkv10-94 immunoglobulin kappa variable 
10-94 
1.67 1.23 1.47 1.09 
226180 Ina internexin neuronal intermediate 
filament protein, alpha 
1.67 -1.07 1.57 -1.14 
320631 Abca15 ATP-binding cassette, sub-family 
A (ABC1), member 15 
1.67 1.15 1.39 -1.04 
209176 Ido2 indoleamine 2,3-dioxygenase 2 1.68 1.00 1.30 -1.28 
432576 Tmem95 transmembrane protein 95 1.68 1.11 1.38 -1.09 
72185 Dbndd1 dysbindin (dystrobrevin binding 
protein 1) domain containing 1 
1.68 -1.12 1.43 -1.31 
17231 Mcpt8 mast cell protease 8 1.68 1.23 1.38 1.00 
69902 Mrto4 MRT4, mRNA turnover 4, 
homolog (S. cerevisiae) 
1.69 1.48 -1.43 -1.62 
668257 Dgat2l6 diacylglycerol O-acyltransferase 
2-like 6 
1.69 -1.16 1.54 -1.26 
231290 Slc10a4 solute carrier family 10 
(sodium/bile acid cotransporter 
family), member 4 
1.70 1.09 -1.02 -1.59 
11658 Alcam activated leukocyte cell adhesion 
molecule 
1.70 1.12 2.62 1.73 
21877 Tk1 thymidine kinase 1 1.70 -1.06 1.72 -1.05 
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243755 Slc13a4 solute carrier family 13 
(sodium/sulfate symporters), 
member 4 
1.70 1.09 2.01 1.28 
16016 Ighg2b immunoglobulin heavy constant 
gamma 2B 
1.71 -1.16 2.14 1.07 
19373 Rag1 recombination activating gene 1 1.71 -1.09 1.56 -1.19 
17285 Meox1 mesenchyme homeobox 1 1.71 1.27 -1.02 -1.39 
18125 Nos1 nitric oxide synthase 1, neuronal 1.71 1.08 1.45 -1.08 
107993 Bfsp2 beaded filament structural protein 
2, phakinin 
1.72 -1.05 2.01 1.11 
258985 Olfr1256 olfactory receptor 1256 1.72 1.21 1.22 -1.16 
258383 Olfr1347 olfactory receptor 1347 1.72 -1.29 2.05 -1.08 
18072 Nhlh2 nescient helix loop helix 2 1.72 1.05 1.13 -1.44 
12709 Ckb creatine kinase, brain 1.73 1.46 1.27 1.08 
94215 Ugt2a1 UDP glucuronosyltransferase 2 
family, polypeptide A1 
1.73 -1.07 1.78 -1.04 
193034 Trpv1 transient receptor potential cation 
channel, subfamily V, member 1 
1.74 1.10 1.33 -1.18 
83380 Prp2 proline rich protein 2 1.75 -1.04 1.60 -1.13 
434484 Sp140 Sp140 nuclear body protein 1.75 -1.19 1.55 -1.34 
258541 Olfr800 olfactory receptor 800 1.75 -1.18 1.90 -1.09 
434017 Vmn1r20 vomeronasal 1 receptor 20 1.76 -1.09 -1.01 -1.96 
404336 Olfr1380 olfactory receptor 1380 1.76 1.18 1.67 1.12 
269019 Stk32a serine/threonine kinase 32A 1.76 -1.11 2.45 1.24 
20965 Syn2 synapsin II 1.77 -1.03 3.24 1.76 
11688 Alox8 arachidonate 8-lipoxygenase 1.77 -1.07 2.33 1.22 
14408 Gabrr1 gamma-aminobutyric acid 
(GABA) C receptor, subunit rho 1 
1.78 -1.03 1.99 1.08 
66120 Fkbp11 FK506 binding protein 11 1.78 1.20 2.17 1.45 
380702 Shisa6 shisa homolog 6 (Xenopus 
laevis) 
1.79 -1.14 2.23 1.08 
54150 Rdh7 retinol dehydrogenase 7 1.80 -1.18 1.64 -1.30 
229302 Tm4sf4 transmembrane 4 superfamily 
member 4 
1.81 1.22 1.55 1.05 
71970 Scand3 SCAN domain containing 3 1.82 -1.10 1.75 -1.15 
330581 Vmn2r69 vomeronasal 2, receptor 69 1.83 -1.19 1.42 -1.53 
15965 Ifna2 interferon alpha 2 1.83 1.25 1.18 -1.23 
258525 Olfr1170 olfactory receptor 1170 1.84 1.17 1.07 -1.46 
18346 Olfr47 olfactory receptor 47 1.84 -1.00 1.31 -1.41 
233870 Tufm Tu translation elongation factor, 
mitochondrial 
1.84 1.10 2.14 1.28 
387132 Ssxb2 synovial sarcoma, X member B, 
breakpoint 2 
1.85 1.03 1.22 -1.45 
17116 Mab21l1 mab-21-like 1 (C. elegans) 1.85 -1.11 1.65 -1.24 
16017 Ighg1 immunoglobulin heavy constant 
gamma 1 (G1m marker) 
1.85 1.09 1.77 1.04 
232345 A2m alpha-2-macroglobulin 1.86 1.09 2.60 1.52 
14065 F2rl3 coagulation factor II (thrombin) 
receptor-like 3 
1.86 -1.14 1.63 -1.29 
20301 Ccl27a chemokine (C-C motif) ligand 
27A 
1.86 -1.33 1.49 -1.67 
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74091 Npl N-acetylneuraminate pyruvate 
lyase 
1.87 -1.00 1.96 1.04 
53610 Nono non-POU-domain-containing, 
octamer binding protein 
1.87 -1.16 1.38 -1.57 
16007 Cyr61 cysteine rich protein 61 1.87 1.33 1.49 1.06 
14407 Gabrg3 gamma-aminobutyric acid 
(GABA) A receptor, subunit 
gamma 3 
1.87 1.31 1.18 -1.20 
23882 Gadd45g growth arrest and DNA-damage-
inducible 45 gamma 
1.87 1.31 1.98 1.39 
59069 Tpm3 tropomyosin 3, gamma 1.88 1.01 1.26 -1.46 
14816 Grm1 glutamate receptor, metabotropic 1 1.88 1.24 -1.26 -1.92 
213649 Arhgef19 Rho guanine nucleotide 
exchange factor (GEF) 19 
1.90 1.39 1.16 -1.17 
258156 Olfr605 olfactory receptor 605 1.95 1.06 1.23 -1.48 
71733 Susd2 sushi domain containing 2 1.96 1.08 3.45 1.90 
58243 Nap1l5 nucleosome assembly protein 1-
like 5 
1.96 1.18 2.70 1.62 
69121 Chrdl2 chordin-like 2 1.99 1.04 2.34 1.22 
16616 Klk1b21 kallikrein 1-related peptidase b21 2.01 -1.32 1.68 -1.57 
74267 Iqcf1 IQ motif containing F1 2.01 1.19 1.72 1.02 
64293 Stk32b serine/threonine kinase 32B 2.01 1.29 2.95 1.89 
636752 Igkv4-62 immunoglobulin kappa variable 4-
62 
2.02 1.00 1.42 -1.41 
625131 Vmn2r87 vomeronasal 2, receptor 87 2.02 -1.01 1.54 -1.33 
66373 Lsm5 LSM5 homolog, U6 small nuclear 
RNA associated (S. cerevisiae) 
2.02 -1.14 1.56 -1.48 
15018 H2-Q7 histocompatibility 2, Q region 
locus 7 
2.03 1.23 1.01 -1.62 
16617 Klk1b24 kallikrein 1-related peptidase b24 2.09 1.07 1.36 -1.42 
258315 Olfr767 olfactory receptor 767 2.14 1.17 2.13 1.17 
636177 Rhox4f reproductive homeobox 4F 2.20 -1.20 3.02 1.13 
320452 P4ha3 procollagen-proline, 2-
oxoglutarate 4-dioxygenase 
(proline 4-hydroxylase), alpha 
polypeptide III 
2.22 -1.11 4.09 1.64 
404737 Igl-J1 immunoglobulin lambda chain, 
joining region 1 
2.26 1.17 1.14 -1.68 
10003894
7 
LOC1000
38947 
signal-regulatory protein beta 1-
like 
2.26 -1.13 1.91 -1.34 
237221 Gemin8 gem (nuclear organelle) associated 
protein 8 
2.27 1.34 1.89 1.12 
19131 Prh1 proline rich protein HaeIII 
subfamily 1 
2.32 1.06 1.35 -1.62 
268697 Ccnb1 cyclin B1 2.44 1.49 1.44 -1.13 
258737 Olfr1316 olfactory receptor 1316 2.46 -1.07 1.34 -1.95 
209195 Clic6 chloride intracellular channel 6 2.83 1.14 3.60 1.46 
19051 Gsbs G substrate 5.10 -1.24 9.25 1.45 
 
A.1.2 Tables of genes dysregulated in KO ventricles 
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A.1.2.1 Enriched in WT atrial chambers 
Gene 
Number 
Symbol Description KOA/
WTA 
Fold 
KOV/
WTV 
Fold 
KOA/
KOV 
Fold 
WTA/
WTV 
Fold 
329502 Pla2g4e phospholipase A2, group IVE -1.43 -1.94 4.13 3.05 
66402 Sln sarcolipin -1.03 -1.81 123.70 70.90 
216616 Efemp1 epidermal growth factor-
containing fibulin-like 
extracellular matrix protein 1 
-1.23 -1.62 4.25 3.23 
239618 Pdzrn4 PDZ domain containing RING 
finger 4 
-1.37 -1.61 4.43 3.78 
22228 Ucp2 uncoupling protein 2 
(mitochondrial, proton carrier) 
1.06 1.51 2.59 3.68 
20250 Scd2 stearoyl-Coenzyme A desaturase 2 1.04 1.53 1.52 2.23 
14190 Fgl2 fibrinogen-like protein 2 1.01 1.55 1.36 2.08 
18162 Npr3 natriuretic peptide receptor 3 1.12 1.60 4.66 6.68 
77674 Defb12 defensin beta 12 -1.11 1.62 1.15 2.06 
23836 Cdh20 cadherin 20 1.37 1.66 2.39 2.89 
245578 Pcdh11x protocadherin 11 X-linked -1.12 1.71 1.17 2.23 
13024 Ctla2a cytotoxic T lymphocyte-associated 
protein 2 alpha 
-1.50 1.71 1.35 3.47 
18260 Ocln occludin -1.03 1.77 1.82 3.33 
14187 Akr1b8 aldo-keto reductase family 1, 
member B8 
-1.10 1.77 1.33 2.60 
72535 Aldh1b1 aldehyde dehydrogenase 1 family, 
member B1 
-1.03 2.00 1.79 3.67 
238447 Igh-2 immunoglobulin heavy chain 2 
(serum IgA) 
-1.07 2.01 1.36 2.95 
18576 Pde3b phosphodiesterase 3B, cGMP-
inhibited 
1.27 2.08 1.32 2.16 
22004 Tpm2 tropomyosin 2, beta -1.12 2.78 2.45 7.63 
545725 Mterf mitochondrial transcription 
termination factor 
-1.07 2.84 -1.22 2.48 
 
A.1.2.2 Enriched in WT ventricular chambers 
Gene 
Number 
Symbol Description KOA/
WTA 
Fold 
KOV/
WTV 
Fold 
KOA/
KOV 
Fold 
WTA/
WTV 
Fold 
56839 Lgi1 leucine-rich repeat LGI family, 
member 1 
-1.41 -10.8 -2.07 -15.8 
26878 B3galt2 UDP-Gal:betaGlcNAc beta 1,3-
galactosyltransferase, polypeptide 
2 
-1.14 -5.54 -2.10 -10.20 
11459 Acta1 actin, alpha 1, skeletal muscle -1.49 -3.54 -2.39 -5.65 
214531 Tmprss13 transmembrane protease, serine 13 -1.29 -3.01 -1.34 -3.14 
106869 Tnfaip8 tumor necrosis factor, alpha-
induced protein 8 
-1.21 -2.74 -1.73 -3.93 
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12477 Ctla4 cytotoxic T-lymphocyte-
associated protein 4 
1.01 -2.56 -1.11 -2.88 
76884 Cyfip2 cytoplasmic FMR1 interacting 
protein 2 
1.39 -2.55 -1.68 -5.98 
233199 Mybpc2 myosin binding protein C, fast-
type 
-1.16 -2.04 -1.86 -3.28 
20750 Spp1 secreted phosphoprotein 1 1.01 -1.99 -2.12 -4.29 
18639 Pfkfb1 6-phosphofructo-2-
kinase/fructose-2,6-biphosphatase 
1 
-1.45 -1.95 -2.84 -3.81 
60440 Iigp1 interferon inducible GTPase 1 -1.03 -1.90 -3.11 -5.75 
105387 Akr1c14 aldo-keto reductase family 1, 
member C14 
-1.50 -1.88 -1.88 -2.36 
24117 Wif1 Wnt inhibitory factor 1 1.03 -1.84 -1.67 -3.17 
56508 Rapgef4 Rap guanine nucleotide exchange 
factor (GEF) 4 
-1.05 -1.75 -1.75 -2.89 
330953 Hcn4 hyperpolarization-activated, cyclic 
nucleotide-gated K+ 4 
-1.03 -1.74 -1.30 -2.21 
667597 BC02310
5 
cDNA sequence BC023105 -1.25 -1.63 -4.16 -5.42 
110595 Timp4 tissue inhibitor of 
metalloproteinase 4 
-1.44 -1.60 -2.49 -2.76 
57816 Tesc tescalcin 1.44 -1.59 -3.88 -8.90 
208618 Etl4 enhancer trap locus 4 -1.20 -1.57 -1.55 -2.04 
626578 Gbp10 guanylate-binding protein 10 1.12 -1.53 -1.31 -2.24 
80903 Fgf16 fibroblast growth factor 16 1.04 -1.50 -6.08 -9.45 
15166 Hcn2 hyperpolarization-activated, cyclic 
nucleotide-gated K+ 2 
1.27 1.56 -3.34 -2.71 
258554 Olfr873 olfactory receptor 873 -1.02 1.57 -3.85 -2.41 
16647 Kpna2 karyopherin (importin) alpha 2 -1.02 1.57 -3.29 -2.05 
109019 Obfc2a oligonucleotide/oligosaccharide-
binding fold containing 2A 
1.20 1.66 -3.91 -2.83 
71911 Bdh1 3-hydroxybutyrate dehydrogenase, 
type 1 
1.37 1.78 -10.70 -8.29 
71889 Epn3 epsin 3 1.44 1.93 -3.72 -2.78 
140781 Myh7 myosin, heavy polypeptide 7, 
cardiac muscle, beta 
1.01 1.99 -4.35 -2.22 
13195 Ddc dopa decarboxylase 1.00 2.41 -5.38 -2.24 
 
A.1.2.3 No enrichment in either WT atria or ventricles 
Gene 
Number 
Symbol Description KOA/
WTA 
Fold 
KOV/
WTV 
Fold 
KOA/
KOV 
Fold 
WTA/
WTV 
Fold 
66212 Sec61b Sec61 beta subunit -1.25 -2.39 1.11 -1.73 
320225 Catsperg1 cation channel, sperm-associated, 
gamma 1 
1.24 -2.38 2.42 -1.22 
625109 Vmn2r86 vomeronasal 2, receptor 86 -1.35 -2.32 1.56 -1.10 
19716 Bex1 brain expressed gene 1 -1.46 -2.14 -1.08 -1.59 
245446 Slitrk4 SLIT and NTRK-like family, 
member 4 
-1.11 -2.14 -1.01 -1.94 
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258276 Olfr960 olfactory receptor 960 1.03 -2.02 1.34 -1.55 
320027 Fstl4 follistatin-like 4 1.10 -2.02 2.20 -1.01 
667277 C1rb complement component 1, r 
subcomponent B 
1.22 -1.92 2.16 -1.08 
241494 Zfp385b zinc finger protein 385B -1.26 -1.92 2.67 1.75 
20616 Snap91 synaptosomal-associated protein 
91 
-1.04 -1.92 2.82 1.53 
218038 Amph amphiphysin 1.17 -1.85 1.16 -1.88 
10004144
9 
Cyp3a59 cytochrome P450, subfamily 3A, 
polypeptide 59 
1.49 -1.81 1.47 -1.83 
52882 Rgs7bp regulator of G-protein signalling 7 
binding protein 
-1.12 -1.78 -1.04 -1.66 
16142 Iglv1 immunoglobulin lambda variable 
1 
1.15 -1.78 1.17 -1.74 
320581 Idi2 isopentenyl-diphosphate delta 
isomerase 2 
1.39 -1.76 1.62 -1.52 
547329 Trav16d-
dv11 
T cell receptor alpha variable 16D-
DV11 
1.26 -1.75 1.52 -1.45 
208076 Pknox2 Pbx/knotted 1 homeobox 2 -1.30 -1.70 1.15 -1.14 
108956 Apol7c apolipoprotein L 7c -1.13 -1.69 1.05 -1.42 
233813 Vwa3a von Willebrand factor A domain 
containing 3A 
-1.05 -1.66 -1.01 -1.60 
258334 Olfr1396 olfactory receptor 1396 -1.21 -1.65 -1.39 -1.90 
243574 Kbtbd8 kelch repeat and BTB (POZ) 
domain containing 8 
1.06 -1.63 1.04 -1.67 
258216 Olfr1034 olfactory receptor 1034 1.20 -1.63 -1.02 -2.00 
212996 Wbscr17 Williams-Beuren syndrome 
chromosome region 17 homolog 
(human) 
-1.33 -1.63 -1.27 -1.56 
385138 BC06123
7 
cDNA sequence BC061237 -1.00 -1.61 1.34 -1.20 
56546 Sec1 secretory blood group 1 1.25 -1.61 1.87 -1.08 
257881 Olfr205 olfactory receptor 205 1.17 -1.61 1.13 -1.68 
258769 Olfr508 olfactory receptor 508 1.08 -1.59 1.08 -1.59 
217721 Mfsd7c major facilitator superfamily 
domain containing 7C 
-1.27 -1.59 1.09 -1.14 
258008 Olfr1513 olfactory receptor 1513 -1.16 -1.59 1.46 1.06 
16979 Lrrn1 leucine rich repeat protein 1, 
neuronal 
1.20 -1.59 1.34 -1.43 
13032 Ctsc cathepsin C -1.39 -1.58 1.73 1.52 
13190 Dct dopachrome tautomerase 1.22 -1.58 1.22 -1.58 
20112 Rps6ka2 ribosomal protein S6 kinase, 
polypeptide 2 
1.17 -1.57 1.60 -1.16 
14664 Slc6a9 solute carrier family 6 
(neurotransmitter transporter, 
glycine), member 9 
-1.26 -1.57 2.14 1.72 
208943 Myo5c myosin VC -1.09 -1.57 -1.16 -1.67 
209268 Igsf1 immunoglobulin superfamily, 
member 1 
-1.30 -1.57 1.01 -1.19 
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18020 Nfatc2ip nuclear factor of activated T-cells, 
cytoplasmic, calcineurin-
dependent 2 interacting protein 
-1.17 -1.56 1.22 -1.09 
192216 Tmem47 transmembrane protein 47 -1.11 -1.55 1.37 -1.02 
331524 Xkrx X Kell blood group precursor 
related X linked 
-1.11 -1.54 1.08 -1.29 
66101 Ppih peptidyl prolyl isomerase H 1.27 -1.54 1.25 -1.57 
76808 Rpl18a ribosomal protein L18A 1.10 -1.54 1.72 1.01 
93695 Gpnmb glycoprotein (transmembrane) 
nmb 
-1.46 -1.53 -1.29 -1.36 
231238 Sel1l3 sel-1 suppressor of lin-12-like 3 
(C. elegans) 
1.01 -1.53 1.10 -1.40 
14776 Gpx2 glutathione peroxidase 2 1.46 -1.53 1.71 -1.31 
233274 Siglech sialic acid binding Ig-like lectin H -1.15 -1.53 1.15 -1.15 
10004026
8 
Olfr157 olfactory receptor 157 -1.09 -1.53 1.33 -1.05 
234779 Plcg2 phospholipase C, gamma 2 -1.02 -1.52 -1.01 -1.50 
217615 Ctage5 CTAGE family, member 5 -1.46 -1.52 -1.38 -1.44 
21788 Tfpi tissue factor pathway inhibitor 1.06 -1.52 2.20 1.36 
22146 Tuba1c tubulin, alpha 1C -1.01 -1.51 1.23 -1.23 
53945 Slc40a1 solute carrier family 40 (iron-
regulated transporter), member 1 
-1.04 -1.51 1.70 1.17 
381777 Igkv1-110 immunoglobulin kappa chain 
variable 1-110 
1.46 -1.51 1.15 -1.92 
245670 Rragb Ras-related GTP binding B -1.12 -1.51 1.14 -1.19 
17171 Mas1 MAS1 oncogene 1.10 -1.50 1.09 -1.51 
218763 Lrrc3b leucine rich repeat containing 3B -1.24 -1.50 1.74 1.44 
15382 Hnrnpa1 heterogeneous nuclear 
ribonucleoprotein A1 
-1.22 -1.50 -1.21 -1.50 
79201 Tnfrsf23 tumor necrosis factor receptor 
superfamily, member 23 
1.06 1.51 -1.61 -1.13 
258242 Olfr955 olfactory receptor 955 1.10 1.51 -1.27 1.09 
56441 Nat6 N-acetyltransferase 6 1.01 1.52 -1.55 -1.03 
547109 Trim43a tripartite motif-containing 43A -1.10 1.52 -1.27 1.32 
17844 Mup5 major urinary protein 5 1.12 1.52 -1.38 -1.02 
668923 Zfp442 zinc finger protein 442 1.09 1.52 -2.14 -1.53 
230903 Fbxo44 F-box protein 44 1.27 1.52 1.00 1.20 
17110 Lyz1 lysozyme 1 1.12 1.52 1.11 1.52 
637898 Vmn2r60 vomeronasal 2, receptor 60 1.01 1.53 -1.20 1.26 
16592 Fabp5 fatty acid binding protein 5, 
epidermal 
1.21 1.53 1.47 1.86 
12683 Cidea cell death-inducing DNA 
fragmentation factor, alpha 
subunit-like effector A 
1.22 1.53 -2.14 -1.70 
240899 Lrrc52 leucine rich repeat containing 52 1.31 1.53 -2.16 -1.85 
72599 Pdia5 protein disulfide isomerase 
associated 5 
1.36 1.54 1.35 1.53 
11520 Plin2 perilipin 2 1.13 1.55 -2.28 -1.66 
192657 Ell2 elongation factor RNA polymerase 
II 2 
-1.04 1.56 -1.93 -1.18 
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75829 Prame preferentially expressed antigen in 
melanoma 
1.34 1.56 -1.04 1.11 
14645 Glul glutamate-ammonia ligase 
(glutamine synthetase) 
1.38 1.56 -1.83 -1.61 
259032 Olfr1134 olfactory receptor 1134 1.18 1.57 -1.49 -1.12 
272428 Acsm5 acyl-CoA synthetase medium-
chain family member 5 
1.29 1.58 -2.03 -1.66 
258902 Olfr1220 olfactory receptor 1220 1.02 1.59 -1.43 1.08 
83672 Sytl3 synaptotagmin-like 3 1.46 1.60 1.10 1.21 
245526 Pgr15l G protein-coupled receptor 15-like 1.11 1.60 -1.24 1.16 
20471 Six1 sine oculis-related homeobox 1 
homolog (Drosophila) 
1.14 1.61 -1.58 -1.12 
258201 Olfr538 olfactory receptor 538 1.01 1.61 -1.88 -1.18 
215061 Trim50 tripartite motif-containing 50 1.42 1.61 -1.24 -1.09 
434903 Mageb4 melanoma antigen, family B, 4 -1.05 1.61 -1.80 -1.06 
10004292
1 
Vmn2r51 vomeronasal 2, receptor 51 1.11 1.62 -1.39 1.04 
620631 Ttc30a2 tetratricopeptide repeat domain 
30A2 
1.40 1.63 -1.56 -1.35 
20425 Shmt1 serine hydroxymethyltransferase 1 
(soluble) 
1.25 1.63 -1.91 -1.46 
23960 Oas1g 2'-5' oligoadenylate synthetase 1G -1.06 1.64 -1.96 -1.12 
320705 Bend6 BEN domain containing 6 1.26 1.64 1.23 1.59 
13646 Klk1b22 kallikrein 1-related peptidase b22 1.40 1.65 1.00 1.18 
18367 Olfr66 olfactory receptor 66 -1.07 1.67 -1.26 1.42 
382427 Best3 bestrophin 3 -1.16 1.69 -2.94 -1.49 
17153 Mal myelin and lymphocyte protein, T-
cell differentiation protein 
1.07 1.71 -1.50 1.05 
11898 Ass1 argininosuccinate synthetase 1 1.28 1.73 -1.00 1.33 
258550 Olfr869 olfactory receptor 869 -1.35 1.82 -4.64 -1.86 
665255 Vmn2r28 vomeronasal 2, receptor 28 1.11 1.84 -1.67 -1.01 
11833 Aqp8 aquaporin 8 1.16 1.85 -2.34 -1.47 
554292 AB09951
6 
cDNA sequence AB099516 -1.05 1.92 -1.80 1.12 
235283 Gramd1b GRAM domain containing 1B -1.05 1.96 -3.58 -1.73 
667666 Zfp600 zinc finger protein 600 1.06 1.98 -2.01 -1.08 
626674 Olfr471 olfactory receptor 471 -1.23 2.03 -1.82 1.37 
18775 Prl3d1 prolactin family 3, subfamily d, 
member 1 
1.21 2.06 1.11 1.89 
13587 Ear2 eosinophil-associated, 
ribonuclease A family, member 2 
-1.18 2.07 -1.41 1.73 
15586 Hyal1 hyaluronoglucosaminidase 1 1.03 2.09 -2.35 -1.15 
620297 Trav6n-6 T cell receptor alpha variable 6N-6 1.34 2.14 -1.29 1.23 
13180 Pcbd1 pterin 4 alpha carbinolamine 
dehydratase/dimerization cofactor 
of hepatocyte nuclear factor 1 
alpha (TCF1) 1 
1.29 2.45 -1.16 1.63 
258602 Olfr150 olfactory receptor 150 -1.06 2.54 -2.04 1.32 
228413 Prrg4 proline rich Gla (G-
carboxyglutamic acid) 4 
(transmembrane) 
-1.12 3.11 -2.43 1.44 
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65969 Cubn cubilin (intrinsic factor-cobalamin 
receptor) 
1.11 3.41 -4.13 -1.34 
 
A.1.3 Table of genes dysregulated in both chambers 
A.1.3.1 Enriched in WT atria 
Gene 
Number 
Symbol Description KOA/
WTA 
Fold 
KOV/
WTV 
Fold 
KOA/
KOV 
Fold 
WTA/
WTV 
Fold 
17901 Myl1 myosin, light polypeptide 1 -13.60 -12.3 2.29 2.53 
12350 Car3 carbonic anhydrase 3 -4.26 1.67 -1.98 3.58 
51788 H2afz H2A histone family, member Z -4.01 -1.85 1.21 2.62 
76376 Slc24a2 solute carrier family 24 
(sodium/potassium/calcium 
exchanger), member 2 
-3.02 -2.28 1.92 2.54 
664608 Rhox4g reproductive homeobox 4G -2.14 1.61 -1.47 2.34 
14169 Fgf14 fibroblast growth factor 14 -2.00 -1.99 2.28 2.29 
24012 Rgs7 regulator of G protein signaling 7 -1.73 -1.88 7.41 6.82 
216188 Aldh1l2 aldehyde dehydrogenase 1 family, 
member L2 
-1.67 -1.55 2.38 2.57 
67547 Slc39a8 solute carrier family 39 (metal ion 
transporter), member 8 
1.54 1.51 8.04 7.87 
14219 Ctgf connective tissue growth factor 1.82 1.62 2.99 2.67 
 
A.1.3.2 Enriched in WT ventricles 
Gene 
Number 
Symbol Description KOA/
WTA 
Fold 
KOV/
WTV 
Fold 
KOA/
KOV 
Fold 
WTA/
WTV 
Fold 
80978 Mrgprh MAS-related GPR, member H -4.29 -2.73 -3.17 -2.02 
12372 Casq1 calsequestrin 1 -3.75 -6.78 -1.62 -2.93 
18670 Abcb4 ATP-binding cassette, sub-family 
B (MDR/TAP), member 4 
-2.10 -2.78 -1.81 -2.41 
76886 Fam81a family with sequence similarity 
81, member A 
-1.87 -4.37 -1.77 -4.14 
620240 Igkv8-26 immunoglobulin kappa chain 
variable 8-26 
-1.83 -3.69 -1.22 -2.47 
20315 Cxcl12 chemokine (C-X-C motif) ligand 
12 
-1.57 -1.79 -1.82 -2.09 
50874 Tmod4 tropomodulin 4 -1.53 -2.36 -1.30 -2.00 
21835 Thrsp thyroid hormone responsive 
SPOT14 homolog (Rattus) 
1.50 3.56 -5.12 -2.16 
 
A.1.3.3 No enrichment in either WT atria or ventricles 
Gene 
Number 
Symbol Description KOA/
WTA 
Fold 
KOV/
WTV 
Fold 
KOA/
KOV 
Fold 
WTA/
WTV 
Fold 
22187 Ubb ubiquitin B -4.74 1.58 -3.75 1.99 
 143 
241431 Xirp2 xin actin-binding repeat containing 
2 
-4.73 -2.09 -4.45 -1.97 
244867 Arhgap20 Rho GTPase activating protein 
20 
-3.65 -3.23 -1.69 -1.49 
234854 Cdk10 cyclin-dependent kinase 10 -2.66 -1.70 -1.13 1.39 
65255 Asb4 ankyrin repeat and SOCS box-
containing 4 
-2.47 -2.03 -1.38 -1.13 
21665 Tdg thymine DNA glycosylase -2.28 1.51 -2.11 1.63 
11431 Acp1 acid phosphatase 1, soluble -2.18 -1.56 -1.31 1.07 
353169 Slc2a12 solute carrier family 2 (facilitated 
glucose transporter), member 12 
-2.01 -1.81 -1.10 1.01 
232413 Clec12a C-type lectin domain family 12, 
member a 
-1.90 -1.78 -1.15 -1.07 
60532 Wtap Wilms' tumour 1-associating 
protein 
-1.83 -1.61 -1.07 1.07 
18583 Pde7a phosphodiesterase 7A -1.78 -2.49 1.23 -1.14 
380614 Intu inturned planar cell polarity 
effector homolog (Drosophila) 
-1.73 -1.73 -1.48 -1.48 
330812 Rnf150 ring finger protein 150 -1.70 -1.63 -1.11 -1.06 
71738 Mamdc2 MAM domain containing 2 -1.68 -1.64 1.93 1.98 
17996 Neb nebulin -1.53 -2.85 2.52 1.35 
12116 Bhmt betaine-homocysteine 
methyltransferase 
1.51 -1.51 1.63 -1.41 
74127 Krt80 keratin 80 1.52 1.70 -1.18 -1.06 
11304 Abca4 ATP-binding cassette, sub-family 
A (ABC1), member 4 
1.57 2.73 -2.77 -1.59 
75668 Rasl10a RAS-like, family 10, member A 1.58 1.66 -1.18 -1.12 
105243 Slc9a3 solute carrier family 9 
(sodium/hydrogen exchanger), 
member 3 
1.62 3.00 -2.74 -1.48 
14695 Gnb3 guanine nucleotide binding protein 
(G protein), beta 3 
1.64 2.04 -2.23 -1.79 
53622 Krt85 keratin 85 1.72 -1.52 1.92 -1.36 
627132 Vmn2r93 vomeronasal 2, receptor 93 1.84 1.73 -1.22 -1.30 
258329 Olfr135 olfactory receptor 135 1.92 2.34 -1.74 -1.43 
17750 Mt2 metallothionein 2 1.96 2.36 1.13 1.35 
20289 Scx scleraxis 1.98 1.76 -1.70 -1.91 
71310 Tbc1d9 TBC1 domain family, member 9 2.79 1.96 2.06 1.45 
11829 Aqp4 aquaporin 4 2.81 2.06 -1.41 -1.92 
72373 Psca prostate stem cell antigen 8.41 2.72 4.65 1.50 
 
A.2 Python script for gene info accession 
“ExtractGeneInfo.py” 
#Importation of tools 
from xlrd import open_workbook 
from tempfile import TemporaryFile 
from xlwt import Workbook 
import time 
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from Bio import Entrez 
 
Entrez.email = "medrano@bu.edu" 
 
#Open the workbook named FIMO.xls and summon first sheet 
book = open_workbook('FIMOfile.xls') 
sheet = book.sheet_by_index(0) 
 
#Prime the new worksheet 
newbook = Workbook() 
newsheet1 = newbook.add_sheet('Sheet 1') 
 
#To perform on all rows in FIMO.xls sheet 
for i in range(sheet.nrows): 
     
    Entrez.email = "medrano@bu.edu" 
     
    #Assign variables 
    genenum = int(sheet.cell_value(i,0)) 
     
    #Fetch genes from Entrez 
    handle = Entrez.efetch(db="gene", id=genenum, rettype="gb", retmode="text") 
     
    #Extract out information 
    print(handle.read()) 
     
    #Begin to save variables into new worksheet 
    handle = Entrez.efetch(db="gene", id=genenum, rettype="gb", retmode="text") 
    newsheet1.write(i,0,genenum) 
    newsheet1.write(i,1,handle.read()) 
     
    #Will repeat until done with all the rows of data 
    time.sleep(1) 
#Save the file 
newbook.save('OUTPUTfile.xls') 
newbook.save(TemporaryFile()) 
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LIST OF JOURNAL ABBREVIATIONS 
Acta Physiol Acta Physiologica 
Am J Physiol Hear Circ Physiol American Journal of Physiology-Heart and 
Circulatory Physiology 
Am J Physiol Physiol American Journal of Physiology-Cell Physiology 
Ann Anat Annals of Anatomy 
Ann N Y Acad Sci Annals of the New York Academy of Sciences 
Annu Rev Cell Dev Biol Annual Review of Cell and Developmental Biology 
Annu Rev Pathol Mech Dis Annual Review of Pathology: Mechanisms of 
Disease 
Auton Neurosci Autonomic Neuroscience 
Basic Res Cardiol Basic Research in Cardiology 
Biochem Biophys Res Commun Biochemical and Biophysical Research 
Communications 
Biochem Cell Biol Biochemistry and cell biology 
Can J Cardiol Canadian Journal of Cardiology 
Cardiovasc Res Cardiovascular Research 
Cell Cell 
Cell Stem Cell Cell Stem Cell 
Cell Mol Life Sci Cellular and Molecular Life Sciences 
Cell Physiol Biochem Cellular Physiology and Biochemistry 
Circ J Circulation Journal 
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Circ Res Circulation Research 
Circulation Circulation 
Cold Spring Harb Perspect Biol Cold Spring Harbor perspectives in biology 
Curr Opin Cell Biol Current Opinion in Cell Biology 
Curr Probl Pediatr Current Problems in Pediatrics 
Curr Protoc Mol Biol Current Protocols in Molecular Biology 
Cytokine Growth Factor Rev Cytokine and Growth Factor Reviews 
Dev Biol Developmental Biology 
Dev Cell Developmental Cell 
Dev Dyn Developmental Dynamics 
Development Development 
EMBO J EMBO Journal 
Eur Heart J European Heart Journal 
Eur J Biochem European Journal of Biochemistry 
FASEB J FASEB Journal 
FEBS Lett FEBS Letters 
Gene Gene 
Genes Dev Genes and Development 
Genesis Genesis 
Genome Biol Genome Biology 
Int J Dev Biol The International Journal of Developmental 
Biology 
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J Biol Chem Journal of Biological Chemistry 
J Cell Biol Journal of Cell Biology 
J Cell Sci Journal of Cell Science 
J Cell Biochem Journal of Cellular Biochemistry 
J Clin Invest Journal of Clinical Investigation 
J Mol Cell Cardiol Journal of Molecular and Cellular Cardiology 
J Mol Endocrinol Journal of Molecular Endocrinology 
J Neurosci The Journal of Neuroscience 
Mech Dev Mechanisms of Development 
Mol Brain Res Molecular Brain Research 
Mol Cell Biol Molecular and Cellular Biology 
Mol Cell Endocrinol Molecular and Cellular Endocrinology 
Nat Cell Biol Nature Cell Biology 
Nat Commun Nature Communications 
Nat Genet Nature Genetics 
Nat Protoc Nature Protocols 
Nat Rev Genet Nature Reviews Genetics 
Nature Nature 
Neurosci Lett Neuroscience Letters 
Oncogene Oncogene 
Oncol Rep Oncology Reports 
Pediatr Cardiol Pediatric Cardiology 
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Pflugers Arch Eur J Physiol Pflugers Archiv European Journal of Physiology 
Pharmacol Ther Pharmacology and Therapeutics 
Philos Trans R Soc B Biol Sci Philosophical Transactions of the Royal Society B: 
Biological Sciences 
Physiol Genomics Physiological Genomics 
Physiol Rev Physiological Reviews 
PLoS Genet PLoS Genetics 
PLoS One PLoS ONE 
Proc Natl Acad Sci U S A Proceedings of the National Academy of Sciences 
of the United States of America 
Science Science 
Semin Cell Dev Biol Seminars in Cell and Developmental Biology 
Semin Fetal Neonatal Med Seminars in Fetal and Neonatal Medicine 
Stem Cells Stem Cells 
Trends Biochem Sci Trends in Biochemical Sciences 
Trends Cardiovasc Med Trends in Cardiovascular Medicine 
Trends Genet Trends in Genetics 
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